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Prognosis in advanced stage lung cancer is extremely poor with few effective 
therapies. EGFR tyrosine kinase inhibitors (TKIs) have high response rates in patients 
with activating EGFR mutations and are now an established part of therapy in selected 
patients. Such advances herald a previously unprecedented enthusiasm for the 
possibilities of targeted therapy. Acquired resistance however is widespread - the 
EGFR T790M mutation in particular represents approximately 50% of these.  MET 
amplification is also an important route of resistance and preclinical data suggests 
synergy between therapies targeting these two receptors. We hypothesized that EGFR 
mutation status determines the EGFR-MET interaction and response to MET inhibition. 
We tested this hypothesis by using cells derived from NCI-H1975, which possess 
L858R and T790M EGFR mutations.  This cell model and a derived murine xenograft 
experiment provided a platform with which to test these ideas by using assays of 
tumorigenicity in vitro; tumour growth/stroma formation in vivo and a selective MET 
kinase inhibitor, SGX523. EGFR-MET interaction was assessed by a Förster 
Resonance Energy Transfer (FRET) Fluorescence Lifetime Imaging Microscopy (FLIM) 
assay developed as part of this thesis that quantified EGFR-MET dimer formation. 
 
SGX523 significantly reduced cell proliferation, xenograft tumour growth and ERK 
phosphorylation in the presence of the EGFR L858R-T790M mutations but not with 
EGFR L858R alone where SGX523 reduced stroma formation but not growth. SGX523 
reduced EGFR-MET dimerisation in the EGFR L858R-T790M mutant but increased 
EGFR-MET interaction in the presence of EGFR L858R alone. Little effect was seen 
with EGFR WT in response to SGX523 for any of these indices. This thesis provides 
novel data for the mechanistic understanding of EGFR-MET heterodimerisation and the 
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Chapter 1. Introduction 
1.1 Lung cancer Background 
Lung cancer was diagnosed in 45,500 patients in the UK in 2013 with 35,400 lung 
cancer deaths recorded in the UK in 2012. Worldwide, lung cancer is the commonest 
cause of cancer deaths; in 2012 these totalled 1.6 million.  These statistics are 
staggering for a disease where prognosis is extremely poor with a median survival of 
six months - only 5% of patients survive 10 or more years (Cancer research UK data, 
accessed April 2016).  The outlook is bleak for such patients, particularly since most 
present with advanced stage, incurable disease. Potentially curative surgery is in fact 
available for fewer than 20% of cases. Unfortunately, in the inoperable, success in 
chemotherapy is usually limited to months and sustained remission is rare. 
Approximately one third of lung cancer patients may receive no anti-cancer therapy at 
all (The National Lung Cancer Audit 2015, Royal College of Physicians). 
 
An inextricable nihilism has therefore surrounded lung cancer care in recent decades. 
Whilst prognosis has improved in other cancers such as breast cancer (e.g. increased 
5 year survival from 75% to 91% between 1975 and 2011), likely as a result of 
improved understanding of disease mechanisms and therapeutic improvements, the 
statistics around lung cancer survival remain sobering (12%, 1975; 18%, 2011) (Siegel, 
Miller et al. 2016). This can be attributed to a poor understanding of lung cancer 
historically and a gloomy pessimism, which accepted that treatment in most cases 
would be futile.  The assumption that lung cancer was a single disease with simplistic 
histopathological classifications that shared clinical features and therefore equal 
approaches to treatment is now out-dated. The considerable effort to overcome these 
challenges is essential to improve prospects for future generations. 
 
Lung cancer is in fact a broad entity. According to the 2015 World Health Organisation 
classification, lung cancer can be categorised into Small cell and Non-Small Cell Lung 
Cancer (NSCLC) based on histopathological appearances of cells and tissue 
architecture, in addition to immunohistochemical markers.  The majority (80%) of lung 
cancers are NSCLC, which includes the commonest subtypes adenocarcinoma and 
squamous cell carcinoma (Reck, Heigener et al. 2013). Lung adenocarcinoma is more 
usually seen towards the lung peripheries and demonstrates a neoplastic glandular 
appearance with cells that characteristically stain positively for thyroid transcription 
factor 1 (TTF1), keratin 7 and mucin (Chen, Fillmore et al. 2014).  Conversely, 
squamous cell carcinoma more usually arises in the proximal airways and is defined by 
the presence of intercellular 'desmosomes', keratin production and p40, p63, 
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Cytokeratin 5/6 (CK5/6), SRY-Box2 (SOX2) and desmoglein immunostaining. 
Squamous cell lung cancer is also more usually associated with smoking and chronic 
inflammation and is typically associated with a more diffuse mutational burden than 
adenocarcinoma (Travis, Brambilla et al. 2013, Chen, Fillmore et al. 2014). 
 
Finally other forms of lung cancer not explored further here include small cell lung 
cancer, a more aggressive tumour defined by the relatively small size and volume of 
cytoplasm, with hyperchromatic nuclei and diffuse necrosis and presence of 
neuroendocrine features; carcinoid which express neuroendocrine features to varying 
extents and finally, large cell and adenosquamous lung cancer (Chen, Fillmore et al. 
2014).  The discussion within this thesis will largely be limited to the non-small cell lung 
cancer cell types and the experiments conducted within systems representing lung 
adenocarcinoma. 
 
1.2 The Limitations of Current Lung Cancer Therapy 
Presently, the most important determinant of effective treatment in lung cancer is 
based on “tumour stage”, for example, invasiveness of tumour margins and anatomical 
spread. The International Association for the Study of Lung defines these phase 
specific features of lung cancer, which group together prognostically into a set of 
recommendations, which it submits to the Union for International Cancer Control 
(UICC) and the American Joint Committee on Cancer (AJCC) who mandate a 
classification most recently updated in the latter part of 2016 and effected in early 
2017. This 'IASLC' classification, known as “TNM staging” of the tumour, now in its 
eighth incarnation provides a classification system for lung tumours based on (T)umour 
characteristics, lymph (N)ode involvement and (M)etastatic deposits (Travis, Brambilla 
et al. 2011, Goldstraw, Chansky et al. 2016).  Stage I, II and some stage III groups 
have the best chance of surgical cure assuming the patient has sufficient physiological 
reserve to endure surgery or alternatively withstand radical radiotherapeutic 
approaches. Unfortunately the remainder are unlikely to be cured and can at best hope 
for prolonged treatment response with optimal systemic therapy, which typically 
includes platinum based combinations but increasingly molecularly targeted 
approaches including immunotherapy. 
 
Immunotherapy with PDL1 inhibitors such as nivolumab and pembrolizumab 
represents a new class of therapy, which impairs the ability of the tumour to defend 
itself against the host immune response.  In these trials PDL1 can be utilised as a 
biomarker to predict response to such agents although a number of trials have also 
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shown response irrespective of PDL1 status (Brahmer, Reckamp et al. 2015, Spigel, 
Reckamp et al. 2015, Herbst, Baas et al. , Herbst, Baas et al. 2016, Johnson 2016, 
Kindler, Karrison et al. 2017, Lievense, Sterman et al. , Rittmeyer, Barlesi et al.). 
 
Significant efforts have been made to achieve early diagnosis where existing treatment 
might be more effective, for example through lung cancer screening programs (Ruparel 
and Janes 2016, Yousaf-Khan, van der Aalst et al. 2017).  In addition, addressing the 
most important risk factor, smoking, through efforts such as legislating against smoking 
in public and plain packaging has been a priority.  There does however remain a 
significant proportion of the population who are not affected by such changes (Peto, 
Darby et al. 2000).  Lung cancer also remains an important disease in never smokers 
who account for 10-25% of sufferers of lung cancer and is the seventh commonest 
cause of cancer deaths in this group (Couraud, Zalcman et al. 2012).  Furthermore as 
preventative efforts to reduce smoking prevalence come into fruition (albeit with several 
decades lag period) the proportion of case in non-smokers rises (Cancer Genome 
Atlas Research 2014). 
 
Therapeutic advances in the lung cancer literature have focused firstly, on enhanced, 
minimally invasive diagnostics and biomarker development, which has supported other 
important efforts into early diagnosis/therapy; secondly, on stage-specific “personalized 
therapy” consisting of novel pharmacological agents and extending to radical surgical 
and radiotherapeutic techniques, where curative treatment is feasible and targeted 
multimodal therapy in locally advanced or metastatic disease where cure is not 
possible (Reck, Heigener et al. 2013); and thirdly, on study of resistance mechanisms 
in search of novel therapeutic avenues to tackle recurrence. The diagnostic and 
therapeutic pathway for each is likely to diverge as our understanding of therapy in 
each subtype broadens. 
 
One of the most important developments in lung cancer research in recent years has 
been the recognition of the potential to further sub-classify lung cancer according to 
genomic aberrations and molecular biomarkers against which stratified therapy could 
be employed.  A number of clinically relevant mutations have now been discovered, 
including those in EGFR, KRAS, ALK-ROS rearrangements, RET, BRAF and HER2 
(Cancer Genome Atlas Research 2014, Sholl, Aisner et al. 2015).  Most success in 
targeted agents has been observed in lung adenocarcinoma and one of the greatest 
sources for optimism and the most significant advances in lung cancer research this 
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decade has been the development of targeted agents against the Epidermal Growth 
Factor Receptor (EGFR) (Devarakonda, Morgensztern et al. 2015). 
 
1.3 The Human Epidermal Growth Factor Receptor Family 
The Human Epidermal Growth Factor Receptor (HER) family also known as by the 
related avian viral erythroblastosis oncogene ErbB consist of 4 cell surface receptor 
tyrosine kinases (ErbB1-4 or HER1-4) which includes the prototypical Epidermal 
Growth Factor Receptor (EGFR or ‘HER1’).  Many tissue types express HER family 
members; some co-express multiple receptor types, although for unknown reasons, 
certain HER family members are more common in one type of cancer rather than 
another.  For example, EGFR is important in lung cancer, glioblastoma multiforme 
(GBM) and head and neck squamous cell carcinoma (HNSCC), albeit with quite 
different genetic differences.  Meanwhile, HER2 and HER3 are the most significant 
receptors in breast cancer (Holbro, Beerli et al. 2003).  All play important roles in 
normal physiological conditions; lead to organ defects and non-viability in knockout 
mice and when dysregulated are important mediators of tumorigenesis in a number of 
solid cancers. As a consequence there is growing interest in these receptors as 
therapeutic targets in lung and other tumour types (Yarden and Sliwkowski 2001, 
Hynes and Lane 2005, Fujita 2013, Hansen and Siu 2013, Mitsui, Yonezawa et al. 
2014). 
 
The HER receptors are similar in their composition of the large extracellular ligand 
binding domain, hydrophobic transmembrane region and cytoplasmic tyrosine kinase 
domain which includes a juxtamembrane region and carboxyl-terminal regulatory 
tyrosine residues which serve as docking sites for downstream signaling proteins. The 
620 amino acid extracellular region consists of 4 domains made up from a tandem 
repeat of a leucine rich domain (190 amino acids) and a cysteine rich domain (120 
amino acids).  Within this, domains I and III are beta-helix solenoid structures, which 
are within the leucine-rich region and can bind a single ligand simultaneously. Domain 
II and IV meanwhile are cysteine-rich and linked by disulphide bonds.  The initial three 
of these domains share up to 20% sequence homology with the insulin-like growth 
receptor although unlike HER1, this receptor does not bind ligand with high affinity 
(Garrett, McKern et al. 1998, Lemmon 2009). 
 
Dimerisation is essential to HER family activation.  This can be homo- or hetero-
dimeric.  EGFR and HER4 undergo homodimerisation and are capable of auto-
phosphorylation.  Meanwhile, HER2 which lacks an identifiable ligand and HER3 which 
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has weak or no tyrosine kinase activity (Steinkamp et al, 2014) must heterodimerise to 
become activated (Yarden and Sliwkowski 2001).  Partnering selectivity in such 
dimerisation appears to be hierarchical.  Heterodimeric pairings in general are 
perceived to lead to more tumorigenic outcomes than their homodimeric counterparts 
and this is thought to be particularly true for those that include HER2 or HER3 partners.  
The HER2-HER3 dimer is thought to be the most oncogenic HER pair despite each 
individually being handicapped by the apparent lack of ligand/kinase domain 
respectively (Citri, Skaria et al. 2003). It is not clear why this should be the case, but 
one hypothesis suggests that the lack of competition from homodimers for these 
obligate heterodimers may be important (Lemmon 2009).  HER1-HER4 heterodimers 
are recognized and may influence cellular behaviour such as migration but appear to 
form less frequently (Yarden and Sliwkowski 2001, Kiuchi, Ortiz-Zapater et al. 2014) 
 
An asymmetric activator-receiver model where each of a pair of HER receptors is 
dedicated to either activating or being activated in the process of phosphorylation and 
signal transduction, appears to be the basis of activation for the HER family in general 
(Zhang, Gureasko et al. 2006). In their inactive, unbound state, the default HER family 
structure is to adopt a closed, tethered conformation. Ligand binding to extracellular 
domain then promotes a conformational change to an extended structure that reveals 
the dimerisation arm.  This engages another ligand-bound receptor molecule, 
overcoming the resting auto-inhibited state with subsequent activation of the kinase 
domain and propagation of downstream signaling through molecules containing SH2-
like domains in a manner resembling cyclin-dependent kinases (Yarden and 
Sliwkowski 2001, Zhang, Gureasko et al. 2006). Interestingly, ErbB receptors are 
unique in this sense compared with other RTK in that the ligand forms no part of the 
dimer interface, which is instead receptor mediated (Lemmon, Schlessinger et al. 2014) 
 
Signal processing by the HER family receptors is mediated by additional effectors such 
as by Ras- or Shc-driven activation of MAPK (proliferation) or the PI3K-AKT (cell 
survival) pathways. Loss of HER-mediated activation of these signals promotes BCL-2 
driven apoptosis (Yarden and Sliwkowski 2001, Arteaga and Engelman 2014).  HER3 
in particular is an important mediator of PI3K-AKT signaling as it has six consensus 
binding sites for the P85 subunit. HER2 alone can activate ERK but requires HER3 for 
PI3K signaling, hence the importance of the HER2-HER3 dimer.  Similarly HER3 
mediated AKT signaling is likely to be important in aberrant EGFR signaling. Src 





Figure 1.1 Signalling heterogeneity in the HER signaling network. 
A range of ligands activate the HER receptors (green squares). There are 10 potential 
dimerisation partnerships between the 4 HER family members which results in various 
possibilities for multi-functionality and signaling specificity (green circles). Each HER 
(ErbB) dimer pair in the cell surface membrane (input layer) can give rise to multiple 
unique downstream signals with MAPK and PI3K-AKT being of particular importance 
(Red circles/blue squares). A range of phenotypical outcomes is thus determined 
through the control of these signaling mediators by the respective HER receptor pairing 
- output layer (yellow squares).   Reproduced from (Yarden and Sliwkowski 2001). 
 
1.4 The Epidermal Growth Factor Receptor (EGFR) 
EGFR is the most important HER family receptor in Non-Small Cell Lung Cancer 
(NSCLC) and has rapidly become established as one of the most clinically relevant 
oncogenes in this tumour type.  Over 60% of NSCLC tumours express EGFR and 
overexpression is associated with increased growth, metastasis and poor differentiation 
(Franklin, Veve et al. 2002, Herbst 2004). 
 
EGFR, a 170KDa glycoprotein is prototypical of the HER receptors and there is 
significant structural and functional overlap. Like the other HER molecules, EGFR has 
a structure that consists of an extra-cellular domain, which receives ligand signal in the 
form of EGF but is also responsive to transforming growth factor-β (TGF-β), heparin-
binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epi-
regulin (EPR), and epigen. There is in addition a transmembrane domain; a 
juxtamembrane (JM) region, which is likely to form an integral, dimer-stabilising 
component of the activated state of EGFR; a tyrosine kinase domain, the enzymatic 
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R E V I EW S
A n twork of networks?
The ErbB network might integrate not only its own
inputs but also heterologous signals, including hor-
mones, neurotransmitters, lymphokines and stress
inducers29 (FIG. 1). Many of these trans-regulatory inter-
actions are mediated by protein kinases that directly
phosphorylate ErbBs, thereby affecting their kinase
activity or endocytic transport29. The most extensively
studied mechanism involves activation of G-protein-
coupled receptors (GPCRs) by agonists such as
lysophosphatidic acid (LPA), carbachol (which specifi-
cally activates muscarinic acetylcholine receptors) or
thrombin (FIG. 2).
Experiments done with mutants and inhibitors of
ErbBs imply that the mitogenic activity of some GPCR
agonists requires transactivation of ErbB proteins.
These agents increase tyrosine phosphorylation of
ErbB1 and ErbB2, either by increasing their intrinsic
apoptosis (FIG. 1). Output depends on cellular context, as
well as the specific ligand and ErbB dimer. This has
been best shown in terms of mitogenic and transform-
ing responses: homodimeric receptor combinations are
less mitogenic and transforming than the correspond-
ing heterodimeric combinations, and ErbB2-containing
heterodimers are the most potent complexes21–23 (FIG. 3).
Perhaps the best example of the ability of the ErbB
module to tune mitogenic signalling is provided by the
ErbB2–ErbB3 heterodimer: although neither ErbB2
nor ErbB3 alone can be activated by ligand, the het-
erodimer is the most transforming24,25 and mitogenic21
receptor complex. The ErbB2–ErbB3 heterodimer also
increases cell motility on stimulation with a ligand26;
but the other NRG receptor, ErbB , which exists in sev-
eral isoforms, has been associated with processes vary-
ing from cellular chemotaxis27 to proliferation and dif-
ferentiation28.
Figure 1 | The ErbB signalling network. a | Ligands and the ten dimeric receptor combinations comprise the input layer.
Numbers in each ligand block indicate the respective high-affinity ErbB receptors8. For simplicity, specificities of receptor binding
are shown only for epidermal growth factor (EGF) and neuregulin 4 (NRG4). ErbB2 binds no ligand with high affinity, and ErbB3
homodimers are catalytically inactive (crossed kinase domains). Trans-regulation by G-protein-coupled receptors (such as those
for lysophosphatidic acid (LPA), thrombin and endothelin (ET)), and cytokine receptors is shown by wide arrows. b | Signalling to
the adaptor/enzyme layer is shown only for two receptor dimers: the weakly mitogenic ErbB1 homodimer, and the relatively
potent ErbB2–ErbB3 heterodimer. Only some of the pathways and transcription factors are represented in this layer. c | How
they are translated to specific types of output is poorly understood at present. (Abl, a proto-oncogenic tyrosine kinase whose
targets are poorly understood; Akt, a serine/threonine kinase that phosphorylates the anti-apoptotic protein Bad and the
ribosomal S6 kinase (S6K); GAP, GTPase activating protein; HB-EGF, heparin-binding EGF; Jak, janus kinase; PKC, protein
kinase C; PLCγ, phospholipase Cγ; Shp2, Src homology domain-2-containing protein tyrosine phosph tase 2; Stat, signal
transducer and activator of transcription; RAF–MEK–MAPK and PAK–JNKK–JNK, two cascades of serine/threonine kinases that
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core of the receptor and an intracellular domain where tyrosine residues are found 
which can become phosphorylated by kinase activity, and act as docking sites to 
facilitate binding of signal mediators (Schlessinger 2002, Harris, Chung et al. 2003, 
Hubbard 2009). 
 
The EGFR gene lies on the short arm of chromosome 7 at the 7p12 locus consisting of 
approximately 200,000 base pairs containing 30 exons (Reiter, Threadgill et al. 2001).  
A number of genetic aberrations have been described which dysregulate EGFR 
function.  Increased EGFR copy number is reported in up to 45% of lung cancers whilst 
EGFR mutations have been described in up to two thirds.  It is not clear whether one 
event precedes the other, although it is likely that both events increases genomic 
instability and both are correlated with EGFR overexpression (Liang, Zhang et al. 
2010). Increased EGFR copy number is also highly prevalent in head and neck 
squamous cell carcinoma (HNSCC) and glioblastoma multiforme (GBM). In GBM the 
EGFRvIII mutation in the extracellular domain drives ligand independent signaling.  A 
clearly dominant EGFR mutation has not been established in HNSCC (Kalyankrishna 
and Grandis 2006, Hatanpaa, Burma et al. 2010, Worsham, Ali et al. 2012). 
 
EGFR mutations are of established importance in lung cancer clinical practice. 
Mutations found within the tyrosine kinase domain encoded by exons 18-21 of the 
EGFR gene are of particular relevance. This region gives rise to an important part of 
the ATP binding pocket. As seen in figure 1.2, the most frequently recognized are 
deletions in exon 19, within codons 746-750 (the ELREA motif) and a point mutation at 
codon 858 (L858R), which together account for 90% of these mutations. Other larger 
deletions or combined deletions/substitutions are also recognized and 3-5% of 
mutations occur at codon 719 (G719X).  Another 1-3% are insertion mutations in exon 
20. A subset of mutations including T790M on exon 20 are rarer but become more 





Figure 1.2 The EGFR gene exons and corresponding functional regions. 
EGFR mutations are common in the kinase domain encoding region within exons 18-
21, which alter residues important for ATP interaction with its binding pocket.  As a 
consequence, mutations result in either increased sensitivity to EGFR TKI (purple 
boxes) or treatment resistance (yellow boxes).  Adapted from Sharma 2007 (Sharma, 
Bell et al. 2007). 
 
Many EGFR kinase domain mutations result in constitutive kinase domain activity that 
causes EGFR to act as an oncogenic driver in tumour cells (Sharma, Bell et al. 2007, 
Suda, Onozato et al. 2009, Mitsudomi and Yatabe 2010). L858R, a Leucine 
substitution (also labelled L834R in alternative nomenclature) for example, lies in the 
activation loop and results in kinase activity that is 50 times more active than the 
wildtype (WT) form (Yun, Boggon et al. 2007). Interestingly there appears to be a 
difference in activity between these activating mutations. The del19 mutant is 10-fold 
more active than WT. Additionally L858R and del19 mutations differ in their affinity for 
ATP with the del19 EGFR having a 10-fold higher Km ATP than L858R and a higher 
auto-phosphorylation rate (Carey, Garton et al. 2006, Yun, Boggon et al. 2007).  
Double mutants, such as L858R combined with T790M are also recognized which 
modulate the behaviour of the initial mutation, which as in the case of T790M can 
increase the affinity for ATP which appears to change the dynamics of EGFR activation 
and have important consequences for susceptibility to agents targeted at these regions 
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A cohort of patients identified 
on the basis of tissue diagnosis 
but not correlated with 
biomarkers (that is, sequencing 
of the EGFR gene was not used 
as a selection criterion).
Ligand independence
The activation of a receptor in 
the absence of interaction with 
its cognate ligand.
Kcat
The overall catalytic rate of an 
enzyme (that is, the number of 
substrate molecules converted 
to product by each catalytic 
site per unit of time.
Km
The Michaelis–Menten 
constant. Km is a measure of 
the affinity of a substrate for an 
enzyme, and is the substrate 
concentration at half the 
maximal velocity of an enzyme.
Ki
The dissociation constant for 
the binding of an inhibitor to an 
enzyme.
Phage-display method
A method in which proteins or 
peptides are displayed on the 
surface of filamentous 
bacteriophages, which can 
then be used to study the 
interaction of the peptide with 
other proteins or chemicals.
gefitinib or erlotinib monotherapy. The sequencing of 
the EGFR gene in tumour samples from these responders 
showed somatic gain-of-function mutations20–22 (FIG. 1). 
Overall, the incidence of EGFR mutations in NSCLC 
among clinical responders to gefitinib or erlotinib is 77%, 
compared with 7% in NSCLC cases that are refractory 
to gefitinib or erlotinib20–22,28,30,33,61–73. Additional studies 
have shown some differences in the clinical outcomes 
that are associated with different mutations27,30,74,75. For 
example, NSCLCs that harbour exon 19 deletion muta-
tions seem to respond better to gefitinib and erlotinib 
than tumours with point mutations in exon 21, such 
as L858R30,74,75. So far, insertion mutations in exon 20 
have n ver been ound to confer gefitinib or erlotinib 
sensitivity in vitro, nor have they ever been reported to 
occur in responsive cases, despite the fact that, at least 
in some instances (for example, ins 770 (NPG)), they 
seem to activate EGFR to a similar degree as sensitizing 
mutations in exons 19 or 21 (REF. 40).
Although EGFR mutations were present in most 
cases of NSCLC that were identified by virtue of 
their dramatic clinical response to TKIs, controversy 
has surrounded the predictive value of EGFR muta-
tions in unselected patients31,32,61,69. Approximately 
10–20% of patients who do show a partial response 
to gefitinib do not have identifiable EGFR muta-
tions, indicating that EGFR mutations are not the sole 
determi ants of TKI response20,22,28,30,31,33,61–64,68–70,72,73,76. 
Figure 1 | Gefitinib- and erlotinib-sensitizing mutations of EGFR in NSCLC. A cartoon representation of epidermal 
growth factor receptor (EGFR) showing the distribution of exons in the extracellular domain (EGF binding), 
transmembrane domain (TM) and intracellular domain (comprising the tyrosine kinase and autophosphorylation 
regions). The cysteine-rich regions in the extracellular domain (EGF binding; purple shaded region) and the tyrosine 
kinase region in the intracellular do ain (cyan shaded region) are also represented. Exons 18–21 in the tyrosine kinase 
region where the relevant mutations are located are expanded (represented by the cyan bar), and a detailed list of EGFR 
mutations in these exons that are associated with sensitivity (magenta boxes) or resistance (yellow boxes) to gefitinib or 
erlotinib is shown. The most prevalent of EGFR kinase domain mutations, accounting for 45% of EGFR mutations in non-
small-cell lung cancer (NSCLC), are in-frame deletions of exon 19, nested around the LREA string of amino-acids located 
between residues 747–750 of the EGFR polypeptide175. Another recurrent mutation is the L858R substitution in exon 21, 
within the activation loop of EGFR, which comprises approximately 40–45% of EGFR mutations. Nucleotide 
substitutions in exon 18 (for example, G719C or G719S) account for another 5% of EGFR mutations, as do in-frame 
insertions in exon 20. The most noteworthy, clinically relevant mutation in exon 20 is T790M, which is detected in 50% 
of the cases (denoted by *) as a second site mutation associated with acquired gefitinib and erlotinib resistance25,35–39. 
Recently, D761Y, a T790M-like secondary mutation in exon 19 of EGFR (at the border of exon 19 and exon 20), was also 
reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR 
mutation71,176. Although the inclusion of most of these sensitizing mutations are based on their occurrence in drug 
responders, increased biochemical and cellular activity of these mutations has been documented in some cases. The 
main mutations in each class are shown in bold type. Data compiled from20–22,28,30,31,33,71,177.
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As with other HER family members, EGFR must dimerise to function.  EGFR can 
become activated by homo-dimerisation of two collocated EGFR monomers, brought 
together by ligand interaction (Bublil, Pines et al. 2010). The extra-cellular domain, 
suppresses a propensity of the kinase domains to dimerise and become activated until 
ligand binding.  Under normal resting conditions, EGFR WT is inactive in an auto-
inhibited state until binding of the EGF ligand.  Ligand binding results in 
autophosphorylation of key tyrosine residues within the cytoplasmic domain which then 
interact with signaling molecules containing SH2 like domains that propagate the 
onward signal downstream towards the nucleus (Yarden and Sliwkowski 2001). An 
important aspect of EGFR dimerisation is its asymmetric nature, whereby the N-lobe of 
an ‘activator’ kinase engages and allosterically activates the C lobe of its receiving 
partner. Figure 1.3 shows a schematic of this process.  This activator-receiver model of 
dimerisation resembles the activation of cyclin-dependent kinases and has been 
highlighted as an important basis of activation for the entire HER family (Zhang, 
Gureasko et al. 2006). 
 
 
Figure 1.3 Schematic of EGFR activation with ligand-induced dimerisation 
EGFR consists of an extracellular region and transmembrane/juxtamembrane 
segments (pink) bound to a kinase domain (blue), which acts to phosphorylate 
downstream tyrosine residues (--Y) which then serve as important docking sites for 
downstream signaling proteins.  Conformational changes arising as a result of ligand 
binding or activating mutations encourage receptor-receptor dimerisation which are 
important to tyrosine phosphorylatio and subsequent signal transduction.  Adapted 





sequence), has been found frequently in lung cancer pa-
tients (accounting for 41% of EGFR mutations in these
cancers) (Jiang et al., 2005; Lynch et al., 2004; Paez
et al., 2004; Pao et al., 2004; Shigematsu and Gazdar,
2006; Sordella et al., 2004). An adjacent leucine residue
(Leu837) is mutated to glutamine in some lung cancer pa-
tients (Shigematsu et al., 2005). These residues are either
partially (Leu834) or completely (Leu837) surface exposed
and do not play an obvious structural role in the active
conformation (Figure 1B). In contrast, the importance of
these two residues is obvious upon consideration of the
Src/CDK-like inactive conformation because both resi-
dues pack against hydrophobic sidechains in the interior
of the kinase domain while buttressing a displaced orien-
tation of a catalytically critical helix in the N-lobe, helix aC
(Figure 1C). Replacement of either leucine by a polar side-
chain is likely to destabilize the Src-like inactive conforma-
tion and thereby activate the kinase domain. Interestingly,
Erlotinib is incompatible with the Src/CDK-like inactive
conformation, which may explain why activating muta-
tions potentiate the effectiveness of the closely related
drug Gefitinib (Lynch et al., 2004; Paez et al., 2004).
In this paper we show that the isolated kinase domain
of EGFR has low basal activity, and that its activity is in-
creased substantially upon replacing Leu834 by arginine.
This demonstrates that the wild-type kinase domain on its
own is indeed in an autoinhibited state, and we wondered
why the original crystal structure of the EGFR kinase do-
main (Stamos et al., 2002) as well as two new structures
we have determined (see below) are in the active confor-
mation. One possibility is that the high protein concentra-
tions used in crystallization (!200 mM) might mimic the
high local concentration of kinase domains that is induced
by receptor dimerization, leading to the formation of an
activated dimer in the crystal lattice. The only available in-
active structure of the EGFR kinase domain (crystal form
B) is likely to be trapped by the bound kinase inhibitor
Lapatinib, which is incompatible with the active structure
seen in crystal form A.
Examination of the crystal lattice of the active form of
the kinase domain reveals two potentially important crys-
tallographic dimers. One is symmetric, with two kinase
domains interacting in a head-to-tail fashion though a
primarily electrostatic interface, as discussed before
(Landau et al., 2004). The second one is an asymmetric
dimer in which one kinase domain interacts with another
in a manner analogous to that of a cyclin with an activated
cyclin-dependent kinase (Jeffrey et al., 1995). We present
Figure 1. Ligand-Induced Dimerization
of EGFR and Active and Inactive States
of Its Kinase Domain
(A) General view of the ligand-induced dimer-
ization and activation process of EGFR. The ki-
nase domain is activated through a previously
unknown mechanism.
(B) Detailed view of the catalytic site of the
EGFR kinase domain in the active conforma-
tion. Leu834 and L837 are surface exposed
and the Lys721/Glu738 ion pair is intact in
this conformation.
(C) Detailed view of the catalytic site in the inac-
tive conformation. Leu834 and L837 pack
against helix aC, preventing the formation of
the Lys721/Glu738 ion pair. The right panel
shows the electron density around residues
834–838 for the V924R kinase domain mutant,
at 3s from a simulated annealing omit map with
coefficients (jFoj " jFcj)eiac, where the calcu-
lated structure factors are generated from
a model that does not contain these residues.
The structures shown in (B) and (C) were deter-
mined in the absence of drugmolecules as part
of this work and are similar to structures deter-
mined previously in complex with the drugs
Erlotinib and Lapatinib, respectively (Stamos
et al., 2002; Wood et al., 2004).
1138 Cell 125, 1137–1149, June 16, 2006 ª2006 Elsevier Inc.
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It is thought that activating EGFR kinase domain mutations induce conformational 
changes that disrupt auto-inhibitory interactions that alter the dimerisation interface and 
would otherwise stabilize the inactive state, thus resulting in a conformation that 
favours transactivation and constitutive kinase activity leading to increased and 
sustained tyrosine residue phosphorylation (Yun, Boggon et al. 2007).  It is also 
apparent that such mutations can interfere with intrinsic disorder, which would also 
favour transactivation (Shan, Eastwood et al. 2012). The L858R mutant EGFR has also 
been shown to possess a greater tendency to dimerisation than WT EGFR. Data from 
the literature suggests that EGFR L858R preferentially forms dimers and higher order 
oligomers than WT EGFR in light scattering and gel electrophoresis assays of 
molecular weight and that dimerisation is a more important consequence of the L858R 
mutation than catalytic potency is on EGFR signaling (Shan, Eastwood et al. 2012). 
Since allosteric interactions between partner EGFR molecules appear to be necessary 
for activation - even in the absence of ligand, this mechanism of asymmetric 
dimerisation may be sufficient for activation (Wang, Longo et al. 2011).  In addition 
EGFR mutations result in differing abilities to dimerise within homodimeric versus 
heterodimeric pairings. This important observation might influence cell phenotype and 
which downstream pathway is activated. For example an EGFR-HER3 pairing versus 
an EGFR-EGFR pairing may preferentially activate AKT/STAT pathways in preference 
to MAPK (Mitsudomi and Yatabe 2010, Littlefield and Jura 2013). 
 
1.5 EGFR Targeted Therapy 
EGFR mutations are important clinically, predominantly as a tool to predict 
responsiveness to treatment (Shan, Eastwood et al. 2012).  Initial study of EGFR 
directed therapy with agents such as the first generation EGFR tyrosine kinase 
inhibitors (TKI) gefitinib or erlotinib, noted a response in as few as 8-15% of 
Caucasians with lung cancer which was as high as 30-40% of Eastern Asian patients. 
These are low molecular weight ATP mimetics that reversibly bind EGFR in a specific 
and competitive manner (Lynch, Bell et al. 2004, Paez, Janne et al. 2004, Suda, 
Onozato et al. 2009).  Young, female, ‘never smokers’ and adenocarcinoma 
classification were identified as clinical features that predict clinical response with 
subsequent identification that such EGFR mutations are enriched in this population 
(Sharma, Bell et al. 2007).  One of the most important observations in EGFR targeted 
therapy was that response rates to these drugs were most striking in patients with the 
presence of an EGFR activating mutation in whom it was thereafter confirmed that 
EGFR TKI are most effective.  For example, del19 or L858R saw responses in up to 
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80% of patients, compared to 10% in those without such mutations (Sharma, Bell et al. 
2007, Gazdar 2009, Mok, Wu et al. 2009). 
 
This increased sensitivity of EGFR mutants to EGFR TKI is likely to result from 
conformational differences arising from these mutations that increase the tendency for 
the receptor to be in the active state to which these EGFR TKI preferentially bind 
(Gazdar 2009).  In addition it appears that significant structural alterations arise as 
result of these mutations at key TKI binding residues, which alters their tendency to 
bind and dissociate in favour of ATP (Carey, Garton et al. 2006, Kumar, Petri et al. 
2008, Rosell, Carcereny et al. 2012).  Four classes of EGFR inhibitors are recognised, 
as defined by their target binding site in the kinase domain that target the active (type I) 
or inactive conformations (type II) and those which inhibit the kinase allosterically (type 
III) or through interference of kinase regulators (type IV) (Muller, Chaikuad et al. 2015). 
 
EGFR targeted therapy is important in a number of other solid tumour types. 
Interestingly, EGFR mutations typical in GBM are extracellular and induce a 
conformation not responsive to gefitinib or erlotinib, but instead by lapatinib, an 
EGFR/HER2 inhibitor that recognizes the inactive kinase conformation (Park, Liu et al. 
2012, Vivanco, Robins et al. 2012).  Here, TKI which recognise the active kinase can 
induce disabled “quasi-dimers”. These dimers differ from ligand-induced dimers in that 
they appear to depend only upon the kinase domain interface rather being held by 
intra- and extra-cellular regions (Bublil, Pines et al. 2010). Again in HNSCC, 
gefitinib/erlotinib are not used – instead a monoclonal antibody inhibitor of EGFR, 
cetuximab is the only FDA approved EGFR targeted therapy (Cassell and Grandis 
2010). A clear role for cetuximab and other monoclonal inhibitors of EGFR (e.g. 
necitumumab) in lung cancer have not been established (Pirker and Filipits 2012) 
(Thatcher, Hirsch et al.).  The multiplicity of EGFR as a target and yet its refractoriness 
to a single therapeutic agent across tumour types provides interesting biological 
insights to its role in different tissue types. 
 
Clinical assays that can identify activating EGFR kinase domain mutations from routine 
clinical biopsies are hence a vital part of the treatment of patients with EGFR targeted 
therapy.  Use of partner tests in this way improves the efficacy and cost effectiveness 
of these costly agents.  Presence of such mutations is an internationally approved 
selection criterion for EGFR TKI and by guiding rationalised therapy by regulatory 
bodies such as National Institute of Clinical Excellence (NICE Guidance TA162 2008). 
Treatment with EGFR TKI in patients with WT EGFR was associated with less 
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favourable prognosis in these trials and hence clinically EGFR TKI are not routinely 
used in these cases, although the evidence remains unclear as to best management of 
such WT patients with regards to TKI (Lee, Hahn et al. 2014). 
 
1.6 Resistance to EGFR TKI 
Despite the rapidly evolving role and potential capability for dramatic clinical responses, 
EGFR TKI as with most HER family targeted therapies are almost universally prone to 
treatment resistance.  A standardised criteria of EGFR TKI resistance requires that a 
patient with an EGFR sensitising mutation or whom has shown benefit from EGFR TKI, 
develops progressive disease during or immediately following such treatment 
(Jackman, Pao et al. 2010). Drug resistance can either be primary i.e. it exists prior to 
starting treatment, arising either through germ-line or somatic mutations or be acquired 
through exposure to treatment.  Acquired resistance to TKI often arises when either 
when a mutated form of EGFR evolves which is no longer sensitive to the EGFR TKI of 
choice – for example through structural alteration of its TKI binding site to preclude 
binding or through changes to the competitive nature of TKI binding versus ATP.   
Another common route of TKI resistance is seen when the tumour escapes 
dependency or ‘addiction’ to the pathway targeted by the TKI in question.  This ‘kinase 
switch’, allows signaling to be sustained via an alternative pathway as can be seen in 
gene amplification of MET, HER2 or MAPK). Alternatively dysregulation of downstream 
signaling (e.g. PIK3CA or BRAF mutations) and transformation to an alternative 
phenotype (e.g. Epithelial-Mesenchymal Transition or conversion to small cell lung 
cancer) are also important (The Cancer Genome Atlas Research 2014, Stewart, Tan et 
al. 2015). See Table 1. 
 
The T790M mutation is the most important mechanism of resistance to first generation 
EGFR TKI (~50%).  This mutation results in increased affinity for ATP relative to EGFR 
TKI hence rendering them ineffective (Yun, Mengwasser et al. 2008)(NICE TA162 
2008). Interestingly T790M has also been reported to increase EGFR activity in vitro 
and has been identified in hereditary lung cancer in TKI naïve patients (Bell, Gore et al. 
2005, Godin-Heymann, Bryant et al. 2007). It is thus plausible that T790M alone or in 
combination with other activating mutations provides a survival advantage in TKI-naïve 
patients. Only recently has this detail of the origin of T790M in the evolution of 
resistance been clarified. Whilst T790M may arise during treatment, T790M positive 
clones have been observed to exist prior to TKI exposure and thus expand upon 
treatment with EGFR TKI therapy. This is of importance as the response to third 
generation EGFR-TKI differs between the two forms and provides evidence that multi-
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target treatment regimes may be required to pre-empt resistance (Maheswaran, 
Sequist et al. 2008, Hata, Niederst et al. 2016).  A number of other EGFR TKI 
resistance mutations have also been observed on exon 20 e.g. D770-N771 (see figure 
1.2) and also exon 19 (D761Y) indicating structural relevance of these residues for 
EGFR TKI binding (Gazdar 2009). 
 
Some of the most convincing evidence for a kinase switch leading to EGFR resistance 
was observed in data that suggested that activation of MET can bypass EGFR 
signaling via HER3 activation in order to sustain downstream PI3K/AKT signaling 
(Engelman, Zejnullahu et al. 2007, Campbell, Amin et al. 2010). The literature that 
associates EGFR TKI resistance with HER family dimer formation is not well 
established, however the HER3 receptor is of considerable importance in breast cancer 
therapy and is implicated in the response to the widely utilized trastuzumab (Herceptin) 
which targets HER2 (ERBB2), another key signaling mediator in this type of cancer 
(Holbro, Beerli et al. 2003, Claus, Patel et al. 2014).  HER2 has also been linked to 
EGFR TKI resistance in lung cancer directly (Takezawa, Pirazzoli et al. 2012). 
 
Another important route of resistance includes phenotypical change for example 
epithelial-mesenchymal transition (EMT) or conversion to Small Cell Lung Cancer.  
This route accounts for resistance EGFR TKI in approximately 10% of patients and the 
original activating EGFR mutation can be detected at the time of the small cell biopsy 
excluding a de novo tumour. These observations have raised interesting questions 
about a possible mutual cell of origin of both cancer types (Oser, Niederst et al. 2015).  
In EMT meanwhile, tumour cells acquire mesenchymal features such as loss of E-
Cadherin, and increased expression of vimentin, fibronectin and N-cadherin, which is 
associated with increased motility and invasiveness (Morgillo, Della Corte et al. 2016). 
 
Table 1. Summary of mechanisms of EGFR TKI resistance 
Mechanism Estimated frequency 
EGFR Target changes (e.g. T790M) 60% 
Small Cell Lung Cancer Conversion 10% 
MET amplification 5-10% 
HER2 amplification 8-13% 
Epithelial-Mesenchymal Transition 1-2% 
Others: BRAF, PI3K 2-3% 
Unknown 15-20% 




It is inevitable that legion other resistance mechanisms are yet to be discovered e.g. 
undetected mutations, chromosomal rearrangements or more complex resistance 
mechanisms (e.g. receptor recycling/degradation, crosstalk) to account for the 
remaining cases of resistance.  Decoding these is of obvious interest as it could 
provide novel avenues to broaden the use of EGFR TKI in the context of relapse.  The 
important role of tumour heterogeneity in resistance is also increasingly recognized 
(Burrell and Swanton 2014, de Bruin, McGranahan et al. 2014). 
 
A major focus of research in this area is now to identify and surpass routes of treatment 
resistance and to better understand the mechanistic features of TKI treatment.  Much 
attention has been placed upon the T790M mutation and hence alternative structural 
approaches to EGFR inhibition. Second-generation EGFR inhibitors that bound EGFR 
irreversibly and thus not susceptible to ATP competition e.g. afatinib were not 
successful in early trials due to dose-limiting toxicity although afatinib remains of 
interest and demonstrated encouraging results in brain metastatic lung cancer. 
Subsequent “third generation” approaches have targeted the mutated sensitized and 
resistant (T790M) forms of EGFR directly e.g. rociletinib and AZD9291 (Cross, Ashton 
et al. 2014, Park, Tan et al. 2016, Schuler, Wu et al. 2016). Although such approaches 
are likely to encounter similar difficulties when further EGFR mutations arise, the 
success of these agents in clinical trials with response rates of up to 60% and 
prolonged control is encouraging and will increase the possibilities for patient fitness for 
further lines of treatment available now and in the development pipeline. Of further 
note, rociletinib was also beneficial in T790M-negative patients highlighting further work 
that is needed in this important area of the literature (Pao and Chmielecki 2010, 
Sequist, Soria et al. 2015, Yu, Tian et al. 2015, Tan, Cho et al. 2016). 
 
1.7 Mesenchymal-Epithelial Transition (MET) Receptor 
Another key player in this network of receptors is MET, a receptor tyrosine kinase 
found on the cell surface, which has seen a growing interest in the lung cancer 
literature.  MET, also known as the Hepatocyte Growth Factor Receptor is encoded by 
a proto-oncogene located on chromosome 7q31 consisting of 21 exons and 120Kb.  
The transcribed peptide is synthesized as a 190KDa glycosylated peptide that is 





Derailment of normal MET signaling is associated with ‘invasive growth’ – a growth 
program important for morphogenesis in early embryonic development (Boccaccio and 
Comoglio 2006). A parallel thus exists between a role for MET in embryogenesis such 
as during formation of the gastrula, where separation of the endoderm, mesoderm and 
ectoderm requires cell motility and branching and a similar invasiveness of cancer cells 
at the tumour front. Sacrifice of proliferative behaviour of tumour cells in favour of 
acquisition of properties that can facilitate cell migration and invasion is known as 
Epithelial Mesenchyme Transition’ (EMT) – a process with which MET is well 
associated (Boccaccio and Comoglio 2006). 
 
HGF, the cognate ligand of MET, also known as scatter factor, stimulates a number of 
cellular processes leading to growth, motility and invasion.  HGF is secreted from cells 
derived from a mesenchymal origin including stroma, fibroblasts and monocytes, 
reinforcing the importance of MET in the interaction of the tumour with the 
microenvironment.  HGF has also been shown to induce EGFR resistance highlighting 
how this ligand of MET could tie together the MET signaling pathway with EGFR 
(Yano, Wang et al. 2008). 
 
Like EGFR, MET is thought to become activated by dimerisation. The stoichiometry of 
this reaction in relation to HGF is not well understood but is thought to involve a seven-
bladed propeller structure known as the Sema domain to which HGF binds. The Sema 
domain would then be responsible for mediating receptor cross-linking and thereafter 
activation (Gherardi, Youles et al. 2003, Wickramasinghe and Kong-Beltran 2005). 
Whilst this region is critical for ligand binding it may also allow ligand-independent MET 
activation in the context of MET amplification (Kong-Beltran, Stamos et al.). The 
juxtamembrane region of MET is also of importance in regulation of catalytic function, 
as with HER family proteins, mutations in this region result in altered cell morphology, 
proliferation and motility in small cell lung cancer cell (Ma, Kijima et al. 2003).  
Mutations affecting these Sema and juxtamembrane regions have been detected in 
lung cancer specimens although have not yet been translated into the context of 
biomarker trials or partner therapeutics (Ma, Jagadeeswaran et al. 2005). 
 
The evidence for a potential clinical role of MET in lung cancer is strong.  MET has 
been linked to tumorigenesis, propensity to metastasis and poor outcomes in a number 
of solid cancers (Gelsomino, Facchinetti et al. 2014).  MET is also widely 
overexpressed in lung cancer cell lines and clinical specimens.  A number of studies 
have reported MET overexpression by immunohistochemistry in particular at the 
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tumour front.  Strong MET staining by immunohistochemistry correlates to earlier 
progression and increased expression of MET is also seen in brain metastases and as 
already discussed is an important resistance mechanism to EGFR TKI (Ma, 
Jagadeeswaran et al. 2005, Zucali, Ruiz et al. 2008, Benedettini, Sholl et al. 2010). 
 
1.8 MET Biomarkers 
According to the literature, MET is frequently overexpressed in lung cancer, but assays 
of protein expression haven’t been translatable into clinical assays. MET amplification 
is currently viewed as being the most suitable clinical biomarkers of MET activity in 
NSCLC.  This can be measured using real-time polymerase chain reaction (RT-PCR), 
comparative genomic hybridization or fluorescence in situ hybridization (FISH). FISH is 
one of the most widely employed approaches, because of reliability, selective 
measurement of tumour cells (rather than stroma) and its suitability to be applied to 
archival formalin-fixed paraffin embedded (FFPE) tissue as is routine for clinical 
specimens (Go, Jeon et al. 2010). Two criteria are recognized, the Cappuzzo scoring 
system sets a threshold of 5 copies to define amplification whilst the University of 
Colorado Cancer Center (UCCC) considers MET copy number as a ratio against a 
control locus on the same chromosome e.g. Cep7. Because copy number can be 
increased in isolation but not meet these criteria, later clinical studies have favoured a 
definition based on copy number ratio (Bean, Brennan et al. 2007, Okuda, Sasaki et al. 
2008, Cappuzzo, Janne et al. 2009, Go, Jeon et al. 2010).  
 
MET amplification predicts poor survival and has been associated with a higher 
incidence of metastatic disease with increased MET copy number observed in 
intracranial metastatic tumours (Bean, Brennan et al. 2007, Benedettini, Sholl et al. 
2010).  Mutations are also recognized in MET, most in relation to exon 14.  These may 
be more frequent in an older population and moreso in smokers than with EGFR 
(Awad, Oxnard et al. 2016). Whilst such MET mutations have been shown to induce 
tumorigenesis, they are in comparison rarer events in clinical series and their 
significance prognostically and how they relate to MET amplification remains poorly 
defined (Cancer Genome Atlas Research 2014, Awad, Oxnard et al. 2016). 
Interestingly none of the patients in the aforementioned series had EGFR mutations 
unlike MET amplification which is implicated in up to 20% of patients with acquired 
resistance to EGFR TKI (Bean, Brennan et al. 2007, Tanaka, Sueoka-Aragane et al. 
2012). Clinically these indices are of greatest potential interest in the context of 




1.9 MET Targeted Therapy 
Therapeutic agents targeted at MET are broadly divided into three groups (Gherardi, 
Birchmeier et al. 2012): 1) Small molecule kinase inhibitors such as crizotinib and 
tivantinib (ARQ197); 2) Antibody based approaches which interrupt HGF binding at the 
MET extracellular domain for example onartuzumab (METMab). 3) Other agents which 
specifically target HGF. MET inhibitors have been validated experimentally in a number 
of in vitro and in vivo models of extra-thoracic cancer, including primary brain 
malignancies (Guessous, Zhang et al. 2010), gastric cancer (Kawakami, Okamoto et 
al. 2013, Wiehr, von Ahsen et al. 2013), triple negative breast cancer (Sohn, Liu et al. 
2014), ovarian cancer (Zillhardt, Christensen et al. 2010), and hepatocellular carcinoma 
(Steinway, Dang et al. 2015). 
 
Inhibition of MET alone or synergistic blockade with EGFR has been demonstrated 
within such systems representing thoracic malignancy (Tang, Du et al. 2008, Zhang, 
Staal et al. 2010, Xu, Kikuchi et al. 2012).  Preclinical models of MET therapy in lung 
cancer include use of the small molecule inhibitor crizotinib which can overcome 
HGF/MET-mediated EGFR-TKI resistance in a number of NSCLC cell lines including 
H1975, HCC827 and PC-9 cell lines (Chen, Zhou et al. 2013).  Similar studies have 
confirmed this in vitro effect with tivantinib (ARQ197)(Fong, Jacobs et al. 2013), PHA-
665752 (Christensen, Schreck et al. 2003) and also the multi-kinase agents sunitinib 
and cabozantinib (Gridelli, Maione et al. 2007, Yakes, Chen et al. 2011). Similarly 
monoclonal antibody approaches such as onartuzumab (METMab) to block MET 
receptor signaling through impaired HGF binding, have also been validated in vitro 
(Surati, Patel et al. 2011, Ekert, Johnson et al. 2014, Vigna and Comoglio 2014). 
In patients, data on sole treatment with MET inhibition is limited to early phase trials but 
include the use of crizotinib in tumours with MET amplification or exon 14 skipping 
which suggest crizotinib could be more effective in such cases but again a clear 
subgroup which derives benefit has not been defined (Camidge, Ou et al. 2014, Paik, 
Drilon et al. 2015, Vassal, Ledeley et al. 2015). Despite the pre-clinical data suggesting 
that combination (EGFR and MET) treatment could be beneficial against tumour 
growth, efficacy of dual treatment with such combined regimes have not been 
reproduced clinically (Zhang, Staal et al. 2013).  Even the most advanced agents in 
development, onartuzumab (‘METMab’) – a MET neutralizing antibody which prevents 
HGF binding to MET in proximity to the Sema domain (Merchant, Ma et al. 2013); and 
tivantinib (ARQ197) - a small molecule inhibitor of MET which manipulates kinase 
conformation to prevent kinase activation, have failed in phase III clinical trials which 
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have included EGFR-TKI combinations (Gelsomino, Facchinetti et al. 2014, Pérol 
2014, Scagliotti, von Pawel et al. 2015) 
 
There is good evidence for interaction between EGFR and MET that support a 
combined approach: Both have been shown to be co-expressed in lung cancer cell 
lines (Tang, Du et al. 2008); crosstalk has also been observed between EGFR and 
MET signaling pathways in addition to direct co-immunoprecipitation between this two 
receptors (Jo, Stolz et al. 2000, Tang, Du et al. 2008, Wang, Li et al. 2010). There does 
hence remain hope that as with similar attempts to harness the EGFR pathway, an un-
identified opportunity to isolate subgroups of patients who can benefit from this 
approach awaits discovery, perhaps through personalized (patient-specific), 
combination treatment dictated by an individual tumour interactome (Chmielecki and 
Pao 2010).  Further themes of uncertainty in the literature include the relevance of MET 
inhibition in T790M-mediated resistance, and the role of MET inhibition in EGFR-driven 
lung cancers in patients not already exposed to EGFR-TKI (Pérol 2014). Any potential 
progress with this agents will require more accurate patient selection and mechanistic 
understanding, as was the case for EGFR targeted therapy prior to the elucidation of 
the mutations now widely employed in clinical practice (Lynch, Bell et al. 2004).  
 
1.10 FRET-FLIM Imaging to Understand Receptor Crosstalk 
An evolving theme in the literature is that our understanding of tumour biology needs to 
move on from assays based on single mutations that represent a tumour “on” or “off” 
signal to a deeper understanding of tumour behaviour based on molecular signaling, 
crosstalk and epigenetic dysregulation of malignant cells.  This thesis describes use of 
a comparatively new technology known as Forster Resonance Energy Transfer (FRET) 
to better understand the interaction between EGFR and MET. By using nano-proximity 
microscopy platforms such as Fluorescence Life Time Imaging (FLIM) to image 
protein-protein interactions at the subcellular level it is possible to measure FRET to 





Figure 1.4 Jablonski demonstrating principle of FRET-FLIM. 
The excitation of a donor fluorophore raises an electron to a higher energy state (blue 
arrow). Fluorescence decay of this unstable results in emission of photon of a longer 
wavelength and with less energy. When in close proximity to an appropriate acceptor, 
energy is transferred from the donor to the acceptor (FRET – Førster Resonance 
Energy Transfer). The donor lifetime (tau) becomes shorter which can be compared in 
the presence and absence of an acceptor fluorophore to derive FRET efficiency which 
is proportional to molecular proximity. Adapted from Hochreiter et al 2015 (Hochreiter, 
Garcia et al. 2015). 
 
Fluorophores are used as labelling tools in various biological applications.  The 
fluorescence group within a fluorophore, once excited, emits light at a longer 
wavelength as it returns to its ground state.  Each fluorophore has a specific lifetime 
within which it remains within the excited state.  Fluorescence lifetime (tau) of a donor 
fluorophore will be reduced in the immediate presence of an excess of a spectrally 
related acceptor fluorophore.  FRET describes this energy transfer observed when two 
fluorophores are within nanometre proximity. By directly conjugating two such 
fluorophores (e.g. Alexa 546 and cyanine 5) to antibodies against proteins of interest, 
an assay can be constructed to monitor interaction between two such proteins in 
various biological conditions by quantifying FRET efficiency which is inversely 
proportional to the distance, R between the molecules according to the formula 
(Lakowicz 2013): 
 
FRETefficiency =1/ [1 + (R/R0)6] 
 
Receptors such as the HER family which undergo dimerisation are well suited to such 
technologies since one partner from each pair can be targeted by a labelled antibody. 
FRET FLIM has thus been employed to quantify the relationship between HER2-HER3 
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and other HER family dimer pairs with regards to the basic biology of these receptors, 
their role in resistance and as a biomarker of treatment response (Patel, Kiuchi et al. 
2011).  EGFR related interactions have been explored but to the best of our knowledge 
there have been no such reports of the ability to explore EGFR and MET interaction by 
this means. An assay based on such an interaction would be well positioned to explore 
the effects of mutations that determine TKI sensitivity and resistance and enable us to 
observe at a molecular level the effect of targeted drugs in an in vitro, and in vivo 






The aim of this project is to better understand the mechanisms that underlie resistance 
to EGFR TKI with specific consideration of the putative role of MET activation and how 
we might use MET inhibitors as a means to overcome such resistance.  This work 
explores EGFR and MET crosstalk using derivatives of NCI-H1975 lung 
adenocarcinoma cells established in the laboratory that recapitulate EGFR-TKI 
treatment groups based on the presence or absence of the L858R and T790M 
mutations.  This project investigates the consequence of these mutations for lung 
adenocarcinoma with the hypothesis that EGFR mutation status could influence the 
crosstalk between EGFR and MET and the efficiency of MET inhibition therapy. 
 
Finally, this work develops a novel FRET-FLIM approach to quantify the EGFR-MET 
interaction and explore how such an assay could be predictive of response to MET 
inhibition.  Based on these studies we believe that imaging and quantification of EGFR-
MET interaction at the membrane may act as biomarker to select for and predict 
responses to drugs targeting MET in lung cancer. 
 
1.12 Main scientific objectives: 
 
1. To establish and characterise in vitro and in vivo, lung cancer models based on 
NCI-H1975 to represent the mutational phenotypes of EGFR (EGFR mutated: 
activating and resistance mutations and wild-type). 
2. To determine the role of hetero-dimerisation of EGFR and MET using 
FLIM/FRET imaging within this cell model and in excised tissues from an 
immuno-deficient xenograft mouse model. 
3. To quantify the effect of MET inhibition in the EGFR-MET crosstalk and in the 









Chapter 2. Materials and Methods 
2.1 Cell Lines 
NCI-H1975 lung adenocarcinoma cells were purchased from ATCC. HEK293T and 
MCF-7 cells were a kind gift from Tony Ng. All cell lines were cultured at 37°C in a 
humidified incubator in 5% CO2.  H1975 lung adenocarcinoma cells were cultured in 
RPMI-1640 (Invitrogen) and Phoenix Ampho HEK293T cells and MCF-7 cells were 
maintained in Dulbecco´s modified Eagle medium (Invitrogen). All medium was 
supplemented with 10% Fetal Bovine Serum (FBS), penicillin/streptomycin and L-
Glutamine (Gibco). For serum-starved conditions, FBS was omitted or cells were 
cultured in Optimem (Invitrogen). The H1975L858R and H1975WT cells were previously 
established in the lab. Briefly, a GFP tagged short hairpin (shRNA) against EGFR 
obtained from Sigma (siMission) was used to produce lentiviral particles in HEK293T 
cells.  After transduction, stable cells expressing shEGFR-GFP were selected with 
puromycin (1.5 µg/ml) for 5 days. After selection, a pcDNA3 construct containing WT 
EGFR or L858R EGFR was transfected in the cells with Fugene HD (Roche) following 
manufacturer’s instructions. Selection was performed for 5 days with G418 (50 µg/ml).  
Ongoing culture of H1975L858R and H1975WT cells was in the presence of G418 (50 
µg/ml) and puromycin (1.5 µg/ml). 
 
2.2 Transfections 
Plasmids encoding EGFR and MET were a kind gift from Tai Kiuchi and Peter Parker 
respectively.  For overexpression assays, transient transfections were performed 
according to the manufacturers’ instructions with Fugene6 for MCF-7 cells and 
FugeneHD for H1975 or H1975 derived cells (Promega). Briefly cells were allowed to 
grow for 24 hours. 0.6 micrograms of each plasmid DNA per well was used for 24 well 
plates and 2.5 micrograms per 60mm dish and incubated with Optimem/FuGene at RT 
for 30minutes. The Optimem/DNA/FuGene mix was then added to cells and incubated 
for 24-48hours. 
 
2.3 Cell Pellets 
Pellets were prepared from MCF-7 cells with or without MET overexpression by 
amplifying cells to confluence in 2 x T175 plates per cell line.  These were then 
decanted into 3 x 60mm dishes for transfection. The next day, FFPE cell blocks were 
prepared for testing antibody specificity in FFPE tissue. This was performed in the St 
Thomas’ Hospital Cytopathology laboratory for consistency with standard clinical 
methods. Briefly, cells were transferred into a 50ml centrifuge tube and spun down for 
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5 minutes at 200g to form a pellet. Supernatant was then aspirated off, and the cell 
pellet covered in plasma followed by thrombin to form a thrombus encapsulating the 
cells.  The pellet was then carefully removed from the Falcon and placed in filter paper 
folded to fit inside a biopsy cassette with a lid and placed in formalin. This was 
processed overnight, as standard, through a dehydrating alcohols-xylene gradient, 
followed by embedding in molten paraffin wax. 
 
2.4 Antibodies 
2.4.1 Primary Antibodies: 
The table describes a list of primary antibodies used for various applications. 
Table 2. Summary of primary antibodies. 
Target Source Use 
Phospho-EGFR (Y1173 53A5) Cell signaling WB 
total EGFR (Ab-15) 
(Ab-5 clone H11) 
Thermo Scientific IF/FRET 
total EGFR (038B1) Cell signaling WB 
Total EGFR (SC120) Santa Cruz IP 
Total EGFR (Ab-5) Millipore FRET 
Phospho-MET (Y1234 D26) 
(y1234/1235) 
Cell signaling WB 
Phospho-MET  AbCAM IHC 
Total MET (D1C2) 
(25H2 & D1C2) 
Cell signaling WB/FRET 
Total MET (AF276) R+D systems IF 
BrdU  Abcam IF 
hsc70 (SC7298) Santa Cruz WB 
GAPDH (6C5) Genetex WB 
Phospho-histone H3 Millipore IHC 
Smooth muscle actin (SMA) Anaspec IHC 
CD31 Abcam IHC 
Phosphor-AKT Cell signaling WB 
Total AKT Cell signaling WB 
Phospho ERK Cell signaling WB 
Total ERK Cell signaling WB 
Phospho FAK Cell signaling WB 
FAK Cell signaling WB 
Abbreviations in table: WB – Western Blotting; IHC – Immunohistochemistry; IF 




2.4.2 Secondary Antibodies: 
For immunohistochemistry, peroxidase-conjugated (Envision+) anti-rabbit and anti-
mouse immunoglobulin reagents from Dako were used for 1h. 
For Western Blotting, we used Anti-Mouse or Anti-Rabbit, immunoglobulin/HRP (Dako) 
For Immunofluorescence, we used Anti-Mouse or Anti-Rabbit, Alexa Fluor 488, 568 or 
647 (Life technologies). 
 
2.5 Antibody Labelling 
For FRET, donor antibodies were kindly labelled by Dr Gregory Weitsman. Alexa Fluor 
546 was used for donor antibodies and Cyanine 5 dyes (GE Healthcare) for acceptors, 
both prepared in N,N-Dimethylformamide according to the manufacturers instructions. 
The antibody of interest and dye were combined in a Bicine buffer (pH 8.6, 1M) and 
size-exclusion chromatography used to remove excess dye (ZebaTM Spin Desalting 
microcolumns, Thermo Scientific). A 10µl aliquot of the labelled antibody was used to 
determine labelling reaction: Absorption was measured at 280nm and 558nm for Alexa 
546 and 280nm and 650 nm for Cy5 with the following formulas used to generate the 
dye:protein ratios (see table): 
 
(Alexa 546 D/P) = [1.64 (A558) ] / [A280 – (0.12 x A558)]. 
(Cy5 D/P) = [0.68 (A650) ] / [A280 – (0.05 x A650)] 
 
Target dye:protein was aimed for 3:1 for acceptor fluorophore (Cy5)-labelled protein, 
and 1:1 for donor fluorophore (Alexa 546). 
 
Table 3. Directly labelled antibodies employed in FRET-FLIM imaging 
Target Clone Manufacturer Dye D:P Concentration Use IC/EC 
EGFR Ab-5 Millipore x546 0.9 0.25mcg/ml in vitro EC 
MET AF276 R+D cy5 5.4 10mcg/ml in vitro EC 
EGFR Ab-15 Thermo Scientific x546 0.9 0.5mcg/ml in vivo IC 
EGFR Ab-15 Thermo Scientific cy5 3.5 10mcg/ml in vivo IC 
MET D1C2 Cell signaling x546 0.8 0.5mcg/ml in vivo IC 
MET D1C2 Cell signaling cy5 2.6 10mcg/ml in vivo IC 





2.6 Ligands and Drugs 
Recombinant Human Epidermal Growth Factor (EGF) and recombinant Human Growth 
Factor (HGF) were purchased from Peprotech.  For ligand dependent assays, cells 
were starved overnight in growth factor deficient medium and either left unstimulated or 
exposed to EGF (100ng/ml) and/or HGF (25ng/ml) for 15 minutes or 15, 30 and 60 
minutes in ligand time-course experiments. 
 
SGX523 was purchased from Selleck and solubilised in 100% dimethyl sulfoxide 
(DMSO) and used at 5uM. In the xenograft experiment SGX523 was administered by 
gavage at 60 mg/kg of SGX523 (equilibrated suspensions in 0.5% Methocell A4M). 
Erlotinib was purchased from Cayman chemicals and reconstituted in DMSO for use at 
10uM. For in vitro work drugs were added to culture medium at greater than 12 hours 
before cell lysis or fixation. 
 
2.7 Immunoblotting 
Cells were lysed in in 120uL of sample lysis buffer: TrisHCl (pH6.8), SDS (2.5%), DTT 
(1:40), bromophenol blue (0.02%).  Proteins were separated by Sodium Dodecyl 
Sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE).  A stacking gel (5%) was 
used for sample loading (see Table). 1.5mm Gels were used with 10 or 15 lanes.  
SDS-PAGE was with 8% or 10% gels (see Table) in Tris-Glycine SDS running Buffer 
(Life Technologies).  Samples were electrophoresed at 100V until the running front had 
crossed the stacking gel and then at 160V for approximately 60-90 minutes or 
complete resolution.  Separated gels were transferred to nitrocellulose membranes 
(Bio-Rad) in Tris-Glycine Transfer Buffer (Life Technologies) with 10% Methanol at 40V 
for 90minutes. Membranes were blocked in 5% BSA in 0.1% TBS TWEEN and then 
exposed overnight in primary antibody (see table 1) in 5% BSA solution.  Membranes 
were washed and exposed in secondary HRP conjugated antibodies before developing 
with the ECL/ECL2 blotting system on a Biorad ‘bioanalyser’.  
 
Protein extracts from xenograft tumours was obtained by mechanically homogenizing 
tumour material as follows. Xenograft tumours were snap-frozen in liquid nitrogen and 
thawed on the day of tissue homogenisation. RIPA buffer (50mM Trish-Hcl pH 7.4, 1% 
NP-40, 0.1% SDS, 150mM NaCl, 2mM EDTA, 50mM NaF. 0.5% Na-deoxycholate, with 
protease inhibitor cocktail) was prepared as a homogenisation buffer. Tissue 
homogenisation was then performed using a "Bullet blender" (Next Advance) with 
zirconium silicate beads (1.0 mm diameter) at half of the volume as the tissue with two 
volumes of homogenisation buffer (90 sec blending at room temperature). 
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Supernatants were taken off, centrifuged at 13,000g and the resulting supernatants 
were used for further analysis. 
 
Table 4. Running Gels 
Stock solutions 8% 10% 
 (ml) (ml) 
H2O 23.2 19.8 
30% Acrylamide mix 13.3 16.7 
1.5M Tris (pH8.8) 12.5 12.5 
10% SDS 0.5 0.5 
10% Ammonium persulfate 0.5 0.5 
TEMED 0.03 0.02 
Loading gel recipe with appropriate volumes for 4 gels of 1.5mm (50ml). 
 
 
Table 5. Stacking gels 




30% Acrylamide mix 1.3 
1M Tris (pH6.8) 1 
10% SDS 0.08 
10% Ammonium persulfate 0.08 
TEMED 0.08 
Stacking gel recipe with approprirate volumes for 4 gels (1.5mm), TEMED- 
Tetramethylethylenediamine , H2O-Water, SDS- Sodium Dodecyl Sulphate 
 
2.8 Immunoprecipitation 
Cells were grown to 80% confluence then lysed in IP lysis buffer (50mM Tris-HCl pH 
7.4, 150mM NaCl, 1mM EDTA, 1mM EGTA, 10% glycerol, 1% Triton X-100, 10mM 
NaF, 1mM Na3VO4, 10mM N-ethylmaleimide, 0.01µM Calyculin A) with Protease 
inhibitor cocktail set I (Roche).  Samples were scraped on ice with a cell-scraper and 
centrifuged to remove cellular debris.  Cell lysates were pre-cleared with Protein A/G 
beads for 30 minutes at 4oC (Alpha Diagnostic international) then centrifuged to 
remove the beads. Pre-cleared samples were then incubated overnight at 4oC with 
gentle shaking in the presence of anti-EGFR antibody (Santa Cruz) or irrelevant mouse 
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IgG before finally adding washed Protein A/G beads for 1 hour (Alpha Diagnostic 
International Inc.). Beads and complexes were washed in IP buffer then Immune 
complexes were collected by heat dissociation (95oC for 10 minutes) in sample buffer 
(1X as above) and beads discarded by centrifugation.  After centrifugation, the 
immunoprecipitates were washed and subjected to SDS-PAGE and run on WB as 
described above. 
 
2.9 Immunofluorescence and confocal microscopy 
Cells were plated on glass coverslips at 50-60% confluence and incubated in normal 
growth medium for 24 hours.  Cells were then either received fresh medium or were 
starved overnight in serum-free medium for ligand stimulation experiments.  Cells were 
washed with Phosphate Buffered Saline (PBS) and fixed in 4% Paraformaldehyde 
(PFA) in PBS for 15 minutes at room temperature (RT).  Permeabilisation was 
performed with Triton-100 (0.2%) for 10 minutes at RT. Cells were blocked in 1% BSA 
TBS and stained with primary antibody diluted in blocking buffer overnight at 4C.  For 
secondary antibodies, dilutions were made in TBS and applied in the dark for 1 hour at 
room temperature.  Coverslips were mounted on microscope slides with FluorSave 
Reagent (Calbiochem).  Cells were imaged using the LSM 510 META confocal laser-
scanning microscope (Carls Zeiss, Germany), equipped with 63x plan-APOCHROMAT 




FFPE tissue was cut in 3-5mm sections and mounted onto glass slides.  On the day of 
staining, slides were baked at 60°C for 2 hours and rehydrated through a xylene to 
ethanol gradient.  Antigen retrieval was performed in citrate buffer (0.1M, pH 6) at 120 
ºC for 10 min.  Slides were allowed to cool, washed in TBS then blocked in hydrogen 
peroxide (3%) followed by blocking in TBS-Tween 0.1% + 1% BSA + 1% FBS. Primary 
antibodies were added overnight at 4ºC. As secondary antibodies, peroxidase-
conjugated (Envision+) anti-rabbit and anti-mouse Ig reagents from Dako were used for 
1h. Non-immune (Santa Cruz Biotechnology) or pre-immune rabbit serum was used as 
negative controls. Reactions were developed using diaminobenzidine (DAB) as 
chromogenic substrate. 
 
Specimens were then dehydrated through an ethanol to xylene gradient before 
mounting in DPX mountant (Sigma-Aldrich) and allowed to set before imaging. Images 
from digitalized scans of the glass slide specimens were obtained at magnification 20 
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(0.45 m/pixel resolution) using a Hamamatsu Nanozoomer 2.0 HT. All quantifications 
were done using Image J. Alternatively, for direct staining of tissue we used either 
Haematoxylin and Eosin stain or Masson’s trichrome stain.  Collagen staining was 
reviewed and validated by a histopathologist. 
 
2.11 Cell Proliferation Assay 
Cell proliferation was determined by a 5’-Bromodeoxyuridine (BrdU) based cell 
proliferation assay. Cells were plated to 70% confluence on coverslips in a 24-well 
plate and incubated at 37C in the presence of BrdU (Abcam) for 3 hours.  Coverslips 
were then prepared for immunofluorescence staining as described above with an 
added 15 minute DNA denaturation step using 1.5M Hydrochloric Acid (HCl).  Anti-
BrdU primary antibody was applied for 2 hours (1:150), followed by Alexa-546 
conjugated mouse secondary.  Nuclei were counterstained with Hoechst.  Images were 
obtained LSM510 microscope (Carl Zeiss) and quantified in ImageJ using a macro to 
automate cell counting for red versus blue nuclei.  At least 5 fields per condition were 
obtained at 20X objective. 
 
2.12 Random Cell migration assays 
Cells were plated to 20% confluence in 6 well plates in the presence or absence of 
SGX523 and incubated overnight in a time-lapse microscopy chamber set at 37C in the 
presence of HEPES.  18 hours of images were recorded every 10 minutes and tracked 
for migration in ImageJ using Cell tracker.  Quantification of random migration velocity 
of cells was made ± response to pre-treatment with SGX523 and analysed by 
Mathematica notebook. 
 
2.13 Soft-agar growth assay 
Anchorage-independent growth was evaluated using soft agar embedded colonies. 
1x104 cells were plated in complete DMEM containing 0.3% soft agar in 6-cm plates 
over a solidified DMEM containing 0.7% soft agar layer. Medium was added twice a 
week to maintain humidity. After 5 weeks, colonies were stained with MTT (0.5 mg/ml) 
for 3 hours at 37ºC and imaged by confocal microscopy and colonies counted in 
ImageJ. The assay was repeated in the presence or absence of SGX523. 
 
2.14 Wound healing assay 
H1975 ± shEGFR L858R/WT cells were plated to confluence in wells of a 6 well plate 
and a horizontal wound made through the middle of wells using a micropipette.  Images 
were obtained by bright field microscopy with a field of view aligned to the wound 
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centre at equal distances across the wound. Wound closure was calculated by imaging 
wounds a 0, 2, 8, 20 and 28 hours and calculating % closure with ImageJ. 
 
2.15 Fluorescence in situ hybridization (FISH) 
Cells were plated on coverslips and fixed with Carnoy’s fixative (3:1 methanol to acetic 
acid). After washing with PBS, incubation with the MET/cep7 FISH probe was 
performed for 16 hours at 36oC after a 5minute denaturation at 72°C. The coverslips 
were washed in 0.4xSSC at 72°C for 5 minutes, followed by 2 minutes in 
4xSSC/Tween and two rounds of 2 minutes in PBS at room temperature. The 
coverslips were then mounted onto slides with DAPI counterstain and analysed using a 
fluorescence microscope. 
 
2.16 Digital Droplet PCR 
Cells were plated for confluence and DNA extracted from cells using a DNeasy Blood 
and Tissue Kit (Qiagen) according to manufacturers protocol.  Digital Droplet PCR was 
performed using reference primers/probe sets validated on the Bio-Rad QX100 
mdPCR system (Bio-Rad) using commercially available reference standards (Pinheiro, 
Coleman et al. 2012).  Data was analysed using Quantasoft (Bio-Rad) software. 
Droplets were scored as positive or negative based on relative fluorescence intensity in 
FAM or VIC/HEX channels. 
 
2.17 Generation of xenograft model 
All animal work was conducted in accordance with institutional guidelines.  
H1975L858R/T790M, H1975L858R and H1975WT cell lines (3x106) were injected 
subcutaneously into the two posterior flanks of BALB/c nude mice (Charles River 
Laboratories).  For each cell line, 16 female 5 weeks old mice were used. Mice were 
followed weekly and tumours allowed growing for 13 days after injection. Tumours 
were measured with a calliper in long and short axes recorded three times per week.  
Tumour volume was determined by the formula 4 x A x B2 (A, long axis, B short axis). 
At day 14th after injection mice were divided randomly in two groups (6 animals/group) 
and vehicle or SGX523 (drug treatment) was started. 60 mg/kg of SGX523 
(equilibrated suspensions in 0.5% Methocell A4M) was administered for 12 days, daily, 
by oral gavage.    Mice were culled on either day 1 or day 12 of treatment using CO2 to 
give short or long treatment groups and tumours were removed aseptically with 
dissecting scissors and weighed.  Tumours were immediately subjected to either 
freezing in liquid nitrogen or formalin fixation and dehydration for embedding in a FFPE 
block for later staining. 
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All animals were maintained under specific pathogen-free conditions and handled in 
accordance with the Institutional Committees on Animal Welfare of the UK Home Office 
(The Home Office Animals Scientific Procedures Act, 1986). All animal experiments 
were approved by the Ethical Review Process Committee at King’s College London 
and carried out under license from the Home Office, UK.  The protocol used followed 
the Arrive Guidelines. A time-line diagram of the experiment can be found in Chapter 4, 
Figure 4.9. 
 
2.18 Single Photon Lifetime Imaging 
Coverslips or FFPE tissue were prepared as described as above for 
immunofluorescence except for modification of the antigen retrieval process for FFPE 
tissue being performed overnight in a water bath at 65ºC in Antigen retrieval buffer 
provided by Dr Weitsman (Unpublished) and with the added step of quenching of 
autofluorescence by 15 minute immersion in sodium borohydride (1mg/ml).  Donor 
antibodies were directly labelled with Alexa-Fluor 546 and acceptors with Cyanine 5 
respectively, as described below. Antibody specificity was confirmed in cells expressing 
EGFR or MET constructs respectively. 
 
For in vitro experiments, two cover slips were prepared for each experimental condition 
– the first (“Donor alone”) was stained for EGFR alone using an Alexa Fluor 546-
conjugated mAb to EGFR (Ab-5, Thermo Scientific) whilst the next (“Donor + 
Acceptor”) for EGFR and additionally MET (recognized by a Cy5-conjugated 
monoclonal antibody to MET (AF276, R+D).  For FFPE samples from the xenograft 
and human experiments two slides were prepared, the first (“Donor alone”) with EGFR 
alone but now using EGFR (Ab-15)-Alexa546 and the second (“Donor + Acceptor”) 
using in addition to EGFR, MET (D1C2)-Cyanine 5. Please see earlier paragraph 
describing Antibodies and labelling.  The reverse pair MET (D1C2)-Alexa546 with 
EGFR (Ab-15)-Cy5 was tested as discussed in Chapter 4, but was not optimized 
further. 
 
Samples were imaged on a custom-built open automated single photon microscope 
(Galileo) as previously published (Barber, Tullis et al. 2014), with a 20X air objective 
(Nikon) and a CCD camera.  A 553nm Fianium Laser provides fluorescence excitation 
(BDL-473_SMC, Becker and Hickl) in the form of optical pulses of 40ps at 40MHz.  
FLIM was performed using a PMT detector (PMH-100, Becker and Hickl) and time-
correlated single-photon counting (TCSPC) electronics (SPC830, Becker & Hickl).  
Single photon, time-resolved fluorescence is detected at 593±10nm using a 
45 
 
photomultiplier tube (PMH-100, Becker and Hickl) with a 200ps time resolution and 20x 
(NA0.75) objective. This system is automated with a motorized microscope stage 
(Märzhauser GmbH, Wetzler, Germany), closed-loop objective lens mount with a 
500µm range of travel (Piezosystem Jena GmbH, Jena, Germany) and a motorized 
filter cube selector. 
 
Points for each coverslip or slide were defined manually, logging x,y,z coordinates 
which were then used for imaging the automation facility. Points were focused using 
the high precision (auto-focus in 0.2µm lateral resolution) computer-controlled objective 
stage (Piezo-system). Imaging was then performed sequentially in the Cy3 cube for 
Alexa-546 detection and the Cy5 cube for Cyanine 5 staining. Epifluorescence images 
were saved for each point in both channels and then the microscope switched 
automatically to laser-scanning mode to acquire the single photon data and save time-
resolved images. FLIM images have 256 x 256 pixel resolutions and ADC was set to 
64 time channels. 
 
FRET Analysis was performed in the Tri2 software written by Dr Barber which allows 
exponential fitting for time resolved analysis based on the Levenburg-Marquardt 
algorithm with instrumental response iterative reconvolution capabilities 
(http://users.ox.ac.uk/~raob0009/software.html). This program outputs files with fitting 
parameters for each images pixel into Excel format including a distribution of lifetime, 
and an average lifetime, from which FRET efficiency can be calculated using the 
following equation: 
FRET efficiency = 1 – τ (donor + acceptor)/τ(donor), 
 
Here, τ(tau) is the fluorescence lifetime of the donor fluorophore, in the presence or 
absence of acceptor. All in vitro data was fitted with a single exponential decay 
analysis. To analyse FRET in tissue xenografts samples, batch analysis of tri-
exponential data fitting was performed followed by application of dedicated algorithm 








2.19 Statistical Analysis 
Statistical differences were determined by student T test for parametric data, with 
ANOVA comparison for more than two groups. Probability of P<0.05 was considered 
significant.  Graphs and statistics were prepared in GraphPad Prism or Microsoft Excel.  
Where possible, three or more consistent replicates (N=3) were performed for each 
experiment.  This is shown in each figure.  In experiments where optimization steps 
were consistent with the final result, N is shown accordingly. Averages of multiple 
experiments are shown with the standard error of the mean (SEM). Where plots of a 
single experiment were clearer, Standard deviation (SD) is used and labelled 
accordingly. 
 
In the case of the xenograft experiment there were a total of 48 mice divided between 
the three mutant cell lines (see Chapter 4, Figure 4.9). In the treatment part of the 
experiment, culling was divided between day 1 and 12 to enable comparison between 
short and long groups (N=8 tumours). In the case of analysis of phosphor-Histone H3 
and CD31, short and long groups were combined to simplify analysis as no differences 
were seen at short and long time points, thus allowing us to reduce the number of 
comparisons to mutant types or treatment i.e. this equated to approximately N=16 
tumours per condition (2 tumours per mice). For the preparation of growth curves with 
and without treatment, tumour volumes were normalized and compared to day 1 post 
treatment.  For immunohistochemistry, quantification was performed in ImageJ using a 
macro to score % threshold area (brown staining in representative image) in relation to 
background tissue for 6-10 views per section. Averages were then plotted alongside 
















Chapter 3. EGFR Mutants in Lung Adenocarcinoma 
3.1 Introduction 
The identification of activating EGFR kinase domain mutations as oncogenic drivers in 
lung cancer have been one of the most important discoveries in thoracic oncology in 
the last decade, both for our mechanistic understanding of the tumorigenesis of lung 
adenocarcinoma but also for the parallel development of EGFR targeted tyrosine 
kinase inhibitors (TKI).  The EGFR exon 21 mutation L858R, and in-frame exon 19 
deletions dominate and lead to impressive responses but which are usually short-lived, 
for example through T790M mediated resistance (Sharma, Bell et al. 2007).  Whilst 
primarily used to predict response to small molecule tyrosine kinase inhibitors (TKI) 
such as erlotinib, such mutations are oncogenes in their own right and have 
consequences for EGFR signaling, recycling and dimerisation beyond their modulation 
of drug sensitivity (Pines, Köstler et al. 2010). 
3.1.1 EGFR Mutants in Lung Adenocarcinoma: Beyond TKI response 
The conformation of the EGFR L858R mutant closely resembles the activated WT 
receptor (Yun, Boggon et al. 2007). Like most activating EGFR mutations, the position 
of L858R at the active site of the kinase domain, in the activation loop (see Figure 3.1, 
L858 = L834)(Lynch, Bell et al. 2004), disrupts stabilizing interactions which maintain 
the inactive conformation of the WT EGFR thus promoting the active conformation 
(Yun, Boggon et al. 2007).  Structural alterations have also been shown for other 
EGFR mutants including del19 and T790M that likewise are associated with an 
increase in EGFR activity and signaling and phenotype (Mulloy, Ferrand et al. 2007).  
Tumour cell dependence on EGFR signaling (oncogene addiction) evolves that 







Figure 3.1 The kinase domain of the Epidermal Growth Factor Receptor 
Active (A) and Inactive (B) States of EGFR Kinase Domain. A) L834 (an alternative 
nomenclature for L858, the site of the common L858R mutation) is found within the 
activation loop (green). In the active state, L858 is exposed and the activation loop is 
ejected and thus accesible. K721 and E738 are able to interact in an evolutionarily 
conserved ionic bridge important for catalysis. (Red and blue bars in left-hand 
schematic view).  B. In the inactive state, L858 is packed against the alpha-C loop 
(yellow rod) which interupts pairing of K721 and E738 (right-hand box). Adapted from 
Zhang et al. (Zhang, Gureasko et al. 2006). 
 
Some authors suggest that the EGFR L858R mutant is the most active, whilst others 
argue that acquisition of T790M results in greater catalytic activity – either way both are 
considerably more active than EGFR WT (Godin-Heymann, Bryant et al. 2007, Yun, 
Boggon et al. 2007, Yun, Mengwasser et al. 2008).  Furthermore, whilst T790M is 
recognized to augment EGFR activity alone, it is synergistic in cis with L858R with 
enhanced anchorage independent growth and xenograft growth (Politi, Zakowski et al. 
2006, Godin-Heymann, Bryant et al. 2007). This data and a number of other in vitro 
and in vivo models demonstrate the transforming nature of such mutations beyond their 
role in determining TKI response (Sordella, Bell et al. 2004, Amann, Kalyankrishna et 
al. 2005, Greulich, Chen et al. 2005, Regales, Balak et al. 2007).  In human studies 
too, L858R, del19 and T790M can determine survival irrespective of treatment modality 
(Sequist, Joshi et al. 2007, Rosell, Carcereny et al. 2012, Karachaliou, Mayo-de Las 
Casas et al. 2015). 
 
sequence), has been found frequently in lung cancer pa-
tients (accounting for 41% of EGFR mutations in these
cancers) (Jiang et al., 2005; Lynch et al., 2004; Paez
et al., 2004; Pao et al., 2004; Shigematsu and Gazdar,
2006; Sordella et al., 2004). An adjacent leucine residue
(Leu837) is mutated to glutamine in some lung cancer pa-
tients (Shigematsu et al., 2005). These residues are either
partially (Leu834) or completely (Leu837) surface exposed
and do not play an obvious structural role in the active
conformation (Figure 1B). In contrast, the importance of
these two residues is obvious upon consideration of the
Src/CDK-like inactive conformation because both resi-
dues pack gainst hydrophobic sidechains in the interior
of the kinase domain while buttressing a displaced orien-
tation of a catalytically critical helix in the N-lobe, helix aC
(Figure 1C). Replacement of either leucine by a polar side-
chain is likely to destabilize the Src-like inactive conforma-
tion and thereby activate the kinase domain. Interestingly,
Erlotinib is incompatible with the Src/CDK-like inactive
conformation, which may explain why activating muta-
tions potentiate the effectiveness of the closely related
drug Gefitinib (Lynch et al., 2004; Paez et al., 2004).
In this paper we show that the isolated kinase domain
of EGFR has low basal activity, and that its activity is in-
creased substantially upon replacing Leu834 by arginine.
This demonstrates that the wild-type kinase domain on its
own is indeed in an autoinhibited state, and we wondered
why the original crystal structure of the EGFR kinase do-
main (Stamos et al., 2002) as well as two new structures
we have determined (see below) are in the active confor-
mation. One possibility is that the high protein concentra-
tions used in crystallization (!200 mM) might mimic the
high local concentration of kinase domains that is induced
by receptor dimerization, leading to the formation of an
activated dimer in the crystal lattice. The only available in-
active structure of the EGFR kinase domain (crystal form
B) is l kely to be trapped by the bound kinase inhibitor
Lapatinib, which is incompatible with the active structure
seen in crystal form A.
Examination of the crystal lattice of the active form of
the kinase domain reveals two potentially important crys-
t ll graphic dim rs. One is symmetric, with two kinase
domains interacting in a head-to-tail fashion though a
primarily electrostatic interface, as discussed before
(Landau et al., 2004). The second one is an asymmetric
dimer in which one kinase domain interacts with another
in a manner analogous to that of a cyclin with an activated
cyclin-dependent kinase (Jeffrey et al., 1995). We present
Figure 1. Ligand-Induced Dimerization
of EGFR and Active and Inactive States
of Its Kinase Domain
(A) General view of the ligand-induced dimer-
ization and activation process of EGFR. The ki-
nase domain is activated through a previously
unknown mechanism.
(B) Detailed view of the catalytic site of the
EGFR kinase domain in the active conforma-
tion. Leu834 and L837 are surface exposed
and the Lys721/Glu738 ion pair is intact in
this conformation.
(C) Detailed view of the catalytic site in the inac-
tive conformation. Leu834 and L837 pack
against helix aC, preventing the formation of
the Lys721/Glu738 ion pair. The right panel
shows the electron density around residues
834–838 for the V924R kinase domain mutant,
at 3s from a simulated annealing omit map with
coefficients (jFoj " jFcj)eiac, where the calcu-
lated structure factors are generated from
a model that does not contain these residues.
The structures shown in (B) and (C) were deter-
mined in the absence of drugmolecules as part
of this work and are similar to structures deter-
mined previously in complex with the drugs
Erlotinib and Lapatinib, respectively (Stamos
et al., 2002; Wood et al., 2004).





3.1.2 EGFR Mutants in a dimer-dependent model of EGFR activation 
As discussed in chapter 1, dimerisation and transphosphorylation between two EGFR 
molecules is key to activation. Union of an activator and receiver EGFR kinase in a 
homodimeric (i.e. another EGFR monomer) or heterodimeric (e.g. another HER family 
member) partnership are required to achieve phosphorylation of key tyrosine residues 
required for intracellular signaling. Mutant forms of EGFR appear to have different 
tendencies to dimerisation and can influence the configuration of the dimer formed i.e. 
WT versus mutant EGFR or other partner (Red Brewer, Yun et al. 2013).  One can 
hypothesise that each EGFR dimer arrangements has the potential to produce a 
different downstream signal.  
3.1.3 EGFR mutants and downstream signal transduction 
Downstream signal transduction from EGFR is primarily mediated through PI3K and 
AKT, inhibition of which is seen in EGFR sensitised cell lines treated with gefitinib 
(Engelman, Janne et al. 2005). Whilst EGFR can activate AKT via Gab1, it is thought 
that the dominant pathway through which this occurs is via dimerisation with HER3, 
which has multiple PI3K binding sites (Sordella, Bell et al. 2004). A HER3 “kinase 
switch” from EGFR is thought to augment the role of the PI3K-AKT pathway as a driver 
pathway (Engelman, Zejnullahu et al. 2007). This may account for ligand-independent 
AKT phosphorylation seen in the presence of the EGFR L858R mutant (Sordella, Bell 
et al. 2004, Noro, Gemma et al. 2006). Activation of the RAS-ERK-MAPK pathway via 
Grb2/SOS is also seen with mutant EGFR (Ercan, Xu et al. 2012) although whilst there 
is crosstalk between these signal transducers e.g. through the activation/relief of 
positive/negative feedback signaling, it is not clear whether one downstream pathway 
can become dominant (Turke, Song et al. 2012). 
3.1.4 EGFR mutants and the tumour micro-environment 
The interaction between tumour cells and the surrounding stroma, through creating a 
‘tumour microenvironment’ is also vital for tumorigenesis, local spread and metastasis, 
as well as treatment resistance (Hanahan and Weinberg 2011). EGFR is important in 
this bidirectional relationship between tumour and stromal cells as well as being 
implicated in metastasis to distant sites such as brain and bone (Wood, Pernemalm et 
al. 2014). The importance of the tumour microenvironment is highlighted further by the 
association between resistance to EGFR targeted therapy and epithelial-to-
mesenchymal transition (EMT) (Singh and Settleman 2010, Sequist, Waltman et al. 
2011). Finally stromal expression of EGFR is also recognised and provides a further 
means by which EGFR targeted therapies may not achieve the intended effect (Weber, 





The aim of this chapter was to investigate the effect of EGFR mutations that are most 
commonly seen clinically (L858R and T790M) using a cell model based on NCI-H1975, 
to understand the effects of these mutants in vitro and in vivo. 
 
My objective was to characterise a model derived from an EGFR-TKI resistant lung 
adenocarcinoma cell line by knockdown and reconstitution of EGFR with EGFR WT or 
L858R forms to isolate the changes between cell lines to EGFR. This avoided other 
confounding mutations and genomic aberrations such as can be seen when comparing 
distinct cell lines according to their mutational status. 
 
To understand the impact of these EGFR mutations we selected assays of cellular 
appearance and behaviour alongside EGFR conformation, activation, dimerisation, 























3.2.1 Validation of an in vitro model of EGFR mutation status 
This work is based on NCI-H1975 derived model, previously developed by the Santis 
group to represent a translational model of three clinically relevant forms of EGFR 
(Ortiz-Zapater, Lee et al. 2017).  Briefly, the model was created by modification of the 
NCI-H1975 cell line (hereafter described as ‘H1975 L858R/T790M’) that harbours the L858R 
and T790M (L858R/T790M) double mutated form of EGFR: These H1975L858R/T790M 
cells were subjected to lentiviral shRNA knockdown of EGFR, followed by their 
transfection with pcDNA3 plasmids encoding wild-type (WT) EGFR or EGFR with the 
L858R activating mutation to generate the ‘H1975WT’ and ‘H1975L858R’ cell lines 
respectively.  The parental H1975L858R/T790M cell line thus represented patients with lung 
adenocarcinoma and EGFR TKI resistance whilst H1975L858R, portrayed the activated 
mutant form, which typically responds to EGFR TKI.  At the conception of this project I 
set out to validate this model and understand its significance in the study of EGFR 
mutants in lung adenocarcinoma. 
 
On initial inspection by bright field microscopy, striking differences were apparent in the 
morphology of each cell population - the H1975L858R/T790M parental cells, (i.e. EGFR 
L858R-T790M) were elongated and branching, with a fibroblast-like appearance, 
forming mesh-like monolayers with gaps between cells. In contrast, H1975L858R  (i.e. 
EGFR L858R) and H1975WT  (i.e. EGFR WT) cells were larger both in cytoplasm and 
nucleus, more rounded and epithelial in appearance, forming also better tessellated 
monolayers (Figure 3.2A). 
 
To confirm that the modified cell lines had a genetic constitution consistent with the 
expected mutants, cDNA derived from each cell type was analysed by digital droplet 
PCR (ddPCR) - a recently developed technology that allows selective enrichment of 
rare somatic mutations for either detection or quantification (Day, Dear et al. 2013).  
Using this technique, relative allele frequency (EGFR L858R vs. T790M) in each of the 
cell lines was quantified.  We confirmed that L858R and T790M probes were equally 
represented (80%) in the H1975L858R/T790M parental cells as expected from the literature, 
which describes that the mutations are expected to arise in cis (Pao, Miller et al. 2005).  
In addition, the relative allele frequency for both L858R and T790M probes were 
markedly reduced in the H1975WT cells (Approx. 30%), consistent with effective 
knockdown following shEGFR treatment.  Meanwhile, the H1975L858R cells had near 
complete abrogation of events for the T790M probe whilst demonstrating a high relative 
allele frequency for the EGFR L858R mutation validating the design of this L858R 
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mutated cell line (Figure 3.2B).  Total EGFR protein levels were similar between the 
cell lines as shown by lysates in the immunoblot in Figure 3.2C. 
 
L858R and T790M EGFR mutations are expected to result in constitutive activation of 
the tyrosine kinase domain (Kancha, von Bubnoff et al. 2009). Erlotinib meanwhile is 
expected to inhibit tyrosine phosphorylation in activated EGFR (L858R) but not in the 
presence of T790M (Pao, Miller et al. 2005). Using Western blot (WB) analysis, in 
Figure 3.2D we compared basal phospho-EGFR in the three lines and phospho-EGFR 
response to EGF in the presence of the EGFR TKI erlotinib.  Starved cells retained 
basal EGFR phosphorylation in the presence of either EGFR L858R or L858R-T790M 
in keeping with constitutive, ligand-independent activation in the presence of these 
mutations, as previously described (Kancha, von Bubnoff et al. 2009).  Phosphorylation 
of EGFR was increased in response to EGF stimulation in all three cell lines reflecting 
the ongoing influence of EGF, even in the presence of “activating” EGFR mutations. 
This Western blot demonstrates that the modified H1975L858R and H1975WT cells 
became sensitive to erlotinib upon elimination of the T790M mutated form of EGFR 
from their genomes. 
 
We next visualised the cells using immunofluorescence confocal microscopy to assess 
EGFR localization in the absence or presence of its natural ligand EGF at different time 
points. EGFR staining was identified with an EGFR targeted antibody, detected with 
Alexa Fluor 546 secondary antibody staining.  As seen in Figure 3.3, we saw 
internalisation of EGFR (stained red), from the lace-like membrane pattern to a 
cytoplasmic pattern within 15 minutes of EGF application in H1975L858R/T790M and 
H1975WT cells in the top and bottom rows respectively. In the H1975L858R cells, EGFR 
membrane staining persists strongly at 15 minutes and is only partially internalised 
after 60 minutes.  This is indicative of delayed EGFR internalization in the presence of 
the EGFR L858R mutant alone, consistent with previous reports that the EGFR L858R 
can escape endocytosis. Given that the signaling of EGFR is dependent upon EGF 
from the extracellular environment, the persistent expression of EGFR at the cell 













Figure 3.2 H1975 EGFR mutants differ in appearance and response to EGFR-TKI 
A) Bright field microscopy with a 20X objective showing appearances of 
H1975L858R/T790M cells compared with H1975L858R and H1975WT cells. There is a mesh-
like confluence of elongated H1975L858R/T790M cells compared with rounded H1975L858R 
and H1975WT cells, which formed more tightly packed monolayers. B) Digital Droplet 
PCR of relative L858R-T790M mutation frequency shows copy number of these 
mutations in each cell line. Both mutations are at equivalent levels in the 
H1975L858R/T790M cell line; There is dominance of L858R in the sensitised H1975L858R cell 
line versus relatively lower frequency of both mutations in the H1975 WT cells (N=2). 
C) Western Blot Analysis showing equal expression of Total EGFR (170KDa) in protein 
lysates from each cell line. Tubulin is provided as a loading control. D) Western Blot 
Analysis of Phosphorylated EGFR (170KDa) in the presence of EGF (100ng/mL) with 
or without erlotinib (10µM) in H1975 derivative cells. EGFR phosphorylation response 
to EGF was used as a positive control and blockade by erlotinib for each cell line as a 
marker of EGFR TKI resistance. phospho-EGFR signal was inhibited by erlotinib in 
H1975L858R and H1975WT cells but not H1975L858R/T790M. hsc70 was used as a loading 
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Figure 3.3 H1975 EGFR mutants differ in internalisation 
H1975 derivative cells were plated to sub-confluence, starved, exposed to Epidermal 
Growth Factor (EGF, 100ng/ml) for 15 minutes or 60 minutes and fixed for staining for 
EGFR. Mouse Alexa Fluor 546 (Red) secondary antibody reveals EGFR as red with a 
Hoechst (blue) nuclear counterstain. A membrane-predominant pattern of staining was 
seen as red demarcation of cell boundaries whereas a cytoplasmic pattern consistent 
with internalisation of EGFR, is shown by a more granular staining pattern. 
Internalisation of EGFR was seen in H1975L858R/T790M and H1975WT cells by 15 minutes 
after application of EGF to starved cells. This was delayed in H1975L858R cells and still 
incomplete by 60 minutes where membrane pattern staining can still be seen. Imaging 
performed by confocal microscopy and images prepared in ImageJ, Scale bar 20µm, 























3.2.2 The EGFR L858R ‘Activating’ mutation is associated with a proliferative 
phenotype in lung adenocarcinoma 
In view of the differences we had observed up until this point, we anticipated that we 
would also see phenotypical consequences arising from the different EGFR mutants 
within this model.  As demonstrated in Figure 3.4 (Quantification in A, representative 
images in B), we compared the proliferation rate of the three different cells lines using a 
BromodeoxyUridine (BrdU) incorporation assay.  A higher number of nuclei stained 
pink (red and blue channel co-localisation) representing BrdU incorporation in the 
H1975L858R cell line suggested that this cell line had the most nuclei in active cell cycle 
and hence was the most proliferative.  On the contrary, the H1975L858R/T790M cells from 
which the others were derived were the least proliferative with fewest nuclei with BrdU 
uptake relative to nuclei showing only the blue Hoechst counterstain.  The H1975WT 
cells were intermediary between the H1975L858R/T790M and H1975L858R forms. 
 




Figure 3.4 In vitro assays: H1975L858R cells are the most proliferative. 
A & B) BrdU Proliferation assay. Quantification was performed in ImageJ using a 
macro to count number of nuclei in red (BrdU+ve) versus blue (all nuclei) channels for 
5-10 views per section, with a threshold approach to separate nuclei from background. 
Averages are plotted as a percentage of BrdU positive nuclei. SEM bars are shown  
(*** p< 0.005, N=5). Representative images are shown for each of the three cell lines 
grown at 60% confluence on coverslips after 24 hours. The BrdU positive nuclei (Anti-
BrdU, Mouse Alexa Fluor 546) in the red channel show cycling cells, and in the blue 
channel is the counterstain (Hoechst dye) to indicate nuclei of all cells as a 
denominator. H1975L858R cells show greatest % positive BrdU stained nuclei compared 
with the other cell lines (middle row). Scale bar, 20µm. 
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Using a soft agar growth assay as a measure of growth in an anchorage-independent 
manner, we confirmed again that H1975L858R was the most proliferative with the 
greatest number of colonies and H1975L858R/T790M the least, but this time within a 3D 
environment (Figure 3.5). This trend was similar for both large and small colonies of the 
tumour cells (significant only for small colonies).  Colony numbers represent 
persistence of cells seeded within the anchorage-independent environment and 
therefore represent tumour cell survival in the absence of an adherent surface.  Larger 
colonies are also an indicator of a larger number of cells and thus cell divisions which 





Figure 3.5 In vitro assays: H1975L858R cells produce most colonies. 
Anchorage-independent Agar Growth Assay. Colony formation in H1975 derived cell 
lines. The graph shows the number of colonies after 3 weeks of growth. Quantification 
was performed in ImageJ using a macro to count number of colonies per field of view 
for 5-10 views per section, using a threshold approach to separate nuclei from 
background. Small colonies were defined as 100-1500mm circularity, and large 
colonies, >1500mm circularity. Average numbers of each colony type for the three cell 
lines are plotted. Number of colonies represents cell survival.  Larger colonies suggest 
higher number of cell divisions/proliferation. The number of small colonies was 
significantly greater in H1975L858R cells than the other cell lines as indicated by the dark 













3.2.3 Effect of EGFR mutational status on tumour cell migration 
The ability of tumour cells to migrate is an important cancer hallmark, which allows 
locally invasive growth and metastasis, which are also clinically important prognostic 
indicators in lung cancer. The in vitro model allowed comparison of the ability of the 
cells to migrate independently, using firstly a wound closure assay and secondly, an 
assay of random cell migration by time-lapse microscopy.  In both cases, we could 
observe that the H1975L858R/T790M cell line was the most migratory.  Firstly, in the wound 
closure assay, cells moved to close a wound made with a pipette tip in a confluent 
monolayer representing cell movement away from an injured front of confluent cells.  
Here, H1975L858R/T790M cells migrated faster into the wound to mitigate its closure as 
measured by reduction in wound area (mm2) per hour compared with the H1975L858R 
and H1975WT cells (Figure 3.6).  The H1975L858R wounds healed the most slowly. 
Secondly, in the random migration assay, shown in Figure 3.7, where cells were plated 
to low confluence, then visualized and quantified by time-lapse microscopy in a 
humidified chamber, we saw greatest velocity (microns per microsecond) in 
H1975L858R/T790M cells in comparison to the H1975L858R cells which showed only 
membrane ruffling with minimal migration and the H1975WT which were again 
intermediate. Thus in both assays whether or not in close contact with surrounding 
cells, the H1975L858R/T790M cells were more migratory. 
 
In summary the in vitro proliferation experiments showed that the H1975L858R cell line 
was the most proliferative, suggesting that the expression of the EGFR L858R mutant 
alone is capable of inducing proliferation but that this advantage is lost in the presence 
of the T790M mutation, which conferred a proliferative disadvantage in comparison to 
the WT or L858R mutant forms of EGFR.  The reverse was seen in the migration 
assays where both random migration and wound closure were fastest in the 
H1975L858R/T790M cell line suggesting that the double mutant EGFR L858R-T790M 





































































































































































































































































































































































































H1975L858R/T790M  H1975L858R  H1975WT 
   
Figure 3.7 H1975L858R/T790M Tumour cells show greatest random cell migration. 
A) Representative images of cell tracks (each coloured differently) for a single field of 
view at the end of the timelapse data file. Tracks were made manually in ImageJ by 
isolating the centre of each cell of interest per frame and analysed by Mathematica 
notebook (6 fields of view, 10 cells per image). Bar graph showing speed quantification 
of random migration velocity of cells over 18h. SD bars shown, ***p < 0.0001, N=3. B) 
Representative rose plots shown with tracks for all cells (n = 75, 46, 73) normalised to 
a common origin at the centre of the blot (velocity is µm/minute: x and y axis on plots 
are in µm. Cells with the greatest migrational velocity are shown by longer tracks as 
seen for H1975L858R/T790M in the left-most box which had the greatest migrational 
velocity with a corresponding value in the bar graph that exceeded the other cell lines.   
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3.2.4 Effect of EGFR mutational status on xenograft growth 
We wanted to validate whether the same observations could be reproduced in an in 
vivo setting by using a murine xenograft model based on the H1975 derived mutant cell 
lines. 3 x 106 H1975L858R/T790M, H1975L858R and H1975WT cells were injected into the 
flanks of 5-week old female, immunosuppressed, nude, BalbC mice and tumours were 
allowed to grow for 2 weeks.  We thus had three tumour types representative of the 
same three clinically important forms of EGFR tested within the in vitro model but now 
with the added contribution of local factors within an in vivo tumour microenvironment. 
The model provided bilateral tumours in 8 mice per condition thus giving 16 tumours for 
each of the three mutant cell lines. 
 
Tumour volumes were measured and charted every 2 days and weights of dissected 
tumours were recorded for culled mice. Tumour growth, shown by the increase in 
average volume (mm3) per day after cell injection was most striking in tumours coming 
from the H1975L858R xenografts indicated by the red line compared with the green and 
blue lines representing H1975WT and H1975L858R/T790M respectively, the latter of which 
had the lowest gradient demonstrating the slow increase in tumour volume in these 
xenografts (Figure 3.8).  Dissected tumours from the H1975L858R cell line also showed 
the highest average weight with the points corresponding to each tumour plotted inside 
of their error bars for each tumour type (Figure 3.8B).  H1975L858R/T790M derived tumours 
in comparison had the lowest average culled tumour weights matching the lower 
incremental volume change in Figure 3.8A.  H1975WT derived tumours were again 
intermediary between H1975L858R/T790M and H1975L858R. 
 
We further validated this pattern of increased growth in the H1975L858R xenografts by 
staining for the mitotic marker phospho-Histone H3 as an index of proliferation (Figure 
3.9A and B).  Greatest numbers of nuclei with phosphorylated Histone H3 staining 
(brown nuclei) were observed in the H1975L858R derived tumours suggesting a higher 
rate of mitosis in these xenografts.   The percentage of brown stained nuclei in 
proportion to Haematoxylin counterstained nuclei are plotted for quantification in the 
graph beneath.  H1975L858R/T790M derived xenografts meanwhile showed the lowest 
proportion of phospho-Histone H3 staining suggesting that these were the least 
proliferative tumours in line again with the volume and weight data.     Overall, these 
findings were in keeping with the in vitro results reinforcing the hypothesis that the 
H1975L858R cells and tumours with the activated EGFR L858R mutant alone were the 











Figure 3.8 H1975L858R xenograft tumours show fastest growth 
Xenograft tumour growth curves. 3x106 cells were injected into both flanks of 
immunocompromised BALB/c nude mice and tumours allowed to grow for 24 days. 
N=16 tumours (8 mice, bilateral tumours) per condition. A) At the indicated times, 
tumour volumes were measured using a calliper and calculated using the equation 
0.4xAxB2 (A, the long axis and B, the short axis of the tumour). H1975L858R tumours 
(red line) were largest and H1975L858R/T790M (blue line) were smallest with consistent 
separation throughout. SD bars shown. B) Tumours from culled mice were dissected 
and weighed and were compared between the different xenografts. Tumours from the 
H1975L858R cell line were signinificantly heavier than those coming from the 






Figure2 – In vivo Characterisation of EGFR kinase domain mutant xenograft model. 
a) 3x106 cells were injected into both flanks of immunocompromised BALB/c nude mice and tumours allowed to grow for 
25 days. At the indicated times, tumour volumes were measured using a calliper and calculated using the equation 
0.4xAxB2, (A, the long axis and B, the short axis of the tumour). b) Tumours from culled mice were dissected and weighed. 
c) Representative images of HEOS, collagen, α-SMA and cd31 staining of xenografts tumors (FFPE) grown from each 





Figure2 – In vivo Characterisation of EGFR kinase domain mutant xenograft model. 
a) 3x106 cells were injected into both flanks of immunocompromised BALB/c nude mice and tumours allowed to grow for 
25 days. At the indicated times, tumour volumes were measured using a calliper and calculated using the equation 
0.4xAxB2, (A, the long axis and B, the short axis of the tumour). b) Tumours from culled mice were dissected and weighed. 
c) Representative images of HEOS, collagen, α-SMA and cd31 staining of xenografts tumors (FFPE) grown from each 











Figure 3.9 H1975L858R xenograft tumours show most proliferation 
3x106 cells were injected into both flanks of immunocompromised BALB/c nude mice 
and tumours allowed to grow for 24 days before culling. N=16 tumours (8 mice, 
bilateral tumours) per condition. A) & B) Representative images and quantification. 
Tumour immunohistochemistry for phospho-Histone H3 staining of xenografts tumors 
coming from each H1975 derived cell line as a marker of proliferation. Quantification 
was performed in ImageJ using a macro to score % threshold area (brown staining in 
representative image) in relation to background tissue for 6-10 views per section. 
Averages are plotted. There was sginficantly more phospho-Histone H3 staining in 
H1975L858R tumours than the other 2 xenograft types. The number of cells stained in 
the images and the percentage score on the charts highlights the relatively low 
frequency of staining for this marker. Scale bar, 400µm. SEM bars shown indicate the 







3.2.5 Effect of EGFR mutational status on tumour stroma in vivo 
In light of the clear differences we had observed in the appearances of the cells in vitro, 
we also expected that the murine tumours would differ in architecture and may offer 
further explanation of the differences that we had observed in proliferation.  Examining 
the tumours using Haematoxylin and Eosin (H&E) staining as shown in Figure 3.10E, 
we could make observations about the basic morphology of the tumour cells and see 
that the adjacent stromal tissue in each xenograft type was very different. 
H1975L858R/T790M derived xenografts gave rise to dense, cellular tumours, with tightly 
aligned cells, oriented in similar directions.  Conversely, H1975L858R cells gave rise to 
tumours with abundant intra-tumoural stromal tissue deposition with highly segregated 
cells that appeared to have a greater stromal component (see Figure 3.10). We also 
noticed on examination of the H&E staining that necrosis appeared greatest in 
H1975L858R derived tumours and less so in H1975L858R/T790M tumours (Figure 3.10). 
 
H1975L858R/T790M H1975L858R H1975WT 
 
 
Figure 3.10 H1975L858R xenograft tumour appearances differ 
Representative images of Haematoxylin and Eosin (H&E) staining showing the 
differences in architecture between the different xenografts. Differences in the cellular 
and stromal appearances in the different tumours are presented visually. Quantification 
of necrosis was performed in ImageJ by defining a score of based on proportion of 
entire section occupied by necrotic tissue. Tightly packed cells in the H1975L858R/T790M 
tumours differed from those of the stroma-rich H1975L858R which were separated by 
strands of pink stromal tissue. H1975WT were more clearly necrotic as shown by lack of 
cellular features at the top of the third image and the right hand column on the graph. 






















































To understand if the EGFR mutations resulted in differences in the interaction of the 
tumour cells with the encapsulating stroma we again addressed the tumours coming 
from the same xenograft model.  We stained the stromal compartment within the 
tumours, for collagen deposition (MT, Masson’s trichrome staining) as well as anti-
smooth muscle actin staining ( -SMA), (see Figure 3.11A). As shown in the 
quantifications in Figure 3.11B and C, the H1975L858R tumours possessed the most 
substantial collagen deposition (MT) shown in green against the H&E background and 
a similarly increased proportion of a-SMA positive cells stained brown as a marker of 
activated fibroblasts.  These features of stromal cells and collagen deposition would be 
consistent with a greater degree of interaction with the stroma in the H1975L858R 
xenografts.  These markers were both significantly lower in the H1975L858R/T790M 
tumours in comparison suggesting that there was less stromal tissue in these tumours. 
 
We hypothesized that this might relate to the augmented proliferative capacity of the 
tumours outstripping vascular supply, so sought to quantify neo-angiogenesis with 
CD31 staining.  Using the % of cd31 staining (brown cells) in the tumour sections as a 
marker of endothelial cells we saw the greatest proportion of cd31 positive areas 
representing regions of new blood vessels in the tumours coming from the H1975WT 
and from the H1975L858R cells compared with those from the H1975L858R/T790M cell line 
(Figure 3.12). 
 
In summary, in addition to greatest growth and proliferation, the xenograft tumours 
coming from the H1975L858R cell line demonstrated markedly more prominent stromal 
components in comparison to the H1975L858R/T790M tumours, which were lowest in all 
these aspects.   These results provided an interesting contrast between the H1975L858R 
cells in which the EGFR L858R mutant produced a proliferative phenotype and 
H1975L858R/T790M, which possessed in addition, the T790M resistance mutation, which 
produced a migratory phenotype. H1975WT tumours were intermediary between these 
two cell types except in neovascularization where in this regard, H1975WT had the 
greatest scores, potentially highlighting an important role for EGFR in interacting with 









Figure 3.11 L858R mutant xenografts tumours show increased stroma 
Immunohistochemistry with Masson’s trichrome (MT) or anti-smooth muscle actin (α-
SMA) for collagen from mice xenograft tumours (N=16 tumours per condition).  A) 
Representative images show collagen (green with MT) and anti-smooth muscle actin 
(brown) stained areas were most notable in the H1975L858R xenografts. B & C) For 
Masson’s trichrome, dominance of collagen-rich features (green) were scored by a 
consultant histopathologist (MM) and plotted using Prism Graph Pad. α-SMA 
quantification was performed in ImageJ using a macro to score % threshold area 
(brown staining in representative image) in relation to background tissue for 6-10 
views per tumour. Averages plotted. % Collagen staining and α-SMA were 
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Figure 3.12 H1975WT xenografts tumours have greatest angiogenesis 
Immunohistochemistry xenograft tumours stained for cd31. A) Representative images 
for each tumour type. Brown stained cells represent endothelium and demarcate new 
vessel formation within xenograft tumours. Tissue architecture counterstained with 
haematoxylin. B) Percentage area was quantified in ImageJ as a marker of extent of 
new vessel formation. Quantification was performed in ImageJ using a macro to score 
% threshold area (brown staining in representative image) in relation to background 
tissue for 6-10 views per section. Averages plotted. This marker of neo-angiogenesis 
was greatest in the H1975WT derived tumours and lowest in H1975L858R/T790M. Scale Bar, 
400µm. SEM bars are shown. Of note these are wider in the H1975WT compared with 
the other tumour types which give a better approximation to the mean (**p<0.001, 






The aim of this chapter was to understand the effects of EGFR mutations using a 
model based on a lung adenocarcinoma cell line and derived tumours. We have used 
assays of cell phenotype to compare the EGFR mutants using cell model and have 
thereafter derived xenografts to establish the veracity of literature that suggests there is 
a difference between them. It is not clear if this merely reflects the EGFR activation 
levels induced by the respective mutation or alternatively the modulation of the capacity 
of EGFR for signaling in another manner, for example through altered receptor 
recycling and downstream signaling or through allosteric interactions between partner 
molecules in EGFR dimers (Arteaga 2007, Shtiegman, Kochupurakkal et al. 2007). The 
discussion considers the characteristics of EGFR in the context of the different EGFR 
mutations that might explain this. 
3.3.1 Creating a model of EGFR L858R and T790M mutations in vitro. 
The use of the NCI-H1975 cell line is well established in the lung cancer literature since 
it provides a good experimental model of EGFR TKI treatment resistance (Sharma, Bell 
et al. 2007). This cell line represents patients who have acquired constitutive EGFR 
activity (and enhanced EGFR TKI sensitivity) through acquisition of the EGFR L858R 
mutation, who additionally have gained the EGFR T790M resistance mutation.  The 
L858R and T790M mutations are two of the most commonly encountered EGFR 
mutations, which are used within the routine treatment algorithm for lung 
adenocarcinoma. 
 
We have used the H1975 model since we wanted lung adenocarcinoma cells with 
focus on the significance of these EGFR L858R and T790M mutations. By developing 
derivative cell lines based on the NCI-H1975 parent cell line in this way, we were able 
to specifically address the role of these three forms of EGFR which are amongst the 
most commonly encountered in the clinical environment: i.e. EGFR WT versus L858R 
(activating) ± T790M (resistance).  We used assays assessing cell function and EGFR 
signaling to understand the concepts underlying current clinical approaches.  This 
approach was chosen to be able to assess differences between the cell lines based 
solely on the EGFR mutation status without being confounded by the presence of other 
driver or passenger genomic aberrations present in alternative, commercially-available 
cell lines, representing other TKI sensitive or resistant cell lines derived from different 
patients or tumour material.  Limitations of these alternative approaches consist of 
other sensitising/resistance EGFR mutations when our intention was to focus on 
L858R/T790M, which other than del19 are two of the most relevant EGFR sensitising 
and resistance mutations respectively. We did consider the merits of a CRISPR 
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approach to achieve purer cell populations. However, the validation steps described 
and the tumour cell heterogeneity inherent to our approach could offer a good reflection 
of the clinical situation and CRISPR may not influence cells with increased genome 
copy (since not all copies may be edited) as effectively as a short-hairpin approach 
where excess EGFR is then re-introduced.  In addition, having a WT form of EGFR at 
our disposal within the same system provided a robust internal control against which to 
compare the mutant forms. 
3.3.2 Validating an H1975-derived model EGFR mutant lung cancer. 
Bright field microscopy confirmed that each of the cell lines were clearly different after 
manipulation of EGFR. H1975L858R and H1975WT cells were rounded, and tightly 
packed having acquired a more epithelial appearance than the parental 
H1975L858R/T790M cell line, which was elongated and more typical of a mesenchymal 
appearance (Figure 3.2A). H1975WT showed greater similarity in appearance to 
H1975L858R than H1975L858R/T790M suggesting an important difference between the 
presence of EGFR L858R-T790M and EGFR L858R alone in terms of cell phenotype. 
 
We validated the appropriate allelic frequency of each mutated form of EGFR relative 
to control probes using digital droplet PCR (ddPCR), thus demonstrating satisfactory 
design of the model with cDNA content in each cell line dominated by the expected 
EGFR form.  Such techniques serve a useful purpose in our model to establish the 
effective manipulation of the genetic content of our tumour cells (Day, Dear et al. 
2013).  In the case of the H1975L858R/T790M parental line, both L858R and T790M 
mutants were dominant and present in equal concentrations in line with the supposition 
that they exist in cis with allelic dilution of the WT EGFR by selective amplification of 
the mutant form.  In the case of the modified lines, for H1975WT we saw equal 
suppression of both mutants and consistent with the dominance of the L858R mutation 
in EGFR L858R-driven tumours, ddPCR analysis of the H1975L858R cells showed that 
L858R events dominated in this cell line with near complete elimination of T790M.  
There remained a possibility that EGFR molecules with the L858R-T790M mutation 
persisted.  The ddPCR in this respect is reassuring but also highlights the difficulty of 
the short hairpin approach where complete elimination of the activity of parental EGFR 
L858R-T790M is not possible.  We anticipated for the purposes of the model that this 
was unlikely to be significant since EGFR WT genetic material subsequently 
transfected would exceed this.  In any case we went on to ensure also that an 
appropriate response to erlotinib treatment was seen in EGFR phosphorylation by 




The three cell lines indeed recapitulated the clinical scenario when subjected to 
treatment with the EGFR TKI erlotinib when EGFR phosphorylation was used as a 
marker for activation. We saw, as expected, inhibition of this kinase activity with 
erlotinib in the H1975L858R cells but not H1975L858R/T790M cells with the T790M mutation 
(see Figure 3.2D). There was no remaining phosphorylation signal in the H1975WT cell 
line suggesting that no significant levels of functionally active EGFR L858R-T790M 
protein were present.  EGFR protein levels were comparable between each of the cell 
lines as demonstrated by the Western blot shown in Figure 3.2C.  From the same 
Western blots we also verified the constitutive, ligand-independent activation of 
tyrosine kinase activity in the L858R and L858R-T790M mutated forms of EGFR which 
would be consistent with the expected behaviour of activating EGFR mutations. 
H1975WT only showed phosphorylation in response to stimulation with Epidermal 
Growth Factor (EGF), the natural ligand for EGFR.  All three of the cell lines in addition 
showed increase in the phosphorylated EGFR signal in response to stimulation with 
EGF, highlighting the continued ligand-dependence even in the event of constitutive 
activation (Red Brewer, Yun et al. 2013)(see Figure 3.2D). 
 
Finally, the murine xenograft model provided an in vitro context for the behaviour of 
tumour cells. In particular this gave information of tumour proliferation within a 3-
dimensional architecture of a tumour and gave us the option to compare the stromal 
and vascular components in response to the genetic differences between the cells.  
Whilst the mouse model is not a true representation of lung adenocarcinomas found 
within a human tissue environment with differences expected between murine and 
human host factors and additionally a subcutaneous tumour model in comparison with 
an orthotopic model, it does however add detail to the in vitro data in these 
approximations of the tumour microenvironment. 
3.3.3 Effect of EGFR mutations on in vitro tumour cell characteristics 
We observed that the EGFR L858R mutation alone resulted in increased proliferation 
within the BrdU incorporation assay that was not the case with the addition of the 
T790M mutation.  BrdU staining is highest in cell nuclei with actively replicating DNA 
and thus represents cells in S-Phase as a marker of proliferation.  This is consistent 
with an increased catalytic activity of the L858R mutant form of EGFR.  Similarly the 
agar colony formation assays, which represent the ability of tumour cells to grow 
independently of attachment, a tumorigenic trait in itself, showed greatest numbers of 
both small and large colonies in the H1975L858R/T790M cell line.  Here number of colonies 
overall are a marker of survival, whereas the size and number of larger colonies give 
an indication of frequency of cell division whereby higher rates of cell division give rise 
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to larger colonies consisting of greater numbers of cells and is therefore more closely 
related to proliferation.  These results are consistent with increased proliferation in the 
presence of the EGFR L858R mutation. H1975L858R/T790M was the least proliferative cell 
line, with the fewest colonies in the agar colony forming assay and hence highlights 
that this mutation impedes the activity of the L858R towards proliferation (Figure 3.4 
and Figure 3.5).  Wound healing and random cell migration assays suggested that the 
presence of EGFR L858R did not cause the same capacity for migration as did the 
double mutant form, EGFR L858R-T790M as found in the H1975L858R/T790M cell line, 
which was the most migratory cell line (Figure 3.6 and Figure 3.7). Cells expressing 
EGFR WT demonstrated an intermediate phenotype between the two mutant forms for 
both proliferation and migration suggesting that they polarised towards opposite 
phenotypes. 
 
Existing work that has studied the effects of EGFR mutations on the biological 
characteristics of in vitro models demonstrate that activating mutations of EGFR in 
general increase the proliferative capacities of lung cancer cells and other in vitro 
models in terms of viability and anchorage independent growth models similar to those 
which we have employed.  Such results are thus consistent with our EGFR L858R 
activated cells (Sordella, Bell et al. 2004, Greulich, Chen et al. 2005). EGFR L858R 
mutants within other models such as the A549, H1299 and CL1-0 (NSCLC) cell lines 
increase tumour cell migration and invasiveness compared to WT EGFR but do not 
give us information on how this differs from L858R-T790M (Tsai, Chang et al. 2015, 
Hung, Chen et al. 2016).  Direct comparison between the phenotypical effects of 
L858R versus T790M independently or in cis are unfortunately not common in the 
literature and additionally studies have been conducted in non-‘lung cancer’ cell lines 
(Godin-Heymann, Bryant et al. 2007, Uchida, Hirano et al. 2007). Previous comparison 
of the L858R±T790M mutants has in an agar colony-forming assay using NIH3T3 cells 
suggested that the presence of L858R and T790M combined resulted in the greatest 
number of colonies. This cell line however is fibroblast derived and thus is difficult to 
compare directly with the epithelial H1975 (Godin-Heymann, Bryant et al. 2007).  We 
chose H1975 in this respect as we considered it important to compare these mutations 
in the context of a cell line of established relevance to EGFR TKI resistance in lung 
cancer. 
 
This conflicting data also highlights that relative enzyme activities of the EGFR L858R 
versus L858R-T790M mutants are not clearly defined.  The same authors suggest that 
T790M enhances the tumorigenic properties of the L858R mutation and that this 
mutant is a ‘stronger mutation’ (Godin-Heymann, Bryant et al. 2007).  This may reflect 
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the different behaviour of EGFR in our model compared to that of others. For example 
the relative dominance of other growth factor receptors and downstream signaling 
proteins in different cell lines may alter the effects of EGFR.  Context of EGFR activity 
appears to be more important therefore than specific kinase activity or expression 
levels of the receptor as elaborated on in the paragraphs below.  Our data confirm this 
notion that the L858R and L858R-T790M mutations were each polarizing and induced 
changes dependent on an exact characteristic of this mutation rather than the degree 
of phosphorylation present. 
 
3.3.4 Effect of EGFR mutations on xenograft tumour characteristics 
Differences observed between proliferation of the our H1975 derived cell lines in vitro 
were recapitulated in vivo – the H1975L858R tumours grew most quickly with greatest 
volumes throughout the experiment.  H1975L858R/T790M was conversely the slowest 
growing cell type (Figure 3.8).  This was most noticeable after the full 24 days of the 
experiments although a separation of the curves appeared approximately two weeks 
after injection of the cells.  This most likely represents the time taken to amass a 
recordable difference in cell-doubling time in terms of cell number. Tumour weights at 
the end of the experiment at time of sacrifice and proliferation rate as defined by 
proportion of cells with phospho-Histone H3 staining as a marker for mitosis followed a 
similar pattern (Figure 3.9). These results thus provided internal validity between the in 
vitro and in vivo systems used to test the effects of the EGFR mutations.  We 
additionally scored the tumours for necrosis (Figure 3.10), which were highest in the 
H1975WT and the H1975L858R tumours. This may in part reflect the proliferative capacity 
of the cells where the rapid tumour growth out of proportion to supporting stroma 
predisposes to necrosis. This does not explain the H1975WT finding however. H1975WT 
tumours may potentially lack adaptation to stimulate a supportive stroma. 
 
Findings of others consistent with this data include studies indicating increased tumour 
growth in murine xenografts derived from A549 and NIH3T3 cells transfected with 
EGFR L858R (Greulich, Chen et al. 2005, Hung, Chen et al. 2016); lung tumour 
formation in transgenic mice with tetracycline inducible expression of EGFR L858R 
(Politi, Zakowski et al. 2006); and increased latency of xenograft tumours with the 
addition of T790M to L858R (Regales, Balak et al. 2007).  Again these data are 
focused on L858R more than T790M and the results of Godin-Heymann et. al. conflict 
with our observations, since they observed steepest growth curves for the double 
mutant cell lines with T790M combined with either L858R or del19 (Godin-Heymann, 




Further analysis of the stroma, using other markers, which included Masson’s 
trichrome staining and anti-smooth muscle actin to delineate the tumour cells from 
surrounding collagen and fibroblasts, highlighted other important differences between 
the EGFR kinase domain mutants in the in vivo environment (Figure 3.11).  Tumour 
cells in H1975L858R xenografts were highly interspersed with stromal tissue, positive for 
staining of collagen (Masson’s trichrome) and anti-smooth muscle actin.  This stroma 
tissue appeared to encapsulate ‘packets’ of tumour cells.  Our interpretation was that 
the proliferative capacity for the EGFR L858R mutant led to increased interaction with 
the surrounding stroma in the in vivo environment and that these cells grow most 
effectively in cooperation with the stroma suggesting a paracrine effect from the tumour 
on the stroma. Looking for other differences in the consequences of these EGFR 
mutations in vivo, we also quantified anti-CD31, a marker of angiogenesis, which thus 
represents new blood vessel formation.  This was most prominent in H1975WT tumours 
and thereafter H1975L858R although it was not clear what was driving this trait (Figure 
3.12). 
 
Themes in the literature regarding interaction between EGFR mutants and the stroma 
focus on the tumorigenic effect of ligands coming from the stroma or the potential for 
tumour associated immune responses. Other data reports that disease spread 
(malignant pleural effusions) is increased in the presence of L858R (Tsai, Chang et al. 
2015). In general there is limited data from direct assessment of the effect of EGFR 
mutations in animal models, which instead must be inferred from data on experiments 
assessing TKI response in such models.  For example Hepatocyte Growth Factor 
(HGF), the ligand of the MET receptor, a related tyrosine kinase receptor frequently 
dysregulated in lung cancer (see Chapter 4), can mediate EGFR-TKI resistance in 
murine models (Nakagawa, Takeuchi et al. 2012) with MET inhibition a means of 
demonstrating that EGFR TKI resistance is related to HGF activity (Tang, Du et al. 
2008).  Patient data similarly supports a role for ligands such as HGF in resistance to 
therapy against EGFR (Yano, Wang et al. 2008). 
 
An important influence of ligands such as EGF and HGF on the tumour 
microenvironment is plausible which through both autocrine and paracrine effects could 
provide a control mechanism for coordination of tumour cells traits within the wider 
tumour. Such theoretical differences in secreted ligand may result from the increased 
number of cells present in a more proliferative cell line or be related to another change 
in cell biology arising from EGFR that changes ligand interaction (Riemenschneider, 
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Bell et al. 2005, Wang, Li et al. 2009). Further study of ligands was outside the scope 
of this project. 
 
In summary, the ability to examine the EGFR mutants in an in vivo xenograft model 
highlighted an important difference of tumour cell behaviour between the different 
EGFR mutants with regards to tumour cell growth and also interaction with surrounding 
stroma.  This indicated that in addition to the intrinsic differences between how the cells 
behaved in vitro, there were also consequences for the tumour microenvironment 
(Wilson, Fridlyand et al. 2012, Junttila and de Sauvage 2013, Feldman and Yarden 
2014). 
3.3.5 What are the potential mechanisms to link EGFR mutations and tumour cell 
characteristics? 
In order to understand how EGFR mutations lead to the differences we observed in 
both in vitro and in vivo traits, we looked at mechanistic differences between EGFR 
mutants and considered how these could be implicated. 
 
3.3.5.1 TKI Sensitising EGFR mutations alter EGFR activation 
We looked first to the current literature on EGFR conformational changes arising from 
EGFR mutations and their consequences for EGFR activation.  The accepted 
mechanism of EGFR activation is homodimerisation, driven by ligand binding (Capuani, 
Conte et al. 2015).  It is recognized that dimerisation is asymmetric and requires that 
an allosterically active C lobe of an activator kinase induces a conformational change in 
the receiver-competent N lobe of its partner. Usually, the extracellular domain 
suppresses dimerisation, maintaining an inactive state until ligand binding (Zhang, 
Gureasko et al. 2006).  EGFR kinase domain mutations such as del19 or L858R can 
result in constitutive activation of EGFR through their positioning around the active site 
where they disrupt hydrophobic interactions that exist to protect the auto-inhibited 
inactive conformation of EGFR (Yun, Boggon et al. 2007).  EGFR kinetics analyses 
suggest that these changes arising from the L858R mutation result in constitutive 
kinase activity 50X more active than WT (Yun, Boggon et al. 2007). 
 
It is not clear why the increased EGFR activity of the L858R mutant is so much greater 
than the augmentation (10x) seen with other mutants such as G719S, which is a less 
commonly observed kinase domain mutation (2-3%).  Particularly since both resemble 
the active conformation of the WT receptor.  This does however raise interesting 
mechanistic questions about the consequences of such mutations arising at different 
positions within the kinase domain on EGFR function.  This may be explicable in terms 
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of enzyme kinetics - the Michaelis constant (Km), a marker of the concentration of 
substrate required for catalysis according to the Michaelis-Menten equation, a 
surrogate of enzyme affinity for peptide substrate, is halved for EGFR L858R compared 
with EGFR WT.  Furthermore the ‘turnover number’ (Kcat) which represents the rate of 
substrate molecules converted to product, is elevated to a greater extent in the 
presence of L858R compared with G719S. Consequently there is an order of 
magnitude difference in the second order rate constant Kcat/Km, an overall marker of 
enzyme efficiency between WT and each mutant form (Yun, Boggon et al. 2007). 
Similar data is not available for deletion in exon 19 mutants. 
 
3.3.5.2 The T790M TKI resistance mutation alters EGFR activation 
T790M is located within hydrophobic residues at the posterior aspect of the ATP 
binding pocket, which restores the affinity of EGFR for ATP to near WT levels (Yun, 
Mengwasser et al. 2008). Increased binding affinity of ATP to the EGFR L858R-T790M 
mutant relative to EGFR L858R. The Kcat/Km [ATP] is five-fold higher than for the single 
mutant suggesting that the kinetics of the two mutants differ substantially (Yun, 
Mengwasser et al. 2008).  The presence of the T790M mutation alone confers only a 
modest change from EGFR WT, whereas when combined with activating mutations 
such as L858R, EGFR activity is more substantially altered (Godin-Heymann, Bryant et 
al. 2007).  Despite differences in phosphorylation kinetics and functional behaviour, 
structural similarities between these mutants suggest that these differences arise from 
different energy costs to transition between forms rather than due to the mutations’ 
direct effect on EGFR structure.  EGFR L858R-T790M is the least stable in its inactive 
state followed by L858R and finally WT (Gajiwala, Feng et al. 2013). 
 
Another hypothesis is that the phosphorylation pattern of EGFR tyrosine residues 
differs between the activating EGFR mutants e.g. del 19 vs. L858R; L858R-T790M and 
additionally that this is further modulated by EGF ligand binding (Guha, Chaerkady et 
al. 2008).  For example, higher degrees of phosphorylation are seen at residues 
Y1068, Y1086, and Y1173 in the L858R-T790M mutant form of EGFR (Yen, Liu et al. 
2015). Thus the re-positioning of key residues with each mutation could determine the 
phosphorylation pattern and with it, a unique downstream pathways specific to a 
particular phosphorylation site (Figure 3.14)(Sordella, Bell et al. 2004, Morandell, 
Stasyk et al. 2008). 
 
Our data both matches and conflicts others in the literature, where there is 
disagreement about the relative tumorigenicity of the T790M mutant form of EGFR.  
This may reflect the contextual differences of non-tumour/lung cell models in 
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comparison to the H1975 cell line (Godin-Heymann, Bryant et al. 2007).  With this in 
mind, although the proliferative capacity for H1975L858R could be sufficient to cause an 
increased kinase activity or capacity for phosphorylation of the EGFR-L858R mutant, 
given that we observed very distinct phenotypes for H1975L858R/T790M and H1975L858R 
both in terms of proliferation and migration and additionally stromal deposition, it seems 
likely that the catalytic activity of EGFR alone is not sufficient to explain the differences 
observed in phenotype. 
 
3.3.5.3 EGFR mutant-specific dimers could function differently 
An important evolving concept in the EGFR literature is that receptor dimerisation is 
essential for EGFR signaling and intracellular effect. In WT EGFR, Binding of EGF 
releases auto-inhibitory interactions that render the receptor in a state competent for 
dimerisation. Here EGF is thought to promote EGFR homodimer formation through 
firstly proximity that facilitates transphosphorylation and then stabilization of the 
activated conformation by these phosphorylation events (Hubbard 2006). 
 
The L858R mutation induces changes in the EGFR ectodomain structure that render 
the single mutant L858R form of EGFR in an extended, dimerisation-competent 
conformation which has also been shown to encourage EGFR homodimerisation 
(Valley, Arndt-Jovin et al. 2015, Valley, Arndt-Jovin et al. 2015). This is believed to 
increase dimerisation ability by suppressing local intrinsic disorder in the catalytic 
region of the receiver kinase (Shan, Eastwood et al. 2012, Sutto and Gervasio 2013). 
Crystal studies of the double mutant EGFR L858R-T790M (monomerised with V948R) 
suggest a conformation of EGFR in which the dimer interface is nearly identical to that 
of the active WT EGFR and the oncogenic L858R mutant (Gajiwala, Feng et al. 2013). 
Both L858R and L858R-T790M mutant EGFR retain dependence on an intact 
asymmetric dimerisation interface for full activation suggesting that neither mutation is 
capable of generating a signal as a monomer (Red Brewer, Yun et al. 2013). 
 
Other features of EGFR consistent with an allosteric model of activation include the 
interaction between the alpha-H helix of the activator EGFR monomer with the alpha-C 
helix of the receiver, which initiates the switch to the active conformation.  This results 
in freeing of the activation loop to activate its partner heterodimer molecule (Lemmon, 
Schlessinger et al. 2014). Thereafter the juxtamembrane (JM) region’s c-terminal 
portion latches the activated kinase domain of the receiver to the activator which is 
further augmented by the N-terminal segment, which then engages the transmembrane 




The potential role for dimerisation in the differences in cell phenotype that we observed 
is highlighted by evidence that different EGFR mutants are “specialised” in this way – 
kinase mutant forms of EGFR behave preferentially as ‘receivers’ when expressed with 
WT EGFR and can then hyperphosphorylate the WT conformation (Red Brewer, Yun et 
al. 2013). Here, the authors report that combining the L858R ± T790M mutants or WT 
EGFR with mutations known to disrupt the asymmetric dimerisation interface showed 
that N lobe disrupting mutations which could set the direction of asymmetric activation 
were less effective in the presence of T790M. EGFR L858R-T790M then appeared to 
be more effective in signaling when acting as an acceptor compared with a donor (Red 
Brewer, Yun et al. 2013). Our data that the different EGFR mutants give rise to different 
traits is consistent with this data.  Figure 3.13 suggests how putative combinations of 
EGFR ‘homodimeric’ pairings (single versus double mutant EGFR versus WT) could 
populate the pool of EGFR in each cell line. Certain pairings may be more frequent 
based both on structural tendency to interact and thereafter ability of a given dimer pair 
to activate the EGFR signal. This may suggest that the WT EGFR persists alongside 
mutant EGFR acting in synergy with them (Red Brewer, Yun et al. 2013). 
 
Since EGFR heterodimerisation is also possible, other HER family members may be 
important to the differences induced by the EGFR mutants.  Previous studies have 
shown that cell proliferation and tumorigenesis are enhanced in tumour xenografts co-
expressing HER family heterodimers, e.g. EGFR-HER2, EGFR-HER4 or HER2-HER4, 
compared to those expressing single receptors (Alaoui-Jamali, Song et al. 2003). This 
indicates that in addition to the well-characterized HER2-HER3 pair, the most 
oncogenic in breast cancer (Holbro, Beerli et al. 2003), EGFR heterodimerisation is 
important to oncogenic signaling.  This may also account for differences between our 
results and those of others, whereby EGFR mutants transfected into cell lines without a 







Figure 3.13 EGFR homodimerisation in H1975 derived model 
A number of possible configurations of EGFR homodimers are possible between EGFR 
WT and each of the EGFR mutants we included in our model).  If, as suggested by the 
literature, the L858R-T790M mutations exist in cis, the pairing of EGFR remaining 
chromosome could give rise to EGFR WT/EGFR L858R-T790M heterodimers (A) or 
through selective upregulation of the double mutant, exist as EGFR L858R-T790M 
homodimers (B). If EGFR-L858R persists, for example through increased EGFR copy 
number it is conceivable that a EGFR L858R-T790M/ EGFR L858R heterodimer could 
be observed (C).  In the case of H1975L858R we would expect either homodimerisation 
of EGFR L858R (D) or heterodimerisation between EGFR L858R/EGFR WT (E).  In the 
case of H1975WT a ligand-induced EGFR WT homodimer would be expected.  It is 
possible that any of these interactions can be bi-directional, for example in A – the 
mutant form could activate the WT or vice versa.  However, it is likely that a particular 
direction would be favourable and could alter the signaling consequence observed 
(Littlefield and Jura 2013). 
 
3.3.5.4 Is there a role for defective EGFR L858R internalization? 
We were interested to observe that the pattern of immunofluorescence staining of 
EGFR after EGF stimulation for different times in our cell lines differed.  H1975WT cells 
demonstrated rapid internalization following ligand stimulation.  However, in 
H1975L858R, EGFR showed persistent membrane staining suggestive of delayed or 
defective internalization even after EGF treatment (Figure 3.3). Comparing this with 
H1975L858R/T790M cells where we saw internalization, this provides a further mechanism 
by which EGFR L858R-T790M could differ in signal intensity/specificity beyond the 
capacity for phosphorylation. This defective internalisation may augment the EGFR 
signal due to reduced degradation/recycling to non-signaling cell compartments. This 



























































could result in prolonged EGFR signaling compared with a more transient 
phosphorylation in EGFR WT potentially as a result of protection from phosphatase 
activity.  This accumulation of EGFR at the membrane or within other nearby signaling 
compartments and accompanying increased EGFR activity is likely to be an important 
factor in the increased transforming capacity of EGFR in the presence of this mutant 
and also its availability to encounter other EGFR or HER family molecules which may 
become enriched and available for interaction at the membrane. 
 
These results are consistent with a previously reported defective clathrin-mediated 
endocytosis in L858R mutated EGFR, also a recognised mechanism that precedes 
receptor recycling and degradation (Murthy, Basu et al. 1986, Kirisits, Pils et al. 2007).  
Other authors have shown co-localisation of mutant EGFR with endosomal markers 
whereby H1975L858R/T790M show constitutive endocytosis, which renders them more 
likely to interact with SRC (Chung, Raja et al. 2009). Shtiegman et al related such 
defective ligand-induced internalization of mutant EGFR to differences in c-cbl 
mediated ubiquitinylation, a well recognized regulatory, post-translational modification 
(Lemmon and Schlessinger 2010).   Shtiegman et al also suggested that differences in 
EGFR dimerisation in this mutant could be attributable to heterodimerisation with 
another ErbB receptor, such as HER2 could be the cause of such a delay in 
internalisation. We anticipate that in our model another receptor known to be important 
in lung cancer, for example HER3 or MET might be more important (Engelman, 
Zejnullahu et al. 2007). Little is known of the significance of the acquisition of T790M to 
this process. Although the authors also saw defective ubiquitinylation in similar assays 
with EGFR L858R-T790M they did not compare whether EGFR L858R differed from 
EGFR L858R-T790M in this respect (Shtiegman, Kochupurakkal et al. 2007). 
According to our observations EGFR L858R-T790M differed from EGFR L858R in this 




3.3.5.5 Could this be explained by differences in downstream signaling? 
As discussed above, the literature suggests that different EGFR phosphorylation 
signatures arise from each mutant and this can be linked to different tumoural traits, 
phenotypes and signaling pathways (see Figure 3.14) (Morandell, Stasyk et al. 2008). 
In the case of proliferation, the increased rate of cell division and growth noted in the 
H1975L858R versus H1975WT cells could be mediated by increases in AKT or ERK 
signaling, both of which are linked to survival and growth. There are existing reports 
that driver mutations in EGFR select for EGFR-TKI efficacy by their dependence on 
anti-apoptotic pathways (e.g. AKT), more so than on proliferative pathways such as 
ERK. Additionally EGFR L858R has been reported in the literature to activate ERK less 
effectively than EGFR WT (Lazzara, Lane et al. 2010).  The migratory phenotype we 
associated with the H1975L858R/T790M cell line as well as a reduction in proliferation may 
result in a different propensity to activate AKT, ERK in favour of another mediating 
pathway such as FAK.  
 
 
Figure 3.14 EGFR phosphorylation sites determine specificity for downstream 
signaling pathways 
Phosphorylation of specific tyrosine residues upon phosphorylation are associated with 
particular downstream adaptor proteins. The figure gives examples of Tyrosine 
residues of EGFR homodimer and known mediators (multicolour ovals) alongside their 
accompanying signaling pathways and functional roles. Activating mutations and 
dimerisation can influence the pattern of phosphorylation and therefore downstream 
signaling. Adapted from Morandell et. al. (Morandell, Stasyk et al. 2008). 
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regulation of pho phorylated sites and the bi ding of inter-
action partners to the activated EGFR will be discussed as the
main topic of this review.
1.2 The EGFR signaling network
Adaptor proteins transmit the activation signal from the
receptor to different signaling pathways, regulating the
variety of biological functions connected to the ErbB family
of receptors [1, 5–8]. One ignal transduction pathway stud-
ied in the context of EGFR activation is the Ras/mitogen
activated rote n kin se (MAPK) signaling cascade. The key
interacting molecules for the activation of the MAPKs
extracellular regulated kinase 1 (Erk1) and Erk2 are growth
factor receptor bound protein 2 (Grb2) and Shc (Src
homology 2 domain containing transforming protein) [9].
Other MAPKs activated in EGFR signaling are JNK (c-Jun
terminal kinase) and p38 [10]. Ca signaling and protein
kinase C (PKC) can be activated by the adaptor protein
PLCg (phospholipase C g) [11], protein kinase B (PKB) sig-
naling by docking of phosphatidylinositol-3-kinase (PI3K)
[12, 13]. signal transducer and activator of transcription
(STAT) proteins are activated by direct inte ction with
EGFR [14, 15]. Kinases associated with the regulation of
motility and adhesion of cells such as focal adhesion kinase
(FAK) [16] or Abl (Abelson proto-oncogene homolog) [17]
are activated by interaction partners like c-Src (v-src v-jun
sarcoma virus 17 oncogene homolog) or Crk (v-crk sarcoma
virus CT10 oncogene homolog), respectively [18]. Other
receptor binding proteins are involved in the regulation of
receptor signaling by endocytosis, such as Eps15 (EGFR
pathway substrate 15) [19], or by degradation, initiated by
the binding of Casitas B-lineage lymphoma oncogene (Cbl)
[20]. The specific docking sites for the mentioned interac-
tion partners could be mapped and are presented together
with major pathways and biological functions of EGFR sig-
naling in Fig. 1. These proteins are only a few examples for
signaling molecules involved in the EGFR network. In total,
more than 100 interacting proteins and more than 200 EGF
related substrates are described in the literature. Many
interaction partners and substrates were identified by pro-
teomics approaches, which focused on the detection of pro-
tein complexes, phosphorylated proteins and regulation of
phosphorylation sites upon EGFR activation.
Figure 1. General outline of major pathways in the EGFR signaling network. Tyrosine phosphorylation sites on the EGFR homodimer
activat d by EGF are indicated by black bars. Know binding sites are labeled with colored circles, corresponding colors indicate direct
interaction partners as listed in Table 1 as well as associated biological functions. The receptor kinase domain is shown in dark gray. PM,
plasma membrane.




In conclusion, the commonly encountered EGFR mutations, L858R and T790M, which 
determine EGFR sensitivity/resistance respectively, have additional consequences for 
lung adenocarcinoma both in vitro and in vivo. Within a H1975 derived model, the 
L858R mutation was associated with a proliferative phenotype and an increase in 
markers of stromal activity in tumour xenografts.  The L858R-T790M mutation 
meanwhile led to a more migratory phenotype and resulted in slower proliferation rates 
and smaller tumours in the murine model. 
 
These observations combined with the importance of dimerisation in the EGFR family 
of proteins in general, prompted us to consider if these differences in EGFR and the 
phenotypic observations made might be unified by the tendency of the differentially 
mutated forms of EGFR to dimerise with another receptor. This would fit into our model 
of mutation-specific dimerisation by providing a mechanism by which downstream 
signaling and phenotype might vary with EGFR mutation status.  Specifically, it would 
be plausible that if the activation of each of specific tyrosine residues by its dedicated 
kinase, i.e. SRC, EGFR/another ErbB or MET was altered by the ability of EGFR to 
dimerise, then a particular function role could be exaggerated. Sequestration at the 
membrane may provide an additional layer of regulation to this process. 
 
According to the literature, dimerisation between EGFR and itself and other ErbB family 
members differs depending on the EGFR mutation present as discussed in Section 
3.3.5.3. We can hypothesise that dimerisation of EGFR with another receptor which 
has an increased capacity to activate the PI3K/AKT pathway, for example HER3, may 
lead to a dominance of signaling through this downstream pathway (Arteaga 2007). 
Alternatively, in other mutant forms of EGFR such as EGFR-L858R-T790M which is 
reported to engage HER3 less readily, the importance of another partner molecule 
such as MET may be augmented with the resultant change in the signaling pathway 
affected (Wang, Ma et al. 2015).  This would be an important determinant of tumour 
responsiveness to other receptor tyrosine kinase inhibitors, which would provide 









Chapter 4. Understanding the role of MET in EGFR 
mutant lung adenocarcinoma 
4.1 Introduction 
4.1.1 The overlapping role of EGFR and MET oncogenes 
The MET tyrosine kinase receptor initiates signaling events in multiple biological 
processes. In cancer, over-expression, amplification or mutation of MET is associated 
with invasive growth, tumour progression and metastasis (Olivero, Rizzo et al. 1996, 
Boccaccio and Comoglio 2006, Beau-Faller, Ruppert et al. 2008, Cappuzzo, Janne et 
al. 2009, Cappuzzo, Marchetti et al. 2009, Benedettini, Sholl et al. 2010). The 
recognised link between the tumorigenic effects of MET and a proposed crosstalk 
between MET and other membrane-based receptors such as EGFR is also believed to 
contribute to EGFR TKI resistance. EGFR-MET crosstalk is supported by MET and 
EGFR co-expression in lung cancer cell lines (Tang, Du et al. 2008), crosstalk between 
EGFR and MET in assays of signaling pathways and direct co-immunoprecipitation 
experiments (Jo, Stolz et al. 2000, Tang, Du et al. 2008, Wang, Li et al. 2010). 
 
The phenotypical effects of EGFR-MET crosstalk have been demonstrated in assays of 
proliferation, cell migration and wound healing (Xu and Yu 2007). EGFR inhibition has 
also been shown to inhibit HGF-MET induced invasiveness and scattering (Bonine-
Summers, Aakre et al. 2007). In an important in vitro model of MET amplification, the 
HCC827 cell line (EGFR del 19) can be driven to MET-mediated acquired EGFR TKI 
resistance through prolonged culture in the presence of EGFR inhibitors (Turke, 
Zejnullahu et al. 2010). In these EGFR-TKI resistant HCC827 cells, gefitinib still 
suppressed cell migration and anchorage independent growth suggesting ongoing 
dependence on EGFR even in the context of a switch to MET as a driver (La Monica, 
Caffarra et al. 2013). It is reported that in this and other EGFR mutant cell lines, EGFR 
TKI inhibit the EGFR-MET interaction and suppress MET phosphorylation. Reduction in 
MET expression however was not observed in EGFR WT cell lines such as H1666 and 
no phosphorylation of MET is seen in this cell line (Guo, Villen et al. 2008).  EGFR 
activation by ligand or mutation has also been associated with increased levels of MET 
expression (Xu, Nilsson et al. 2010). These observations therefore support the 
importance of activated EGFR to the tumorigenicity of MET. 
 
The main role of EGFR-MET crosstalk has previously been discussed primarily as a 
resistance pathway to EGFR TKI therapy in EGFR activated tumours mainly, in the 
context of MET amplification (Bean, Brennan et al. 2007). It is not known whether MET 
amplified tumours represent a unique subset of tumours in which EGFR and MET are 
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co-activated or if MET is important in lung cancer in general. It is also not clear how 
EGFR-MET synergism relates to EGFR activating mutations and where MET fits into 
tumour signaling in a non-amplified state. Finally MET mutations bring further 
opportunity to this area (Matsubara, Ishikawa et al. 2010). This chapter explores these 
unmet needs in the potential targeting of MET. 
4.1.2 What is the role of MET targeted therapy in EGFR mutant NSCLC? 
Despite the promising pre-clinical data supporting plausible blockade of MET as a 
therapeutic strategy in EGFR TKI resistant NSCLC, these agents have not yet realized 
clinical use outside of trials (Feng, Thiagarajan et al. 2012, Gherardi, Birchmeier et al. 
2012, Menis, Levra et al. 2013). Early data suggested that EGFR-MET combination 
treatment could be beneficial against tumour growth and hence many trials have 
focused on dual therapy with EGFR TKI (Tang, Du et al. 2008, Zhang, Staal et al. 
2010). The most promising agents in phase III trials, even in combination with EGFR 
TKI, have not provided evidence for MET inhibition (Pérol 2014, Scagliotti, von Pawel 
et al. 2015). 
 
We had the opportunity to study SGX523 (6-[6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4] 
triazolo-[4,3-b]pyridazin-3-ylsulfanyl]-quinoline), an orally available, small molecule, 
ATP-competitive TKI which shows high affinity for the less active, un-phosphorylated 
form of MET (Ki = 2.7 nmol/L) compared with the active phospho-MET (Ki = 23 
nmol/L).  This is indicative of a drug that targets the inactive conformation and has 
shown ‘exquisitely’ high selectivity for WT MET with minimal off target effects on other 
kinases as demonstrated against a panel of 213 protein kinases when used at 
1000nM/L, with a ‘Karaman’ score of 0.005 (Buchanan, Hendle et al. 2009).  An 
important observation regarding the drug-bound structure of MET in the presence of 
SGX523 is that the conformation resembles that more usually seen for inhibitors that 
target the active conformation, with a “DFG-in” structure. Such orientations can be 
important determinants of how kinase domains interact with related molecules.  
SGX523 has shown inhibition of proliferation and growth in lung cancer models in vitro 
and in vivo and acts synergistically with EGFR inhibitors (Guessous, Zhang et al. 2010, 
Zhang, Staal et al. 2010).  Unfortunately, clinical development has ceased because of 
nephrotoxic metabolites detected in phase I safety trials, not observed in animal 
studies (Infante, Rugg et al. 2013) 
 
Although no longer suitable for use in a clinical environment, this agent demonstrates 
potential as an experimental tool to target the MET pathway with high fidelity, without 
‘off target’ effects on other receptor tyrosine kinases such as EGFR (Buchanan, Hendle 
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et al. 2009).  For this reason it provided an ideal agent to use for these studies to truly 
isolate the manipulation of the experimental condition to MET and enable us to 
compare the exact contribution of each of these related kinases to EGFR-MET 
crosstalk independent to that of EGFR activity which could then be modulated 
separately (Buchanan, Hendle et al. 2009). 
4.1.3 Could an EGFR-MET FRET assay add to existing clinical management? 
This area remains highly experimental but critics of failed studies have highlighted the 
need for novel predictive biomarkers to best select such therapies. MET amplification 
outperforms tissue immunostaining although the lack of success of MET targeted 
therapy suggests this approach is inadequate (Tanaka, Sueoka-Aragane et al. 2012).  
Whilst MET mutations are also evolving as a possible means to target MET based 
therapy, these appear to represent a different population of patients. Finally although 
combination therapy are increasingly considered, there is unfortunately no data on 
whether crosstalk between related drug targets such as EGFR and MET could reliably 
direct such approaches. 
 
A novel approach in kinase receptor derived biomarkers includes Förster Resonance 
Energy Transfer (FRET) assays using fluorescence lifetime imaging microscopy (FLIM) 
to analyse the interaction between pairs of molecules (Kelleher, Fruhwirth et al. 2009).  
This is a gold standard technique for measuring protein proximity within the typically 
<10nm range (Ng, Squire et al. 1999, Ng, Parsons et al. 2001, Parsons, Keppler et al. 
2002). Fluorescence Life Time Imaging (FLIM) is well suited to analysis of the 
interaction between EGFR and MET, as discussed in Chapter 1.  Using FLIM, it is 
possible to measure FRET to quantify interactions between EGFR and MET at the 
nanometre scale to establish the potential role that crosstalk might play in lung cancer. 
Such data could be used prognostically to group patients according to EGFR-MET 
interacting or not.  Furthermore, it could help characterise/predict response to EGFR or 













To address these themes and gain mechanistic insight into the role of MET in the 
context of EGFR mutant lung cancer and also to better understand therefore the 
potential circumstances where MET targeted therapy might be relevant we selected a 
highly specific small molecule kinase inhibitor of MET, SGX523. 
 
The two main objectives therefore are to establish whether 
1) EGFR mutations directly influence EGFR-MET binding/dimerisation. 
2) EGFR mutations determine the effect of MET inhibition. 
 
This chapter focuses on the possibility of a direct interaction between EGFR and MET. 
We chose to conduct our studies in the model developed in Chapter 3, based on the 
H1975 cell line which is the stereotypical model of EGFR resistance acquired by the 
T790M route to better understand the significance of MET in the context of the L858R 
activating mutation and the T790M mutation more commonly associated with EGFR 
TKI resistance. 
 
We hypothesised that outcomes from MET inhibition would be influenced by EGFR 
mutation status both at the level of the cell biology and also in terms of cell behaviour.  
This would also address an important clinical question at the bench. We have explored 
this hypothesis by evaluating the response of lung cancer cells with EGFR WT or 
activating mutations, to the MET inhibitor SGX523 using the in vitro and murine 
xenograft model based on the NCI-H1975 derived lung adenocarcinoma cell lines and 







4.2.1 MET copy, protein and localisation are unchanged by EGFR mutation status 
To assess if EGFR-MET interaction is modified by EGFR mutations, we studied the 
MET receptor using the same modified NCI-H1975 lung adenocarcinoma cell lines that 
we investigated in Chapter 3.  We observed no differences in basal MET protein levels 
between the cell lines as evidenced by the Western blot whereby the double band 
representing total MET (140KDa) were of equal intensity in all three cell lines. Tubulin 
was used as a loading control (Figure 4.1A). Given that clinically, MET copy number is 
perceived to be the preferred marker of activation of MET signaling and MET 
therapeutic effect (Tanaka, Sueoka-Aragane et al. 2012), we assessed MET copy 
number using MET/cep7 fluorescence in situ hybridization (FISH) probes.  We 
calculated both the mean copy number of MET and additionally the ratio of MET to 
chromosome 7 centromere signals (Figure 4.1B).  The latter approach defines 
amplification in terms of a “Copy number ratio” standardized to a control probe – in this 
case ‘Cep7’ (Chromosome 7 enumeration probe). MET/cep7 ratio, as shown in Fig 
4.1B as the number of red spots per green control spots was equal (<1) in all three cell 
lines. MET copy number (the total number of red spots) was increased in all three cell 
lines, whilst copy number ratio was equal given chromosome 7 polyploidy. 
 






Figure 4.1 MET expression/genomic copy is high in H1975 derived cells 
A) Western blot (WB) of total MET in H1975 derived cells is shown as equally 
represented double bands at 140KDa. Tubulin levels are shown as loading control.  
B) MET (7q31) copy number analysis is by FISH in the three H1975 derived cell lines 
using the Leica Kreatech MET (7q31)/SE7 FISH probe (KBI-10719). MET is visualised in 
the red channel, Chromosome 7 (Cep7) centromere in green. Scale bar, 10 µm. Average 
copy number/ratio MET:Cep7 below image. The Ratio is equal in all cases with minor 





4.2.2 EGFR-MET binding is influenced by EGFR mutations in lung cancer 
In view of the anticipated possibility of crosstalk between the EGFR and MET 
pathways, we wanted to test our cell lines for EGFR-MET interaction and assess 
whether this was influenced by EGFR mutation status. By undertaking 
immunofluorescence staining of our cells, we could show that both proteins co-
localised similarly at the membrane in each of the three cell types as shown by the 
demarcation of the cell membrane by the EGFR (red) and MET (green) stains 
respectively with a crisp yellow perimeter to the cells where the two receptors co-
localised (Figure 4.2A).  Staining was not seen at the cell nucleus and cytoplasm 
consistent with the main site of action of these receptors being at the cell membrane. 
Direct co-immunoprecipitation (Co-IP) between these two receptors as suggested by 
the literature was confirmed by the data presented in Figure 4.2B below. Pairs of 
samples are presented for each cell type; the first lane of each pair corresponds to 
irrelevant immunoglobulin which acts as a negative control, where no band is detected.  
Conversely, a signal is detected at 170KDa corresponding to EGFR in the samples 
where an EGFR antibody was used for immunoprecipitation, showing that the EGFR 
protein was efficiently immunoprecipitated with the EGFR Antibody.  In support of an 
important interaction between EGFR mutations and crosstalk with MET, the same 
samples immuno-blotted with MET antibody showed a band at 140KDa corresponding 
to detection of MET as an EGFR-MET complex in these lanes.  Input lanes are shown 
as a positive control to confirm that lysates contained EGFR and MET prior to 
subjecting the samples to the immunoprecipitation reaction. 
 
Co-immunoprecipitation also showed that bands representing amount of total MET 
protein were of greatest intensity in the lanes corresponding to H1975L858R/T790M lysates 
EGFR co-immunoprecipitate. In the same blot in comparison, the lanes corresponding 
to H1975L858R and H1975WT cells showed a weaker intensity of band consistent with a 
reduction in the co-immunoprecipitation between these two proteins in the latter cell 
lines (Figure 4.2B).  This provides evidence of potential differential interaction between 









Figure 4.2. EGFR MET interaction differs with EGFR mutation status 
A) Immunofluorescence of EGFR (red channel) and MET (green channel) in H1975 
derived cells. Demarcation of cell periphery by immunofluoresence indicates receptor 
localisation to the membrane. Cell peripheries are similarly demarcated by both stains 
with yellow membrane staining on the merge channels suggesting EGFR and MET co-
localisation at the membrane. Hoechst dye (blue channel) acts as nuclear counterstain. 
Merge panels show colocalised pixels as yellow. Scale bar, 20 µm. N=3. Co-
immunoprecipitation (IP) of EGFR in H1975 derived cell lines. EGFR antibody was 
used to immunoprecipitate. EGFR (170KDa) and MET (140KDa) levels are shown in 
both bound and input fractions to highlight EGFR-MET binding or as positive control for 
presence of these proteins prior to the IP reaction. MET signal (bottom panel) coming 
from the lane with the sample immunoprecipiated with EGFR is most prominent in 
H19757L858R/T790M suggesting EGFR and MET might interact in this cell line. N=4 (Final 
IP blot kindly Provided by Dr. E. Ortiz-Zapater).      
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4.2.3 Validating an EGFR-MET FRET assay in vitro 
To further validate a direct protein interaction between MET and EGFR as suggested 
by these experiments, we employed a Förster Resonance Energy Transfer (FRET) 
assay to analyse the interaction between EGFR and MET. We labelled antibodies 
known to be reliable for staining against EGFR (Ab-5) and MET (AF276) as discussed 
in Chapter 2 Methods and subjected them to validation in cells manipulated to 
overexpress EGFR or MET.  This was usually compared with an unlabelled primary 
antibody and secondary fluorophore conjugated not expected to cross-react with the 
labelled species.  For example in Figure 4.3, we see how the control MET (D1C2) 
antibody with Rabbit secondary (Alexa Fluor 546) compared with the directly labelled 
MET (AF276)-Cyanine 5 antibody co-localised. 
 
Figure 4.4A shows the Lifetime heat maps and intensity images for EGFR and MET 
staining.  The intensity images for the Alexa Fluor 546 (EGFR) and Cyanine 5 (MET) 
channels confirm appropriate membrane pattern staining that is similar between the 
cell lines.  The heat maps demonstrate the degree of FRET for each condition – Red 
represents high FRET (%) i.e. where there is greatest EGFR-MET interaction versus 
Blue where the interaction is weakest.  This reflects the fact that lifetime is measured in 
the donor fluorophore channel. Fluorescence lifetime falls when donor and acceptor 
fluorophores are co-localised i.e. at cellular locations where there is direct interaction 
between the EGFR and MET receptors since bound to the fluorescently labelled 
antibodies corresponding to these neighbouring fluorophores.  Our results show that 
highest FRET efficiency between MET and EGFR occurred in H1975L858R/T790M cells.  In 
contrast, significantly lower FRET efficiency was seen in the H1975L858R and H1975WT 
cells. These results demonstrate that EGFR and MET can interact directly at the cell 
membrane and that the level of interaction is significantly higher in H1975L858R/T790M 
compared to H1975L858R and H1975WT cells. Quantification for averaged data from 









Figure 4.3. Validation of EGFR-MET FRET antibodies for in vitro use  
Example antibody validation steps.  MCF-7 cells, which lack endogenous EGFR/MET 
are shown transfected with EGFR-GFP or MET and exposed to fluorophore labelled 
antibodies against EGFR or MET respectively.  Hoechst counterstain (blue) used to 
demonstrate cell nuclei. A) MCF-7 EGFR-GFP+ cells stained on coverslips with EGFR 
(Ab-5)-Alexa Fluor 546 directly labelled antibody. The first panel shows the green 
channel for GFP-containing EGFR construct. The red panel shows labelled antibody. 
Colocalised signal in yellow shows overlap confirming equivalent staining even after 
fluorophore labelling. B) MCF-7 MET+ cells stained on coverslips with MET (AF276)-
Cyanine5 directly labelled antibody shows specific staining pattern confirmed by MET 
(D1C2) revealed with Rabbit secondary-Alexa Fluor 546. Scale bar, 20µm. Both 
EGFR and MET antibodies demonstrate specific staining unimpaired by fluorophore 
labelling. 
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Figure 4.4. EGFR-MET binding in vitro vs. EGFR mutant status 
A) Fluorescence lifetime imaging performed in the three H1975 derived cell lines 
plated to sub-confluence on coverslips.  Representative pseudocolour lifetime 
images showing FRET efficiency accompanied by corresponding grayscale donor 
(EGFR-Alexa Fluor 546) and acceptor (MET-Cyanine 5) intensity images. 
Pseudocolour images demonstrate different patterns for each EGFR mutant. Scale 
bar, 50µm. B) Bar chart shows quantification of average FRET efficiency 
representing interaction between EGFR and MET in each of the cell lines. Interaction 
between EGFR and MET is greatest in H1975L858R/T790M and lowest in H1975L858R. 
FRET measurement data obtained by time-resolved analysis in Tri2 for 3-5 fields of 
view per condition per experiment imaged. SEM bars shown (***p<0.0005, N=6). 




4.2.4 SGX523 results in effective and sustained blockade of phospho-MET  
Having demonstrated the importance of EGFR-MET interaction in our model, we 
wanted to explore the therapeutic effect of MET inhibition on the model and how it 
could differ according to the presence of EGFR mutants.  We utilized SGX523, as a 
MET kinase inhibitor because of its extremely high specificity.  Although not in clinical 
development because of renal toxicity, its selectivity ensured that we were 
manipulating MET without off-target effects and set about validating its activity in our 
models in vitro and in vivo (Buchanan, Hendle et al. 2009).  In the first instance it was 
important to verify the efficacy of SGX523 in the blockade of MET phosphorylation.  
The western blots in Figure 4.5 show an increase in the intensity of the bands 
corresponding to MET phosphorylation from a basal state with the addition of its 
cognate ligand, Hepatocyte Growth Factor (HGF).  Subsequently at all time points, 
there are no bands visible for phosphorylated MET once samples had been treated 
with SGX523.  Corresponding lysates were electrophoresed and blotted to total MET 
antibody to confirm that MET was expressed in these samples and were equivalent 
between the conditions to allow appropriate comparison (Figure 4.5 A). 
 
 
Figure 4.5. SGX523 effectively inhibits MET phosphorylation in vitro 
WB of phospho- and total MET from cell lysates of the untreated H1975 derived cell 
lines treated with HGF (25ng/mL) for 15 min ± pre-treatment with SGX523 (5mM) for 
the indicated times. Phopshorylated (P-MET) and Total MET (140KDa) levels are 
shown in separate blots. Lanes with samples exposed to SGX523 are indicated by their 
respective time points. hsc70 was used as loading control (70KDa), N=2. Images 
prepared on the Biorad analyser, scanned with Biorad Image Lab. In these blots we 
can see that in all cell lines, HGF increased basal phospho-MET signal. SGX523 
completely inhibited MET phosphorylation immediately and without recovery by 48h in 




4.2.5 In vitro effects of MET inhibition on cell proliferation and migration 
In order to assess the functional consequences of MET kinase inhibition, we assessed 
proliferative responses to drug treatment after 24h.  We only observed a significant 
decrease in the proliferation rate after MET inhibition in H1975L858R/T790M cells (Figure 
4.6) where the percentage of BrdU incorporating cells (red channel) was reduced. 
Representative images are shown and quantified in the bar graph.  We found that the 
proliferation of H1975L858R cells were not significantly inhibited by SGX523 in a BrdU 
incorporation assay, as evidenced (Figure 4.6) by a lack of change in the number of 
BrdU positive nuclei labelled by an anti-BrdU antibody with subsequent application of 
Alexa Fluor 546 conjugated secondary antibodies.  In this figure we see that the 
percentage of red “proliferating” nuclei stained for BrdU, as a proportion of the number 
of all blue, Hoechst counter-stained nuclei is unchanged after treatment (Figure 4.6). 
 
We also assessed proliferation in a 3D environment using an anchorage independent 
growth assay. In the presence of SGX523, there was a significant decrease in the 
number of colonies in the case of H1975L858R/T790M cells and in the number of large 
colonies in the H1975L858R cells. SGX523 had no effect in the 2D or 3D proliferation 
rate in the case of the H1975WT cells (Figure 4.6C). Total colony number reflects cell 
survival, whereas larger colonies as was the case of H1975L858R suggest greater 
proliferation with large numbers of cell per colony.  SGX523 therefore appears to be 
inhibiting different characteristics of the agar colony assay. 
 
Finally, using a random migration experiment, we established that cell motility was 
reduced by MET inhibition but was only significant in H1975L858R cells.  H1975L858R/T790M 
cells demonstrated reduced random migration also after treatment with SGX523, but 
this was not significantly different to baseline. Representative rose blots and 
quantification shown in Figure 4.7. 
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Figure 4.6. SGX523 inhibits proliferation in H1975L858R/T790M cells 
BrdU Proliferation assay. A) Representative images of the three cell lines grown at 
60% confluence on coverslips and treated or not with SGX523 for 24 hours. Scale 
bar, 20µm. BrdU positive nuclei (Anti-BrdU, Mouse Alexa Fluor 546) in the red 
channel show cycling cells, Hoechst dye is used a counterstain for all nuclei as a 
denominator (blue channel). B) Quantification was performed in ImageJ using a 
macro to count number of nuclei in red (BrdU +ve) versus blue (all nuclei) channels for 
5-10 views per section, using a threshold approach to separate nuclei from 
background. Averages plotted as a percentage of BrdU +ve nuclei. H1975L858R cells 
(top right panel) show the greatest % positive BrdU stained nuclei. Only 
H1975L858R/T790M cells however show significant inhibition of proliferation with SGX523 
treatment as shown by the reduction in red stained nuclei and the quantification in the 










Fig 4.6. (ctd) SGX523 inhibits proliferation in H1975L858R/T790M cells 
C) Anchorage-independent Agar Growth Assay. Soft agar colony formation in the 
H1975 derivate cell lines in the presence or absence of SGX523 (5µM). The 
graph shows the number of colonies after 3 weeks of growth. Quantification was 
performed in ImageJ using a macro to count number of colonies per field of view 
for 5-10 views per section, using a threshold approach to separate nuclei from 
background. Small colonies were defined as 100-1500µm circularity, and large 
colonies, >1500µm circularity. Number of colonies represents cell survival.  
Larger colonies suggest higher number of cell divisions/proliferation. Averages 
plotted. SGX523 treatment led to signficant reduction in small colony formation 
(dark grey) in H1975L858R/T790M cells. For large colonies (light grey), a signficant 
drug response was seen in H1975L858R instead.. SD Error bars shown (* p< 0.001 
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Figure 4.7. SGX523 inhibits random cell migration in H1975L858R 
A) Random migration assay of H1975 derived cells plated to low confluence in 
presence or absence of SGX523 (5µM) with timelapse microscopy >18h. 
Representative rose plots shown with tracks for all cells normalised to a common 
origin at the centre of the blot (velocity is µm/minute: x and y axis on plots are in µm. 
Tracks were made manually in ImageJ by isolating the centre of each cell of interest 
per frame and analysed by Mathematica notebook (3 fields of view, 10 cells per 
image).  B) Bar graph showing speed quantification of random migration velocity. SD 
bars shown (*p<0.005, **p<0.0001, N=4). Greatest migrational velocity is shown by 
longer tracks as in the case of the H1975L858R/T790M. Greatest change in track length 
were noted in the H1975L858R cell line and hence were considered the most 







4.2.6 Inhibition of MET changes the EGFR-MET interaction in vitro 
In view of the observed differences in the interaction between MET and EGFR in our 
cells resulting from the EGFR mutations at baseline, we hypothesised that MET 
inhibition would alter the interaction between EGFR and MET in the different mutant 
cell lines. To test this we measured the changes in the interaction between MET and 
EGFR using FRET-FLIM, before and after MET inhibition by SGX523 (see Figure 4.8) 
As is demonstrated in the quantification of average FRET across all pixels, we found 
that the interaction between MET and EGFR in H1975L858R/T790M cells was significantly 
reduced in the presence of SGX523 (see Figure 4.8A and B).  This is represented by 
the heat map images where the FRET interaction is changed from a predominantly 
high FRET, red pixel dominated image to a predominantly low FRET, blue pixel 
dominated image in the treated cells.  By contrast, in the H1975L858R cells, SGX523 led 
to a significant increase in EGFR-MET interaction compared to baseline, shown in the 
representative images as a switch from a blue heat map than the red treated heat map. 
There was no significant difference in the FRET between MET and EGFR before/after 
SGX523 treatment in the H1975WT cells which had generally low FRET values, shown 
in the representative images as blue pixels.   The intensity images (grayscale) show 
the EGFR and MET staining alone to confirm accurate staining of EGFR/MET. These 
FRET results provide evidence to support the hypothesis that MET kinase inhibition by 
SGX523 altered the direct interaction between MET and EGFR in a mutation-specific 










Figure 4.8. SGX523 changes the EGFR-MET interaction in vitro 
A) Fluorescence lifetime imaging performed in the three H1975 derived cell lines plated 
to subconfluence on coverslips with or without treatment with SGX523 (5µM) for 24 
hours.  Representative pseudocolour lifetime images with FRET efficiency 
accompanied by corresponding grayscale donor (EGFR-Alexa Fluor 546) and acceptor 
(MET-Cyanine 5) intensity images are shown. Scale bar, 50µm. B) Bar chart showing 
quantification of average FRET efficiency of EGFR-MET interaction performed in 
H1975 derived cells in presence or not of SGX523. Interaction between EGFR and 
MET is reduced with SGX in H1975L858R/T790M and increased in H1975L858R as in seen in 
the heat maps: becoming more blue (less FRET) or more red (more FRET) in line with 
the EGFR-MET dimer quantification. FRET measurement data was obtained in Tri2 for 
3-5 fields of view per condition per experiment imaged. SEM bars shown (**p=0.001, 
***p<0.0005, N=6). Quantification in Excel and GraphPad Prism. The variation 
indicated by the SEM highlights the consistent nature demonstrated by the data across 
multiple experiments.  
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4.2.7 Oral administration of SGX523 results in effective and sustained blockade 
of MET phosphorylation in vivo 
To test whether the differential effects of SGX523 on MET and EGFR interaction could 
be reproduced in vivo, we utilised the xenograft model based on the H1975-derived 
mutant cell lines.  H1975L858R/T790M, H1975L858R and H1975WT cells were injected into the 
flanks of immunosuppressed BalbC mice and tumours were allowed to grow for 2 
weeks.  Mice were then subjected to 12 days of treatment with SGX523 or vehicle 
alone, administered daily by oral gavage. Figure 4.9 demonstrates timings of drug 
administration. The intention of this part of the in vivo study was to obtain tumour tissue 
from murine xenografts grown in the presence of SGX523 or mock treatment for each 
mutant and to be able to compare their growth and biology. 
 
Figure 4.9. Time-line schematic of the murine in vivo model. 
Red bars indicate days of tumour measurement. The time-line divides on day 14 to 
represent initiation of treatment and separation of mock versus treatment mice.  
Vehicle or SGX523 were administered by gavage daily. See Chapter 2 Methods and 
figure legends for details about tumour numbers in individual experiments. 
 
Target tissue drug delivery was confirmed by WB and immunohistochemistry (IHC). A 
band at 140KDa corresponding to phosphorylated MET was visible in lysates coming 
from xenograft tumour specimens in the untreated cohort but not in the SGX523 
treated samples (Figure 4.10A). Phospho-MET immunostaining of xenograft tumours 
from each group also confirmed loss of phospho-MET signal in SGX523 exposed mice 
only suggesting that the drug was delivered effectively to the tumours with complete 
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Figure 4.10. SGX523 effectively inhibits MET phosphorylation in vivo and 
reaches xenograft tumours when administered by gavage 
A) WB of phospho- and total-MET in xenograft tumourlysates grown from each of the 
H1975 cell lines. Vehicle (mock) or SGX523 treated mice (60mg/kg) were used as 
indicated. B) Representative images of phospho-MET staining, in xenografts tumors 
grown from each H1975 derivate cell line coming from mice treated with vehicle 
(mock) or SGX523 as indicated. Scale bar, 250µm. The phospho-MET WB bands (2 
samples per tumour type) and strong brown staining of the phospho-MET 
immunohistochemistry were convincingly eliminated by treatment with SGX523 






4.2.8 In vivo effects of MET inhibition on tumour growth/proliferation 
We then analysed the in vivo effect of oral administration of SGX523 on tumour growth 
and proliferation. Tumour volumes were measured every two days to establish whether 
there was a direct effect arising from the treatment compared between groups.  This is 
shown in the linear graph of relative tumour growth normalized for each tumour type to 
1 (Figure 4.11A).  As was the case for the cells in vitro, The H1975L858R/T790M-derived 
tumours in SGX523 treated mice grew more slowly (lower line) than in vehicle treated 
mice (upper line); this effect was evident after 4 days of SGX523 administration and 
was sustained up to 14 days, where continued separation of the growth curves were 
seen. H1975L858R and H1975WTderived tumours lacked significant SGX523 responses 
over the 14-day growth period with both growth lines being closely apposed. This result 
was confirmed using a phospho-Histone H3 antibody and HRP developing (brown 
stained nuclei) as shown in (Figure 4.11B).  As shown in the quantification, the 
proportion of phospho-histone H3 positive nuclei being significantly reduced after 
SGX523 treatment is only seen in the H1975L858R/T790M xenografts. 
4.2.9 In vivo effects of MET inhibition on the tumour microenvironment 
To characterise the differences in response to SGX523 between the tumour xenografts 
further, we compared haematoxylin and eosin (H&E) staining in the mock and 
SGX523-treated groups for each of the three xenograft tumours types. As per the 
quantifications, we observed significant reduction in staining for collagen by Masson’s 
trichrome (MT) in H1975L858R as evidenced in the representative images by a reduced 
percentage of tumours with green collagen fibres between the cells (Figure 4.12A).  
Consistent with this, α-SMA was also significantly reduced in H1975L858R. In this case 
the representative images show stromal tissue stained brown in a similar pattern to the 
MT images (Figure 4.12B).  Finally the cd31 staining, which indicates endothelial cells 
in newly formed vessels, i.e. neo-angiogenesis (Figure 4.13) was also significantly 
reduced in the H1975L858R in the SGX523 treated tumours.  A drug effect was not 








Figure 4.11. In vivo effects of MET inhibition on cell proliferation 
Xenograft tumour growth curves. 3x106 cells were injected into both flanks of 
immunocompromised BALB/c nude mice and tumours allowed to grow for 14 days at 
which point administration of SGX523 (60mg/kg) or mock vehicle was commenced. 
N=16 tumours (8 mice, bilateral tumours) per condition. A) Graphs showing the fold 
change in volumes in the xenografts tumours coming from the three H1975 derived cell 
lines during the 12 days of treatment.  Tumours were measured at the indicated times 
using a calliper and volumes calculated (0.4xAxB2 where A=long axis and B=short axis 
of the tumour). SD bars shown. N=8-10 tumours per condition. We can see separation 
of the growth curves in H1975L858R/T790M suggesting SGX523 treatment effect in terms 
of proliferation in this cell line only. B) Quantification and representative images of 
tumour immunohoistochemistry for phospho-histone H3 (P-H3) of xenografts tumours 
coming from each H1975 derived cell line in the presence or absence of SGX523. 
Quantification was performed in ImageJ using a macro to score % threshold area 
(brown staining in representative image) in relation to background tissue for 6-10 views 
per section. Again there was more phospho-Histone H3 staining in H1975L858R tumours 
suggesting greatest % of proliferating cells. This was significantly reduced by SGX523 
in H1975L858R/T790M tumours.  Averages and SEM bars shown (**p<0.05). N=12-15 
tumours per condition. phospho-Histone H3 stained brown for actively proliferating cell 









Figure 4.12. In vivo effects of MET inhibition on stroma remodelling 
Xenograft immunohistochemistry from H1975-derivate mice treated with 
SGX523 or mock vehicle. Quantification and representative images shown for 
(A) Masson’s trichrome (collagen stains green) and (B) α-smooth muscle actin 
(α-SMA) staining of xenografts tumours. Quantification of the staining is shown 
above the images in plots from Prism Graphpad. For Masson’s trichrome, 
dominance of collagen-rich features in H1975L858R were scored to be highest by 
a consultant histopathologist (MM).  Averages plotted using Prism Graph Pad. 
α-SMA quantification was performed in Hamamatsu Nanozoomer software 
according to % staining (brown staining in representative images) in relation to 
background tissue. Both markers of stromal deposition were significantly 
reduced in H1975L858R. N=8 Tumours per condition. A) SD; B) SEM, *p<0.05, 







Figure 4.13. In vivo effects of MET inhibition on vascularisation 
Xenograft immunohistochemistry from H1975-derivate mice treated with SGX523 
(60mg/kg) or mock vehicle. Representative images and quantification shown for  
CD31 staining of xenografts tumours (FFPE). CD31 staining (brown) indicates 
neovascularisation. Scale bar, 250 µm. Quantification was performed in ImageJ 
using a macro to score % threshold area (brown staining in representative image) in 
relation to background for 6-10 views per tumour. Averages and SEM bars shown 
(*p<0.05, **p<0.01). CD31 indicating neovascularisation was significantly reduced in 
H1975L858R only. More heterogeneity for this marker was seen in H1975WT tumours. 
N=16 tumours per condition. 
 
4.2.10 Validating an EGFR-MET FRET assay in vivo 
We subjected the FRET antibodies validated earlier in this chapter (Section 4.2.3) to 
assessment in FFPE tissue. This is necessary since there is a high degree of 
autofluorescence in this tissue type and increase care required for antigen retrieval, 
both of which can impinge on FRET signal.  Although the MET (AF276) antibody could 
be demonstrated to provide specific staining in FFPE prepared tissue (Figure 4.14), the 
staining intensity in FFPE specimens was considered unfavourable for successful 
detection of FRET with the pre-existing in vitro pair and hence an alternative strategy 
was sought. We hence determined an alternative pair of antibodies, both of which were 
intracellular.  The first was the MET (D1C2) antibody, which had been recommended to 
us before by the histopathologist (MM) for other MET tissue staining within the group 
(seen in indirect staining in Figure 4.3).  This was employed alongside an EGFR (Ab-







A customised azide/BCA-free preparation of the MET (D1C2) antibody was obtained 
from the manufacturer and separate aliquots labelled with Alexa Fluor 546 or Cyanine 
5 dyes to establish whether the EGFR-MET pair would perform most reliably with MET 
as the donor or acceptor.   Labelling reactions were undertaken with assistance of Dr 
Weitsman who also provided advice on modification to the antigen retrieval method 
(See Chapter 2 Methods) to provide enhanced staining of FFPE specimens with the 
FRET antibodies. 
 
Figure 4.15 demonstrates staining of a mouse xenograft section from the mock group.  
Both EGFR (Ab-15) and MET (D1C2) provided adequate staining of FFPE prepared 
xenograft tissue. A low concentration of donor antibody in the presence or absence of 
an excess of acceptor was designed as is typical of FRET experiments. It was seen 
that the staining intensity of the EGFR (Ab-15) donor-pair was most favourable with the 
concentrations as specified and EGFR (Ab-15)-Alexa Fluor 546 selected as preferred 
donor and its concentration titrated accordingly against staining appearances in the 




Figure 4.14. Directly labelled antibodies remain specific on FFPE MCF7 pellet 
Antibody validation compared unlabelled and labelled antibody for use in FRET.  MCF-
7 cell pellet (FFPE) shown has been transfected with MET.  Hoechst counterstain 
(blue) used to demonstrate cell nuclei. MCF-7 MET+ cells co-stained with MET (D1C2)-
Alexa Fluor 546 (red channel) and MET (AF276)-Cyanine 5 (green channel) 
respectively. Co-localised signal (yellow) seen in merged channel shows that the 










 Figure 4.15. Donor:Acceptor staining intensity for EGFR vs MET donor in 
xenograft tumours (FFPE specimens) 
Example antibody titration steps. Example intensity images in Cy3 and Cy5 chanels 
for specified antibody combinations for a donor and acceptor pair of labelled 
antibodies against EGFR and MET.  A) MET Donor: MET (D1C2)-Alexa Fluor 546 
(red channel) and EGFR (Ab-15)-Cyanine5 (green channel) versus B) EGFR Donor: 
EGFR (Ab-15)-Alexa Fluor 546 (red channel) and MET (D1C2)-Cyanine 5 (green 
channel) staining within FFPE processed murine xenograft tumours at the antibody 
concentrations specified. EGFR and MET Co-localisation is shown (yellow) in merged 
channels with good quality staining that would be consistent with that expected for 
each antibody.  The epifluorescence images at these concentrations would be 
appropriate for FRET. Acceptor antibody is always required in excess. Imaging 
intensity for the combination in B was favourablle, with greater intensity even with 
lower concentrations of acceptor antibody. 
  
MET (D1C2) x546 (donor) EGFR (AB-15) Cy5 (acceptor) MERGE 
5mcg/ml 20mcg/ml      Red: MET; Green: EGFR 
EGFR (AB-15) x546 (donor) MET (D1C2) Cy5 (acceptor) MERGE 








Figure 4.16  Optimising donor antibody concentration antibody in vivo 
A) Representative FRET heat maps and grayscale images shown for Donor EGFR 
(Ab-15)-Alexa Fluor 546 staining in xenograft FFPE in presence or absence of dual 
staining with acceptor MET (D1C2)-Cyanine5. B) Quantification of FRET efficiency in 
the xenograft tumours at the donor antibody concentrations specified. Both show 
staining that favours the cell membranes with co-localisation (yellow) in merged 
channels. Acceptor antibody was used at 10mcg/ml. P<0.05 (0.5 vs 1mcg/ml). N=5 
points per condition. Each point represents FRET efficiency from the average of pixels 
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4.2.11 Inhibition of MET changes the EGFR-MET interaction in vivo 
We observed very similar results in the FRET assay optimized for use in the xenograft 
tissues (Figure 4.17) as we had in the in vitro data (Figure 4.8).  These samples were 
different from the in vitro cells on coverslips in that they required processing to exclude 
autofluorescence both in terms of the methodology and also in a requirement for tri-
exponential imaging to mask autofluorescence with an algorithm to exclude extremely 
low lifetimes correlating to such autofluorescence rather than that of the donor 
fluorophore.  Again we observed the highest FRET between MET and EGFR in 
H1975L858R/T790M derived tumours, and this was again significantly reduced by SGX523 
as reflected by a similar colour change from red to blue heat map pixels. In H1975L858R 
derived tumours, MET-EGFR interaction at baseline was low and increased 
significantly by SGX523.  There was no significant FRET change in xenograft tissue 
derived from H1975WT cells.  The FRET results were within narrow standard errors 
reflecting increased uniformity in the tumour sample lifetime readings coming from the 







































































































































































































































































































Figure 4.17. SGX523 changes the EGFR-MET interaction in vivo (Continued) 
B) Quantification of average FRET of EGFR-MET interaction performed in xenograft 
tumours from each H1975 cell line in mice receiving mock or SGX523 treatment for 12 
days. FRET efficiency is a quantitative measure of EGFR:MET interaction. 
Approximately 30 data points (within 4-6 tumours) per condition per experiment were 
imaged. SGX523 decreased FRET in H1975L858R/T790M and increased FRET in 
H1975L858R. Average and SEM bars shown (* p<0.05, *** p<0.001 N=2). 
 
4.2.12 EGFR-MET FRET can be detected in human FFPE biopsies. 
Finally we performed a brief validation of our FRET EGFR-MET assay in human tissue 
bank lung cancer biopsy specimens to establish if such an assay could be used to 
detect a FRET signal in human samples.  Time and resource constraints prevented an 
extensive comparison of different samples but this proof of principle experiment 
demonstrated that FRET could be detected in human tumour samples that had been 
processed routinely by FFPE and stored in a tissue biobank. A range of FRET values 
were obtained within each tumour and between different tumours likely representing 
intra-tumoural and inter-patient heterogeneity.  The range is demonstrated both in 
FRET but the demonstration of consistent donor lifetimes between different specimens 
is supportive of a robust assay with consistent performance of the assay across these 
intra- and inter-tumoral difference.  The FRET results were similar for three tumours 
although the FRET pattern within each differed, likely indicating intra-tumoral 








Figure 4.18. Proof-of-principle for EGFR-MET FRET assay in patient derived 






































































Figure 4.18. Proof-of-principle for EGFR-MET FRET assay in patient derived 
human lung cancer tissue bank specimens (FFPE) 
A) Representative FRET lifetime images for EGFR:MET FRET in three tissue biobank 
patient tumours accompanied by corresponding grayscale donor EGFR (Ab-15)-Alexa 
Fluor 546; 0.5mcg/ml and acceptor MET (D1C2)-Cyanine 5; 10mcg/ml) intensity 
images. Scale bar, 50µm. Lifetime images are tri-exponentially analysed and enable 
masking of artefactual lifetimes as is seen between the bright spots in the grayscale 
EGFR intensity images and the colour lifetime images (masked areas appear black). 
This is important as FFPE prepared specimens are more prone to artefact and 
autofluorescence due to processing techniques. Areas of high EGFR-MET FRET, 
corresponding to increased EGFR-MET interaction are indicated by red pixels. Low 
FRET is scored by blue pixels. B) Quantification of average FRET of EGFR-MET 
interaction performed in resection specimens from 13 human NSCLC tumours from the 
Guy’s tissue bank (FFPE). FRET efficiency is a quantitative measure of EGFR:MET 
interaction. 8-12 data points per tumour per experiment were imaged. Average and 
SEM bars shown. N=13 patients. The range of values seen are likely to represent both 
intra-tumoural heterogeneity and variability between different patients.  
 
4.2.13 Effects of MET inhibition on ERK, AKT and FAK signaling 
In light of the differential effects of MET kinase inhibition between the different cell lines 
on MET and EGFR FRET, cell proliferation and stroma remodelling, we looked for 
differences in AKT, FAK and ERK to explain this.   All have been linked to MET 
signaling and we expected also to see differential effects of MET kinase inhibition on 
this signaling pathway (Gusenbauer, Zanucco et al. 2015).  We treated 
H1975L858R/T790M, H1975L858R and H1975WT cells in normal replete medium, with 
SGX523 for 24 hours and assessed phosphorylation levels of ERK.  
 
Figure 4.19A shows the western blots and the corresponding phosphorylated forms.  
SGX523 effect on MET was confirmed by the absence of a band for phosphorylated 
MET in each of the treated lanes.  There was no effect on EGFR phosphorylation in 
response to the MET inhibition. There was a significant reduction in ERK 
phosphorylation in SGX523 treated H1975L858R/T790M cells as shown for the 
quantification for these western blots which represents the intensity of the phospho-
ERK band compared to total ERK.  This could account for the reduction that we saw in 
proliferation in this cell line, but as per the Western blot the inhibition of ERK 
phosphorylation was incomplete and was only observed in this H1975L858R/T790M cell line 
(Figure 4.19B). Analysis of xenograft tumour lysates obtained from SGX523 or vehicle-
treated animals also showed reduction in the band for phosphorylated ERK in 
H1975L858R/T790M-derived xenografts alone (Figure 4.19C). Bands for total levels of 
these proteins were comparable. We then looked for AKT and FAK as an alternative 
explanation for the different responses in inhibition of the stroma and migration in the 









   
Figure 4.19. Effect of SGX523 on ERK phosphorylation in H1975L858R/T790M 
A) WB of phospho- and total EGFR, MET, AKT, ERK and FAK from cell lysates of the 
different H1975 cell lines treated or not with SGX523 for 24 hours. hsc70 levels are 
also shown as loading control. B) Quantification of the P-ERK vs T-ERK WBs shown in 
(A) in the three H1975 derivate cells. SD Bars shown. (*p<0.05, N=3). C) WB of 
phospho- and total-ERK in the extracts coming from the H1975L858R/T790M  xenografts 
tumours in mock vehicle (lanes 1-4) and SGX523 treated mice in lanes 1-4 and 
SGX523 lanes 1-3 corresponding to different tumours from each of these respective 
treatment groups. hsc70 is also shown as loading control. D) WB of phospho- and total 
AKT and FAK from cell lysates of the different H1975 cell lines treated or not with 
SGX523 for 24 hours.  The only change in signaling we observed from this data was a 
reduction in phospho-ERK in response to SGX523. This was not marked but was 
confirmed by densitrometry (see B) and also observed in vivo (C). No effect was seen 







Since we had expected to see differences in AKT in response to MET inhibition we 
hypothesised that this could be due to an absence of ligand in these experiments.  We 
proceeded to assess the cell lines for the signaling response (P-AKT and total AKT) to 
SGX523 treatment, using the respective ligands for EGFR/MET i.e. EGF and HGF, to 
mimic more closely the tissue microenvironment. Phosphorylation signal was visibly 
changed from baseline in pAKT blots following EGF exposure in all conditions.  HGF 
increased pAKT signal in H1975WT. In the other cell lines it was less easy to distinguish 
this visually. In H1975L858R/T790M there appeared to be a reduction in the EGF (and EGF 
+ HGF) exposed samples with SGX523 treatment consistent with the crosstalk 
expected in this line. It was not possible to clearly delineate a response to SGX523 in 
the presence of ligand in the other cell lines, nor with HGF, even after densitometry.   
We concluded that the only ligand response in these two signaling pathways that 
resulted in a different response to SGX523 was the reduction in EGF-mediated signal 
in the H1975L858R/T790M cells consistent with the loss of the EGFR-MET dimer in this line.  
From this we could conclude that HGF is not able to overcome the inhibition produced 
by SGX523, and that EGF is not the ligand responsible for the differences in the other 




 H1975L858R/T790M H1975L858R H1975WT 
 
Figure 4.20. Response to EGF/HGF stimulation versus MET inhibition on AKT 
and phosphorylation In vitro 
 
WB of phospho- and total AKT from cell lysates of the different H1975 derived cell lines 
treated or not with SGX523 (1h) in the presence or absence of EGF, HGF or both for 
15 minutes. hsc70 levels were used as loading control. Quantifications are shown for 
phospho-AKT normalised to hsc70. The x-axis of the quantifications matches the labels 
above the Western blots, re-labelled with the following letters for clarity B-Basal, E-
EGF, H-HGF or EH-EGF+HGF (untreated then SGX523 treated lanes accordingly). 
EGF alone or in combination with HGF increases the pAKT signal. HGF only increases 
pAKT in the case the H1975WT cell line but this is negligible when accounting for the 
loading control in HSC70. No change was observed from SGX523 treatment except 
modulation of a pAKT signal change seen in response to EGF in H1975L858R/T790M 
(N=2). This is reminiscent of HER2 which alone can activate ERK but requires 
dimerisation with HER3 for PI3K/AKT signaling and supports an interaction between 
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In summary, MET interacts with EGFR differently in cells that encode WT, L858R and 
L858R-T790M-EGFR and modulates the tumour cell behaviour as well as the 
interaction with the stroma. More importantly, the inhibition of MET by SGX523 
modulates this interaction depending on the EGFR mutation. This interaction appears 
to be in opposite directions in L858R and EGFR L858R-T790M encoding cells in vitro 
and in vivo.  Namely EGFR and MET are dimerised when EGFR is double mutated 
(H1975L858R/T790M) but not with the single mutant form (H1975L858R). MET therapy 
seemed to be active in both mutated cell lines but in the case of the single mutant 
(H1975L858R), it enhanced formation of the EGFR-MET dimer where as in the presence 
of the double-mutant it reduced it (H1975L858R/T790M).  We saw downstream changes in 
ERK in H1975L858R/T790M that may account for the reduced proliferation but couldn’t 
establish downstream pathways that accounted for the drug response in the other cell 
lines. 
 
Unfortunately I had no further time/resources to explore downstream pathways more 
comprehensively.  We were clear that the EGFR-MET dimer differed with the EGFR 
mutations. Another hypothesis would be that these dimers had consequences for an 
additional receptor depending on the EGFR mutant present.  A good candidate to 
explore further would be HER3, which is a preferred heterodimer partner of EGFR and 
HER2 and has also been linked to MET amplification.  I explore these themes further in 







In this section I focus on our observation that in a model of lung adenocarcinoma, 
EGFR-MET crosstalk depends on EGFR genotype and we believe as a consequence 
so does the response to MET inhibition. 
4.3.1 Do EGFR and MET interact in lung adenocarcinoma? 
Consistent with a wealth of existing literature that supports EGFR-MET crosstalk (Jo, 
Stolz et al. 2000, Puri and Salgia 2008, Tang, Du et al. 2008, Zhang, Staal et al. 2010), 
we used our in vitro model, to confirm EGFR and MET proximity at the cell membrane 
by immunofluorescence and interaction with co-immunoprecipitation (co-IP).  This 
provided us with evidence that within our H1975 derived lung adenocarcinoma model 
based on the L858R and T790M EGFR driver and resistance mutations, EGFR and 
MET can exist alongside each other at the cell membrane. Our co-IP results supported 
a direct interaction between these receptors and additionally the conjectured EGFR 
mutational status dependent differences in this EGFR-MET crosstalk that we saw 
between the cell lines by FRET-FLIM. 
 
In our FRET experiments we saw high levels of FRET in the H1975L858R/T790M cells and 
xenografts that were not seen in the H1975L858R cells or tumours.  This would be 
consistent with a high proportion of EGFR existing as EGFR-MET dimers in the 
presence of the EGFR-TKI resistance mutation T790M. EGFR-MET dimerisation in 
H1975L858R/T790M is consistent with the existing literature of EGFR-MET crosstalk in lung 
adenocarcinoma and also our earlier results showing co-localisation of the two proteins 
at the membrane. Equivalent findings were seen in vitro and in vivo affirming the 
validity of this approach (Engelman, Zejnullahu et al. 2007). 
 
Dimerisation is known to be a critical component of both EGFR and MET signaling. In 
the case of EGFR, we have already discussed how receptor homodimerisation and 
heterodimerisation are crucial to activation of the kinase domain and known to be 
influenced by EGFR mutations (Shan, Eastwood et al. 2012).  MET is also recognized 
to signal as a dimer and is also sensitive to ligand independent dimerisation in the 
presence of mutations and genomic amplification (Wickramasinghe and Kong-Beltran 
2005). However, little is known about the physical or structural nature of a putative 
EGFR-MET dimer.  We could infer from the conformational changes seen in EGFR 
dimerisation in general that a similar mechanism might apply. For example this may 
occur through allosteric interactions mediated through the dimerisation arm or 





As discussed in chapter 3, L858R induces changes in the EGFR ectodomain structure 
that render the single mutant L858R EGFR in an extended, dimerisation-competent 
conformation which has also been shown to encourage EGFR homodimerisation 
(Valley, Arndt-Jovin et al. 2015, Valley, Arndt-Jovin et al. 2015). MET activation 
resembles that of the HER receptors, whereby autophosphorylation following HGF 
induced dimerisation ejects the activation loop into an extended conformation 
reorienting the alpha C helix to form a viable active site.  We might have expected that 
the extended confirmation of EGFR L858R was more able to interact with MET. 
However this hypothesis does not match the observations from the FRET experiments 
where untreated H1975L858R cells/tumours had low levels of EGFR-MET interaction.  In 
the case of H1975L858R, EGFR structural changes may therefore favour EGFR 
homodimer formation in preference over the EGFR-MET heterodimer or even sterically 
preclude the interaction with MET. 
 
In H1975L858R/T790M, EGFR-MET dimerisation occurs basally. It is not clear why the 
L858R and T790M mutants behave differently in this respect but there is a free-energy 
difference between the two mutants that alters the propensity for transition between the 
active and inactive states and as well as the positioning of residues known to be 
important in EGFR homodimerisation. Such conformational changes could alter the 
dimerisation domains to favour interaction with MET in the presence of the L858R-
T790M double mutation but not L858R alone (Yun, Mengwasser et al. 2008, Rickert, 
Patel et al. 2011, Sutto and Gervasio 2013). 
 
It is also not clear whether an EGFR homodimer is required to activate MET (see 
Figure 4.21A) or whether union EGFR and MET monomers would suffice. In the case 
of the latter, it is possible that a MET ‘donor drives activation of EGFR as the acceptor 
or vice versa (Figure 4.21B & C). This is well aligned to the model of specialisation of 
EGFR mutants as discussed in chapter 3 since one of the orientations might be 
favoured by an EGFR mutant acting as a more efficient acceptor as is described for the 
EGFR L858R mutant (Red Brewer, Yun et al. 2013).  This preference for a role as 
donor or acceptor might differ between the L858R and L858R-T790M mutants for the 





Figure 4.21 Models of EGFR-MET dimerisation. 
Schematic of interaction between EGFR mutants to homodimerise with EGFR or 
heterodimerise with MET.  Solid black arrow demonstrate transactivation of receiver 
kinase by activator.  Dotted line shows possible reciprocal activation of the activator by 
the receiver.  In A) the homodimeric EGFR complex may lead to MET activation.  The 
models depicted in B) and C) suggest that EGFR and MET interact directly with 
transactivation that would result in phosphorylation. In B) MET is in the activator 
position whereas In C) EGFR is an activator. Additional allosteric interactions between 
partner kinase domains may act to alter the activation state. Adapted from (Littlefield 
and Jura 2013). 
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4.3.2 MET TKI effect on the EGFR-MET interaction 
MET mediated resistance to EGFR TKI is primarily attributed to MET amplification.  
Use of MET therapies has potential in this group but is still poorly defined. A number of 
pre-clinical studies also demonstrate enhanced efficacy from dual EGFR and MET 
inhibition but there is also sparse data on the role of other EGFR TKI resistance 
mechanisms such as T790M.  For example, in the H1975 and H8227 cell lines, both of 
which have increased MET expression, there is a synergistic response to combined 
EGFR and MET therapy - in H8227 this overcomes EGFR TKI resistance mediated by 
MET amplification whilst in H1975 it is an EGFR T790M gatekeeper resistance 
mutation that can be surmounted (Engelman, Zejnullahu et al. 2007, Wang, Li et al. 
2010, Zhang, Staal et al. 2010). 
 
We hypothesised that the different responses of each cell line to SGX523 would be due 
to the effect of this drug on MET in the direct physical interaction with EGFR. The 
physiological effects observed e.g. proliferation/stromal interaction following MET 
inhibition would then either represent the effect of SGX523 on one or both of: 
1) MET inhibition modulates dimer formation between EGFR and MET which has 
consequences for EGFR and MET signaling. 
2) MET inhibition prevents the capability of MET to phosphorylate EGFR within the 
heterodimer, which therefore alters the EGFR mediated signal. 
 
According to our results from Figure 4.8 and Figure 4.17, MET inhibition does alter the 
interaction between EGFR and MET differently according to EGFR mutation status, 
thus supporting the first example.  EGFR L858R-T790M preferentially bound to MET in 
the absence of SGX523, suggesting this is related to its activated form, whereas once 
bound to SGX523 the conformation of MET is unfavourable to EGFR binding.  The 
reverse would thus be true of the EGFR L858R conformer. No such modulation was 
seen in H1975WT suggesting that the altered binding by MET in its active or inactive 
form was related to the presence of mutated and not WT-EGFR. 
 
Mechanistically, a possible explanation relates to the consequences of TKI binding on 
the kinase structure with relation to partnered N and C-lobes opposed around a cleft 
into which either ATP or such ATP-competitive inhibitors can bind (Stamos, Sliwkowski 
et al. 2002). ATP competitive inhibitors can present hydrogen bonds to the active site 
than mimic those of the adenine ring of ATP (Zhang, Yang et al. 2009). Inhibitors that 




SGX523 preferentially binds an un-phosphorylated, inactive conformation of MET 
which upon binding results in occupation of the ATP binding site by a tyrosine residue 
(Buchanan, Hendle et al. 2009).  This stabilises an unusual “DFG-In” conformation 
more usually associated with enzymatic activity (Buchanan, Hendle et al. 2009). 
SGX523 has a bivalent structure of which a quinolone moiety engages the MET hinge 
region resembling the binding of other ATP competitive inhibitors, which bind at this 
position but instead stabilizes an atypical activation loop conformation that internalises 
the kinase activation loop into the ATP binding pocket to preclude phosphotransfer at 
this site (Buchanan, Hendle et al. 2009). Thus whilst SGX523 is ATP-competitive, 
unlike other similar kinase inhibitors which target the ATP binding site in the active 
conformation, SGX523 binds the ATP binding site of an inactively conformed MET (Liu 
and Gray 2006). Interestingly, the DFG-in conformation is more often associated with 
an extended conformation that ejects the activation loop usually seen with the 
activated, phosphorylated form of MET (Rickert, Patel et al. 2011) This conformation 
could favour allosteric interaction with EGFR in H1975L858R cells. 
 
The wider literature surrounding drug inhibition of receptor tyrosine kinases provides a 
number of examples of how these agents can alter the tendency of kinases to dimerise 
and in some cases paradoxically increase receptor-receptor interaction.   For example 
there is evidence that EGFR homodimer formation can be enhanced by gefitinib or 
erlotinib treatment (Coban, Zanetti-Dominguez et al. 2015). In fact, various 
intermediates of EGFR oligomerisation are recognized following EGFR kinase 
inhibition (Bublil, Pines et al. 2010). HER2-HER3 dimer formation also occurs in breast 
cancer following treatment with Lapatinib (EGFR/HER2 directed TKI)(Scaltriti, Verma et 
al. 2009, Claus, Patel et al. 2014). This can also be associated with unexpected 
phenotypical responses to TKI treatment. 
 
The clinical significance of TKI-induced dimers is further exemplified well by BRAF 
resistance arising as a consequence of transactivation of RAF dimers in the presence 
of ATP-competitive RAF inhibition (Poulikakos, Zhang et al. 2010). This paradox 
whereby TKI can increase tendency to dimerisation suggests our understanding of the 
mechanism of tyrosine kinase signaling and the translation of their blockade to cancer 
therapy is incomplete. 
 
Beyond inducing or preventing dimer formation, inhibition of kinase activity, the primary 
goal of TKI should have inevitable consequences for crosstalk. Previous studies 
demonstrate that EGFR inhibitors can block MET phosphorylation and conversely that 
MET inhibitors can block EGFR phosphorylation (Lutterbach, Zeng et al. 2007, Guo, 
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Villen et al. 2008, Tanizaki, Okamoto et al. 2011). However, in all cell lines we saw 
complete inhibition of MET phosphorylation in response to SGX523 implying that any 
direct action arising from MET independently of EGFR would not appear to differ 
between the cell lines. 
 
With regards to crosstalk mediated signaling, as demonstrated in Figure 4.22, the 
effect of SGX523 would differ between the two mutant cell lines in the following way: 
 
1) In the case of H1975L858R/T790M, SGX523-treated cells, the EGFR-MET dimer 
separates and consequently eliminates any signal that was emanating from 
MET acting on EGFR or EGFR acting on MET (cross-phosphorylation or 
allosteric interaction that promoted autophosphorylation). Inhibition of MET 
autophosphorylation would persist  (MET kinase inactivated by SGX523). 
2) Conversely, in the case of H1975L858R there is now an EGFR-MET dimer.   
MET autophosphorylation signal is still lost  (again, MET kinase is 
inactivated by SGX523) but MET can still act allosterically on EGFR via 
EGFR mediated signaling mediators. EGFR can now also allosterically alter 
the activity of MET. 
 
In summary, in H1975L858R/T790M the EGFR-MET dimer is disrupted by SGX523 whilst in 
H1975L858R it appears that EGFR L858R cannot bind with MET unless in an SGX523 







Figure 4.22 SGX523 effect on EGFR-MET heterodimers 
The possible points of SGX523 interference with signaling downstream of EGFR and 
MET are highlighted. In H1975L858R/T790M untreated cells could cross-phosphorylate and 
interact allosterically.  All such interactions are lost with breakage of the dimer and 
whilst EGFR could autophosphorylate as a homodimer, MET kinase activity is inhibited 
by SGX523. Conversely in the case of H1975L858R, formation of the EGFR-MET dimer 
following SGX523 treatment, although not able to become activated due to MET kinase 
inhibition, allosteric interaction could still change the behaviour of the receptor. 
 
4.3.3 MET inhibition and tumour cell traits? 
In chapter 3 we observed an association between EGFR mutation type and cell 
phenotype, which resulted in different tendencies towards proliferation, migration and 
tumour microenvironment traits such as stroma formation. In this chapter we see that 
these phenotypes respond differently to MET inhibition across the cell lines.  Since 
EGFR-MET interaction also differs with EGFR mutation status and SGX523, we 
expected that these features would be linked to the changes we saw in proliferation, 
migration etc. (Trusolino, Bertotti et al. 2010).  We thus began to contemplate a model 
of how the EGFR and MET interaction when modified by targeted MET therapy could 
influence tumour cell traits. 
 
Proliferation was only significantly inhibited in the ‘double mutant’ cell line 
H1975L858R/T790M as shown by the BrdU incorporation assay and agar colony formation 
and similarly in the xenograft model we only saw a significant reduction in growth and 
phospho-Histone H3 staining in xenografts coming from this this cell line.  We observed 










































xenografts following SGX523 administration but with no effect in the other cell lines.  
The MET inhibition effects on proliferation are most consistent with the EGFR-MET 
dimer being an important determinant of proliferative growth that is responsive to MET 
inhibition since we saw loss of EGFR-MET dimer in H1975L858R/T790M cells and tumours 
with SGX523 treatment, along with suppression of proliferation. It is likely that there is 
redundancy between EGFR and MET, since we saw low amounts of EGFR-MET FRET 
in the more proliferative H1975L858R cells/tumours, suggesting that here EGFR exerts a 
greater effect on cell cycling either as a homodimer independently of MET or in 
association with another receptor heterodimer pairing, for example HER3 as we 
discussed with the data on defective internalisation in Chapter 3.  According to our 
FRET data, the apparent increase in the features of the tumour microenvironment 
(collagen, anti-SMA) in H1975L858R xenografts is unlikely to have arisen through direct 
EGFR-MET interaction since we did not observe the EGFR-MET dimer under basal 
conditions in this mutant.  The increased capacity for proliferation of EGFR L858R-
driven cells may itself increase the degree of interaction with the stroma. 
 
The effect of SGX523 on cell migration and the xenograft microenvironment were 
however most apparent in H1975L858R and in this cell line, SGX523 also increased 
dimerisation of EGFR with MET.  MET in this interaction is presumed to be inactive and 
dephosphorylated. The response to SGX523 could therefore reflect the inhibition of 
MET alone, independent of EGFR.  Alternatively, the dephosphorylated, SGX523-
bound form of MET could allosterically modulate EGFR in a more regulatory capacity.  
It is also conceivable that MET inhibition has an effect on the tumour stroma 
independent to its direct activity on tumour cells, for example it has been shown that 
HGF enhances fibroblast migration towards an HGF gradient and HGF secretion by 
fibroblasts can stimulate the invasive activity of tumour cells (Qian, Mizumoto et al. 
2003, Matsumoto and Nakamura 2006). We saw reduction of anti-SMA staining, a 
marker of fibroblasts in response to SGX523 suggesting that these cell types 
additionally were directly inhibited by MET inhibition, that may not have reflected a 
direct effect of the EGFR-MET dimer. 
 
The complexity of these observations highlights how even exploring the interaction of a 
pair of molecules, whilst advantageous compared to analysis of a single protein e.g. 
EGFR mutations, still lacks clarity to explain the wider protein network.  In any case, 
the different response to MET inhibition between the cell lines suggested that we were 
modifying not only MET, but that this effect also involved EGFR in one or more of the 
cell lines.  Alternatively another signaling pathway that was regulated by the EGFR 
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mutant status was also altered by MET inhibition.  The FRET data provided evidence to 
support the hypothesis that the EGFR-MET interaction could be responsible. 
4.3.4 MET inhibition and downstream signaling in EGFR mutants 
To validate and extend upon our observations and to understand how the EGFR and 
MET signals could be differentially transduced to traits of proliferation versus 
microenvironment interaction and invasiveness, we explored alterations in downstream 
signaling pathways in response to treatment that would explain the intracellular effector 
pathway through which this was acting.  In the H1975L858R/T790M cells, where we 
observed EGFR-MET dimer presence at baseline, we expected that MET would 
modulate EGFR binding sites e.g. for AKT or ERK or alternatively, the interplay with 
MET could provide a secondary set of effector molecules through MET binding sites or 
other receptors (Engelman, Zejnullahu et al. 2007).  It was thus surprising that we 
found only subtle differences in the most common downstream signaling pathways 
AKT and FAK, between the three cell lines. 
 
We did see that SGX523 suppressed MET derived downstream activity through ERK 
but this occurred only in the H1975L858R/T790M cell line.  ERK is an important mediator 
linked to EGFR and MET signaling and provided a plausible mechanism for the 
inhibition in proliferation we saw in the H1975L858R/T790M cells and tumours but not the 
other cell lines.  There was not time to extend this work to other signaling pathways but 
this suggests that another downstream effector might be involved or alternatively there 
could be further complexity in the downstream changes seen in these pathways that 
meant that we did not see a clear signal change. 
 
When we relate these findings back to the consequences of EGFR-MET interaction on 
downstream signaling as described above, we considered that the loss of the EGFR-
MET dimer in H1975L858R/T790M with SGX523 treatment, occurred alongside a loss of 
ERK signal suggesting that an active EGFR L858R-T790M-MET dimer is favourable for 
effective ERK signaling.  This observation was unique to H1975L858R/T790M suggesting 
that the dimer is relevant in the suppression of this pathway.  We saw no effect here in 
AKT/FAK. In the case of the H1975L858R, the induction of the EGFR-MET dimer by 
SGX523 resulted in no detectable alterations in downstream signaling such as ERK, 
AKT or FAK.  This may imply an alternative pathway is effected or that the 
complexity/redundancy in the system preventing us from detecting a clear difference in 
signaling in response to SGX523 exposure.  Alternatively there may be a paracrine 
consequence for EGFR-MET signaling in the context of MET inhibition or an effect of 
SGX523 on the stroma itself. 
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4.3.5 The challenges of using FRET-FLIM to develop a MET biomarker 
Companion diagnostic biomarkers are important to enable more rapid and effective 
deployment of drugs in clinical trials by enhancing outcomes as a percentage of trial 
participants. There is potential to learn more about the differences between different 
MET inhibitors by studying subgroups of patients positive for different biomarkers to tell 
us more about which patients may or may not respond. Biomarkers indicative of 
resistance through MET activation may also become increasingly relevant with 
evolution of later generations of EGFR TKI where MET-mediated resistance remains a 
problem (Shi, Oh et al. 2016).   
 
Our FRET-FLIM assay using EGFR and MET antibodies directly labelled with 
neighbouring fluorophores provides an alternative means by which to study the EGFR-
MET interaction directly. Although nanoproximity approaches have been used to 
explore other EGFR/HER (Human Epidermal Growth Factor Receptor) family 
interactions in other cancers (Tao, Castel et al. 2014, Coban, Zanetti-Dominguez et al. 
2015), to the best of our knowledge, this is the first work that utilises FRET-FLIM 
imaging to demonstrate EGFR-MET interaction and one of a limited number of studies 
using this approach in lung cancer.  FRET-FLIM assays are unique in their study of 
dimer formation in that they are able to quantify interaction at the nanometre scale (5-
10nm)(Kelleher, Fruhwirth et al. 2009).  Using this technique of imaging antibodies with 
directly conjugated fluorophores in overlapping spectra, it is possible to measure the 
extent of fluorescence decay in the donor antibody-fluorophore conjugation when in 
close proximity to an acceptor fluorophore directly ligated to a partner antibody against 
another protein of interest. 
 
 
Figure 4.23. Schematic: EGFR-MET FRET Asssay 
EGFR bound to antibody conjugated with donor fluorophore (e.g. Alexa Fluor 546) is 
measured in presence or absence of an antibody labelled with the acceptor fluorophore 
(e.g. Cyanine 5) targeted against the second protein of interest, i.e. MET. Binding of 
EGFR and MET is shown by interaction (FRET) between donor and acceptor 
fluorophores quantified by reduction of lifetime measurement (τ) in the donor 





We designed and optimized an assay for an EGFR antibody-bound donor fluorophore 
(Alexa Flour 546) and a MET antibody bound acceptor (Cyanine 5).  Initially an 
extracellular pair, EGFR (Ab-5)x546; MET (AF276)Cy5 provided specific staining when 
assessed on in vitro and FFPE specimens overexpressing EGFR/MET respectively.  
Poor FRET assay performance of this pair on FFPE tissue however, required 
converting to the intracellular pair.  After searching for an appropriately specific MET 
antibody, a labelled version was then subjected to further validation to assess 
specificity using transient transfection for overexpression and review of donor:acceptor 
antibody concentrations/ratios most compatible with a FRET signal.  Attempts to 
optimize a similar assay using a MET donor (and corresponding EGFR acceptor) 
identified this combination as a less effective FRET pair.  In the interests of time and 
resource constraints, we proceeded with the EGFR (Ab-5)x546-MET(D1C2)cy5 
combination.  Tissue preparation including borohydride quenching steps to suppress 
autofluorescence and a purpose-made algorithm validated previously, capable of 
eliminating noise from residual autofluorescence was employed to mask any residual 
autofluorescence at the extremes of expected lifetime measurements observed in the 
FFPE specimens (Tao, Castel et al. 2014). 
 
It is common for FRET assays to behave differently in the in vitro and in vivo settings in 
this way as a consequence of differences in EGFR-MET interaction with surrounding 
tissue.  There is also often an increased problem with auto-fluorescence in formal fixed 
paraffin embedded (FFPE) specimens.  For our FFPE tissue, we utilized a specialized 
algorithm for tri-exponential analysis with gating that masks out the very-low non-
specific lifetimes typical of auto-fluorescence that had been developed in the lab 
previously and enabled more consistent data analysis. Overall there was good 
concordance between the data in each of these settings. 
 
The increased FRET observed between EGFR and MET in the H1975L858R/T790M cell 
line represents an increased proportion of EGFR bound by MET.  This is likely to reflect 
a greater affinity between this ‘double mutant’ form of EGFR with MET that exceeds 
that seen for the other EGFR mutants and WT.  Alternative explanations of the 
differences observed could potentially have resulted from intrinsic differences in the 
behaviour of EGFR and MET in the three different cell types – either determined by 
EGFR directly or its interaction within a larger system of cancer-driven signaling.  This 
may alter the quantities of EGFR and MET available to dimerise and thus a difference 
in the quantities of EGFR or MET and a different EGFR: MET ratio between the cell 
lines could be significant.  Against this argument we found MET copy number and 
expression levels to be broadly similar between each of the cell types.  EGFR levels 
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similarly were comparable and we considered it more likely that the presence of the 
designed mutations would be of greater significance, although this may have 
influenced the pattern of EGFR homodimers relative to EGFR-MET heterodimers.  
Given the promiscuity in receptor dimerisation and lateral signaling recognized with the 
EGFR family, it is possible that a third protein or receptor could influence the EGFR-
MET interaction to a different degree depending on the EGFR mutation present i.e. one 
mutant form might be more sequestered by another molecule and therefore less able to 
interact with MET. 
 
Additionally, our studies cannot discriminate between the binding of MET with 
monomeric EGFR as 1:1 or with an EGFR homodimer in a 1:2 or 1:many ratio or if 
EGFR and/or MET dimer: dimer or higher order oligomerisation is required for EGFR-
MET crosstalk and how this differs depending upon the presence of EGFR mutations. 
This could be explored further with overexpression experiments in in vitro based 
assays, which quantify FRET in varying ratios of EGFR: MET availability.  Other 
nanoproximity studies such as single molecule imaging could be of utility here. In the 
case of higher order oligomers, MET may facilitate or impede EGFR homodimer 
formation or modulate the kinase activity of EGFR molecules within the homodimer. 
 
Furthermore, the FRET results for our chosen EGFR donor - MET acceptor pair 
representing the proportion of EGFR bound to MET, may differ when compared with 
the alternative (MET donor with EGFR acceptor pair), which would signify the 
proportion of MET bound to EGFR.  The stoichiometry of the EGFR-MET crosstalk 
could be significant to the interpretation of this format of the assay.  When FRET signal 
is low, there are fewer EGFR molecules dimerised with MET and the reverse with 
increased FRET.  This does not tell us whether this reflects a change for example of 
15% to 5% of the total EGFR pool or 70 to 50%.  We have no data on the relative 
receptor concentrations of EGFR and MET and how this is affected by EGFR 
activation, by the presence of each mutation or MET inhibition. We could also consider 
that not all EGFR molecules are likely to be occupied by a MET heterodimer pairing 
(and vice versa) and that this may not be constant but instead dynamically altered by 
the presence of these mutations/kinase inhibitors. It could be possible to establish 
further information by choosing a MET donor to increase sensitivity although there is a 
time and cost implication to be considered in so doing.  Nonetheless, the information 
that we have obtained remains useful but must be interpreted in the context of the 





In summary, these results highlight the effects of EGFR mutation status and MET 
inhibition using the novel approach of FRET-FLIM imaging to explore the interaction 
between EGFR and MET. We noted that EGFR mutant status alters the propensity to 
EGFR-MET interaction, in that the EGFR L858R-T790M mutant interacted more readily 
than EGFR L858R or EGFR WT forms. This could be relevant to the differences 
observed between the phenotypes of each of the cell lines in Chapter 3. 
 
The further important observation was that response in terms of changes in these cell 
phenotypes e.g. proliferation and migration in vitro and xenograft tumour growth and 
microenvironment following MET inhibition with SGX523 is dependent upon EGFR 
mutational status. We also saw that MET inhibition altered the EGFR-MET interaction 

























Chapter 5. Discussion 
This thesis adds important data to the literature on the mechanistic details of the 
EGFR-MET interaction.  In this discussion I consider the possibilities on how this fits 
with existing structural data on EGFR dimerisation, how this might be useful in clinical 
studies, what an EGFR-MET assay would add to EGFR mutation testing and how this 
relates to MET targeted therapy. 
 
5.1 Why does EGFR genotype influence EGFR-MET interaction? 
EGFR mutations in lung cancer are widely studied in the context of sensitivity and 
resistance to EGFR Tyrosine Kinase Inhibitors (TKI).  In chapter 3, I explored the 
hypothesis that EGFR mutations have a role to play beyond this in terms of tumour cell 
traits and EGFR activation.  In Chapter 4, I developed an EGFR-MET FRET assay to 
provide new evidence that EGFR-MET interaction is determined by the same EGFR 
mutations that are important clinical determinants of EGFR TKI responsiveness and 
EGFR homodimerisation (Sharma, Bell et al. 2007, Rosell, Carcereny et al. 2012, 
Shan, Eastwood et al. 2012).  In the case of the double mutant, H1975L858R/T790M EGFR 
and MET could interact whereas in H1975L588R they could not. 
 
EGFR mutation-determined EGFR-MET dimerisation could be the result of structural 
alterations arising from these activating EGFR mutations that are known from the 
literature to affect EGFR homodimerisation (Littlefield and Jura 2013). These likely 
relate to allosteric changes which result in an extended conformation, which align key 
catalytic regions to favour activation and expose the dimerisation arm (Shan, Eastwood 
et al. 2012, Valley, Arndt-Jovin et al. 2015).  We hypothesised that the mechanism of 
EGFR heterodimerisation with MET could be similar to that of EGFR-EGFR 
homodimerisation.  Structural studies such as x-ray crystallography would be required 
to demonstrate this definitively, however although not available FRET does validate 
their binding if not the mechanism. 
 
In view of further evidence that specific EGFR mutants are unique in their capacity to 
dimerise with each other, EGFR WT and additionally other HER family receptors, we 
suggest that EGFR crosstalk with MET could similarly be influenced by EGFR 
genotype (Red Brewer, Yun et al. 2013).  Interestingly this same data shows that some 
mutations act preferentially as ‘acceptors’ in an asymmetric pairing and are accordingly 
more likely to pair and become activated in association with WT EGFR.  On this basis, 
we could deduce that likewise MET could be preferentially positioned in either an 
activator or donor position depending on the EGFR mutation present, which would alter 
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the signaling pathways transduced and potentially also signal permanence/recycling 
too as we saw for EGFR (Figure 3.3).  EGFR-MET interaction may also depend on the 
activation status of EGFR prior to encountering MET, whereby the interaction is only 
effective when EGFR has already homodimerised leading to one activated MET 
monomer in the presence of more than one EGFR molecule in a one:many relationship 
(Figure 4.20). 
 
5.2 Are EGFR-MET dimers central to the responsiveness of lung 
adenocarcinoma to MET inhibition? 
The fact that we observed different phenotypic responses to MET inhibition in each cell 
line is consistent with the hypothesis that tumour cells with different EGFR mutants 
have different susceptibilities to MET inhibition. Chapter 4 also provided evidence 
linking EGFR-MET dimers to MET inhibition response. In the H1975L858R/T790M cell line 
we saw that the basal interaction between EGFR and MET is interrupted by SGX523 
treatment.  Conversely, in the H1975L858R cell line, EGFR and MET did not interact 
under resting conditions, but the addition of SGX523 results in an increase in EGFR-
MET dimerisation. H1975WT cells had no substantial EGFR-MET interaction and are 
not modified by SGX523. 
 
Our key findings of the phenotypical effects of MET inhibition on lung adenocarcinoma 
coming from the in vitro and in vivo studies were that with disruption of the EGFR 
L858R-T790M-MET dimer following SGX523 treatment there was reduction in 
proliferation and tumour growth.  In the more proliferative H1975L858R cell lines in which 
the stromal components had been most significant, EGFRL858R functioned as an 
oncogenic driver without evidence for EGFRL858R-MET binding until SGX523 treatment, 















H1975L858R/T790M H1975L858R H1975WT 
Figure 5.1 Effect of SGX523 on EGFR-MET heterodimerisation 
Schematic model demonstrating the effect of SGX523 on EGFR-MET dimerisation 
pattern and consequences for tumour characteristics following treatment. In 
H1975L858R/T790M cells the EGFR L858R-T790M-MET dimer is disrupted alongside 
reduced proliferation. In H1975L858R cells, EGFR L858R and MET do not interact until 
SGX523 binding to MET which presumably alters conformation to allow EGFR 
binding and with it reduces stromal deposition and migration.  We observed no 
dimers in either scenario in H1975WT. 
 
These findings follow previous observations in our group that TKI therapy can increase 
or decrease EGFR dimerisation and that the likelihood of this happening differed 
between different EGFR mutants (Coban, Zanetti-Dominguez et al. 2015).   The 
tendency for EGFR and MET to interact depending on the presence of the MET 
inhibitor could reflect conformational change in the MET kinase domain. In the 
untreated cells/tumours MET was more able to bind the double mutant form of EGFR.   
Since we did not see EGFRL858R-MET dimer formation at baseline, we assumed that 
EGFRL858R was only able to bind MET in its drug bound conformation arguing that the 
conformation of both EGFR and MET are both important determinants of the ability of 
EGFR and MET to dimerise and potentially function and that the SGX523 bound 
conformation of MET is altered in a way that favours interaction with EGFR L858R. 
 
The different responses we observed to SGX523 between the cell lines in terms of 
phenotypical differences and to a lesser extent downstream signaling, suggested that 
these differences in EGFR-MET dimer formation are likely to determine specific 
downstream pathways between the mutant types.  Changing the dominant downstream 
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pathway by influencing the EGFR-MET dimer could be a key component of how MET 
inhibition differs so notably between our EGFR mutants.   Whether MET is bound to 
EGFR or not could alter the sites available for docking proteins to transduce a specific 
signal that results in a given cellular response.  These sites could be within MET itself 
or alternatively be EGFR residues as part of an EGFR-MET dimer modulated 
allosterically by SGX523 through the EGFR-MET dimer. 
 
Understanding the phenotypical responses to therapeutic agents in cell models helps 
us to appreciate the mechanisms in which these treatments could paralyse important 
tumour hallmarks – to slow or block growth, impede local or distant metastasis or 
prevent angiogenesis. They also suggest there is a specificity to particular treatment 
approaches that can govern the outcome expected and that should be incorporated 
into predictive assays that can be used to ascertain if a therapy is working or even 
determine which tumour types require targeting of an anti-proliferative agent rather 
than an anti-dimerisation agent for example. 
 
Numerous MET inhibitors have been trialled in lung and other solid cancers ranging 
from the humanised monoclonal antibody onartuzumab (‘METMab’) to the small 
molecule inhibitor tivantinib. Most agents have failed in phase 3 trials (Scagliotti, von 
Pawel et al. 2015). In view of our data, and observations in the literature about the 
different mechanisms of action of different forms of MET targeted therapy, there may 
be different consequences for the EGFR-MET interaction depending on the particular 
kinase inhibitor selected and the conformation induced (some favour allosteric changes 
to active-like conformations whilst others compete at the ATP binding domain).  
Consequently there could be benefit in assessing the specific response to MET 
treatment for different classes of inhibitor. Small molecule kinase inhibitors are likely to 
have different effects to antibody-based therapies targeted against other parts of the 









5.3 Can we use EGFR/MET FRET assays on patient biopsies? 
Having optimised our EGFR-MET FRET assay to the in vitro setting we thereafter 
made adjustments to the protocol to enable detection of FRET in FFPE specimens, 
This included enhancing the antigen retrieval technique, utilising a new donor:acceptor 
antibody pair and conducting the data analysis with a dedicated algorithm that 
subjected the data to tri-exponential fitting that excludes autofluorescence lifetimes.  
This approach demonstrated FRET signal in murine xenografts that had been prepared 
according to the standard FFPE preparation used for clinical specimens suggesting 
that human biopsy samples should be similarly amenable to this approach. 
 
We thereafter processed several human tissue samples from human lung cancer tissue 
bank specimens as proof-of-principle that this approach could be employed in human 
specimens. In doing this we have repeated previous work by our collaborators that 
FRET-FLIM assays can be designed that would serve in biomarker studies (Tao, 
Castel et al. 2014).  To our knowledge, this analysis of the EGFR-MET dimer and 
particularly examining FRET of HER family members in lung cancer specimens is novel 
and confirmed that FRET analysis could be reproducible in the context of standard 
clinical FFPE tissue processing techniques.  In order to develop this assay into a 
clinical test, it would need to function in high throughput systems which may well need 
to be automated (Kelleher, Fruhwirth et al. 2009). 
 
A number of governance steps would be required to bring such a FRET assay to 
clinical practice. Further validation in human specimens and development of the assay 
within the resource constraints of a clinical laboratory would be required. There would 
need to be validation in clinical studies in terms of the ability of an assay to detect a 
reliable signal from human cancer samples. It would also be necessary to understand 
which point of the natural history of a patient’s tumour would be most useful to analyse 
with such approaches.  Finally such a test must be demonstrated to be both an 
accurate and cost effective means to select targeted therapy. Thereafter, if there were 
particular subgroups of patients in whom differences in EGFR-MET crosstalk could be 
detected, it might be possible to determine a treatment strategy which differs in the 
same group and to protocolise such a therapy accordingly.  For example responders 
versus non-responders to EGFR, MET and other kinase inhibitors (Kelleher, Fruhwirth 
et al. 2009, Tao, Castel et al. 2014).  This would need approval by the appropriate 
research ethics, R & D and local and national technology appraisal boards including 
the MHRA. Beyond this appropriate training and clinical infrastructure investment would 
be required to develop this into a robust clinical service. Finally this has to be shown to 
be deliverable on the scales required of science delivered in a healthcare setting. 
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5.4 Would an EGFR: MET FRET assay offer more than EGFR 
genotype testing alone? 
An outstanding question remains over whether it is sufficient to predict the efficacy of 
MET therapy using EGFR genotype alone, given that this approach would be 
achievable with current clinically utilised technology. Alternatively, and more likely, it 
will be necessary to explore such dedicated assays as we have explored to understand 
physiological EGFR-MET receptor crosstalk as a predictive biomarker. 
 
Whilst thoracic oncology research has snowballed in recent years with significant 
developments such as the detection of EGFR activating mutations, this is likely to be 
barely the tip of the iceberg.  There is increasing recognition of the complexity of 
mutational burden in lung cancer and furthermore of the diversity within individual 
patients and between different cases of lung cancer (de Bruin, McGranahan et al. 
2014, Rizvi, Hellmann et al. 2015, Tan, Mok et al. 2015).  This demands an 
increasingly personalized approach to therapeutic strategies and will require more 
effective diagnostic tools to classify and direct its treatment. FRET based assays 
provide one such example well suited to tackle the complexity of cancer by improving 
our understanding of interaction between individual players in a network of cancer 
signaling pathways (Kelleher, Fruhwirth et al. 2009, Fruhwirth, Fernandes et al. 2011). 
Consequently, there is clear potential to the translation of an assay of EGFR-MET 
interaction to a clinical test that exceeds the capability of existing approaches if we 
follow the hypothesis that the interaction between two molecules such as EGFR and 
MET is more important than for example protein levels or mutations status of either 
molecule in isolation. 
  
Testing of EGFR mutation status could in principal provide a surrogate of the EGFR-
MET interaction.  In general there is comparatively little understanding of the role of 
EGFR when considering MET amplification.  There is data that addition of a MET FISH 
positive result to any EGFR mutation is more useful as a prognostic marker compared 
to EGFR mutational status alone, alluding to the potential predictive role of EGFR and 
MET in partnership rather than sole testing of either target (Tanaka, Sueoka-Aragane 
et al. 2012). There are additionally other aberrations of MET signalling which may 
hinder EGFR-MET dimer formation that only an EGFR-MET FRET assay could detect 
(Gelsomino, Facchinetti et al. 2014). MET amplification is thought to be rare in EGFR-
TKI naïve patients and whilst co-existence of MET amplification with T790M in patient 
specimens is recognized as uncommon, the extent of the scenarios in which EGFR 
and MET can contribute synergistically to tumorigenesis are not known (Bean, Brennan 
et al. 2007, Kubo, Yamamoto et al. 2009). Finally, testing EGFR mutations alone would 
135 
 
be unlikely to provide a sufficiently reliable surrogate of the EGFR-MET dimer as a 
therapeutic target as there may be other oncogenes present that also influence the 
EGFR-MET interaction. 
 
An example of where a simple test has failed to appreciate the complexity of molecular 
signaling, has included the unexpected side effects seen with BRAF targeted tyrosine 
kinase inhibitors such as vemurafinib in melanoma whereby incomplete saturation of 
receptor by inhibitor results in RAF dimerisation and transactivation. This has led to 
attempts to design therapeutic approaches that dissociate RAF inhibition from 
paradoxical activation (Hey and Pritchard 2013, Samatar and Poulikakos 2014, Zhang, 
Spevak et al. 2015). 
 
This could explain why dual targeting of EGFR-MET in clinical practice has not 
surmounted phase III clinical trials (Pérol 2014, Scagliotti, von Pawel et al. 2015), 
which is hampering the translation of these agents into novel therapies. It is plausible 
that this is because studies of MET targeted therapy have failed to select the 
appropriate subgroup of patients.  Smaller studies continue to suggest a potential 
benefit of MET inhibitors by using newer predictive biomarkers and results in this area 
have been encouraging (Tanaka, Sueoka-Aragane et al. 2012). The preferred 
approaches to these ‘partner tests’ have evolved away from MET protein 
overexpression towards genomic aberrations such as MET copy number amplification, 
although the precise means of measuring this most accurately remains undetermined 
(Weingertner, Meyer et al. 2015). Newer literature has also identified a number of MET 
mutations, but neither is this an established method to predict treatment response 
(Paik, Drilon et al. 2015, Awad, Oxnard et al. 2016). 
 
The priorities of improvements in assay development include better prognostication; 
the ability to rationalise use of these expensive agents; to identify those who would be 
at greatest risk of drug side effects relative to benefit from a given approach and 
rationalisation of drug design and testing.  Thereafter having a test that is quick, easy, 
cost effective and deliverable within a clinical environment, whilst being accurate and 
acceptable to the patient in its means (e.g. blood sample or biopsy) are also important 
goals. This needs to be balanced against the wider cost implications of diagnostic and 
predictive partner tests, particularly in the current economic climate. 
 
Considering the wider impact of this research on clinical practice and ultimately health 
policy, this data informs the need for more research into the potential of MET based 
therapies, the need for partner tests and what form they should take.  Indeed, an 
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important consequence of such tests is that they should enable more rapid and 
effective development of drugs by enhancing outcomes as a percentage of trial 
participants as is shown by the difference between response rates in biomarker 
positive and negative patients in trials that assess the benefit of a drug based on a 
predictive biomarker as is now routinely the case for EGFR mutation testing and EGFR 
targeted therapy (Fukuoka, Wu et al. 2011, Rosell, Carcereny et al. 2012). 
 
5.5 An H1975 derived model that elaborates upon TKI response 
In summary, this chapter explores the wider significance of the findings related in this 
thesis whereby an NCI-H1975 based model of lung adenocarcinoma allowed us to 
observe how the EGFR mutations that define this model can alter tumour cell 
behaviour. I have discussed how the cell lines have enabled us to explore EGFR-MET 
dimerisation and its consequences for the potential therapeutic targeting of MET 
clinically.  I have related this to the existing literature on MET targeted therapy and 
biomarkers in lung cancer and how an EGFR-MET signaling axis could add value to 
targeted therapy in patients with lung adenocarcinoma.  Finally I have discussed the 
limitations of the model and suggest future avenues of research in this area. 
 
The important outcomes of this PhD thesis include: 
 
1) Through manipulation of the NCI-H1975 cell line we were able to directly 
compare the effects of EGFR mutations on EGFR-MET crosstalk and MET 
targeted therapy thus providing an important resource for future work in this 
area. 
2) Design of a novel EGFR-MET FRET assay that allowed direct assessment of 
EGFR and MET interaction in a quantifiable manner. This has potential for 
improved understanding of the EGFR-MET interaction and could be extended 
to clinical applications ranging from prognostication to predicting response to 
treatment. 
3) Thirdly, we have provided new evidence of the role of MET therapy in the 
presence of the EGFR oncogene. The need for further research in this area 
remains but our data suggests more efforts are required to understand the 
crosstalk between these pathways and the potential for assays addressing 






The preparation of this data for publication and presentation in this thesis have 
provided an opportunity to reflect on further improvements that could be made to the 
model and approaches I would consider in future experiments.  The major criticisms 
encountered in formal peer review of this work during the submission process, have 
included the potential for differences between the intrinsic EGFR L858R-T790M 
compared with transfected EGFR L858R and WT when instead transfecting with EGFR 
L858R-T790M may have been more comparable; the limitations of genomic 
manipulation using shEGFR compared with a CRISPR approach and thereafter the 
narrow focus on a pair of mutations within a single cell line. 
 
All are valid concerns, which have contributed to the training provided within this 
fellowship.  Reflecting further on this feedback within the wider group and at other 
scientific meetings reaffirms the strengths the model which has offered robust 
comparison between the mutations studied and has allowed consideration of the 
avenues which with additional time and resources may have been interesting to 
explore. The H1975 cell line approach is commonplace and robust in the EGFR 
translational science literature; whilst a CRISPR approach may have been desirable for 
increased accuracy of the mutational design of the cell lines, the polyclonality within our 
model may have reflected the heterogeneic nature of lung cancer more effectively.  
This could certainly be a direction of future research, potentially in combination with a 
transgenic e.g. FLOX mouse model.  Using a non-cancer cell line such as HEK293, 
which does not have mutant EGFR, would also have been an interesting means of 
comparing the mutations in a purer population although would have been a less true 
representation of lung cancer in vivo. 
 
With extended resources, we could also have combined the purer approach with 
multiple different mutations e.g. including del19 and MET amplification and additionally 
comparing these with other native lung cancer cell lines. It would be interesting to 
understand if the same patterns of dimerisation are observed with other activating or 
resistance mutations such as deletion in exon 19 and to probe the assay against these 
same mutations in other lung cancer cell lines and even to explore them in other 
models of cancer where EGFR or MET are known to be relevant. 
 
Another element of the project, which could be expanded upon, would be the strategy 
of MET inhibition. A number of MET inhibitors are available and if resources allowed, 
comparing several of these would provide valuable insights as to how responses can 
differ between them.  Our choice, SGX523, although clinically not viable, provided a 
highly selective tool to allow us to appreciate the role that the MET kinase contributed 
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to EGFR-MET interaction as directly assessed by FRET without off target effects 
(Buchanan, Hendle et al. 2009).  There would be interest in extending this to other 
MET inhibitors and potentially to compare whether TKI and non-TKI inhibitors 
performed similarly in EGFR-MET dimer formation.  Combinatorial approaches with 
EGFR inhibitors would also have been of considerable interest.  In addition short 
hairpin elimination of MET and kinase dead MET mutants would have provided further 
validity to these approaches. 
 
At the conception of this project some of these ideas and others were considered but 
the project presented was designed keeping in mind the need to maintain focus within 
the time and resource constraints suitable for a PhD thesis including guidance from 
local scientific peers and the MRC and Wellcome funding review bodies. 
 
5.6 Future work and outstanding questions 
Beyond these themes, a number of opportunities present themselves as new avenues 
of experiments to further elucidate the nature of the EGFR-MET interaction and with 
particular interest for the translation of the role of EGFR-MET crosstalk into clinical 
practice other ideas for translational research. 
 
1) More detailed focus on the structural biology of the EGFR-MET dimer could 
reveal novel therapeutic approaches.  For example there could be interest in 
exploring the structural determinants of EGFR-MET dimer with site directed 
mutagenesis aimed at disrupting domains important to dimerisation of one or 
both of these receptors.  The impact of such structural alterations could be 
assessed using EGFR-MET FRET as a surrogate to predict clinical response. 
 
2) Challenging the EGFR-MET FRET assay ex vivo as a screening tool for EGFR, 
MET or other related inhibitors (e.g. using pan-HER inhibitors) as a means of 
identifying potential agents for early clinical trials that might be more effective 
through manipulating the EGFR-MET dimer. 
 
3) Finally developing the EGFR-MET FRET assay as a human biomarker for 
prognostic and predictive analysis of lung adenocarcinoma offers a novel 






Developing the EGFR-MET FRET assay further into a high throughput system would 
be an important step to any of these approaches, both experimentally, in terms of a 
system capable of rapidly assessing multiple experimental perturbations but also for 
use as a drug development screening tool or as a predictive biomarker applicable to 
meaningful numbers of clinical samples simultaneously (Kelleher, Fruhwirth et al. 
2009). 
 
Currently we depend on only a handful of clinical indices to dictate therapy (e.g. EGFR, 
KRAS, ALK, ROS).  Novel biomarker tools such as FRET could prove vital to join up 
our knowledge of the wider promiscuity between receptor networks. Current 
approaches are based on the principal that a tumour tends to be addicted to a single 
oncogenic driver. It would be of interest to use FRET to understand where receptor 
crosstalk fits into this model. When does a passenger mutation emerge as a more 
significant driver and in what circumstances would this arise? Clinically this question is 
apparent in the example where MET amplification is seen to be enriched in samples 
from lung cancer brain metastasis - is MET therapy in the context of such lesions more 
relevant than the EGFR driver that led to the evolution of the first tumour? Single agent 
treatment approaches may not then be the most appropriate strategy - combining 
EGFR and MET therapies may help but understanding how to treat multiple targets 
with “Highly active anti-tumour therapy” may be the most difficult hurdle we are yet to 
face. Arrays of multiple FRET pairs, e.g. EGFR (WT)-MET, EGFR L858R-MET and 
beyond such as EGFR-HER3 assays could provide very interesting data on this front 
(Chmielecki and Pao 2010). 
 
It would also be of interest to explore whether FRET would be most useful in early 
stage, fully resectable tumours or be better directed at tumour recurrence and those 
with advanced disease where other approaches have failed.  In such circumstances 
one would want to compare the primary tumour with other metastatic lesions, 
potentially sampled more than once in the tumour evolution. FRET has also been 
demonstrated on liquid specimens and could thus be applied to circulating tumour cells 
as a blood test (Nedbal, Visitkul et al. 2015). 
 
As medical therapies evolve, and the demand for those who are not surgically curable 
e.g. late stage disease; failed resection or advancing physiological age increase, this 
interesting question surrounding the extent to which we need to understand this system 
in more detail in order to find effective treatments becomes more relevant. We have 
little understanding of how many receptors or downstream mediators need to be 
inhibited to achieve sufficient tumour control.  Similarly to what intricacy do we need to 
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understand the direction of a tumour cell to be able to understand the best clinical tests 
and select relevant therapies? Our knowledge has grown from classification to 
classification. At the outset this was ‘cancer versus benign’, ‘metastatic versus non-
metastatic’.  We are now familiar with ‘EGFR mutant versus non-mutant’, ‘L858R ± 
T790M or L858R with or without MET amplification or mutations.  There will be 
increasing interest in newer technologies to assess these molecular aberrations, 
including approaches such as FRET to assess the wider promiscuity between receptor 
signaling pathways; capturing also the multiple signals likely to be seen with more 
complex treatment regimes that not only target classical inhibition e.g. kinase domain 
phosphorylation but that also look to modify protein-protein interaction more directly. 
 
5.7 Summary 
I have demonstrated that EGFR and MET interact directly and that their interaction is 
determined by EGFR genotype. MET TKI therapy modifies this interaction in a 
genotype specific manner and the response to MET TKI correlates with EGFR-MET 
dimerisation. Further work of interest would be to design clinical approaches to 
understand if this EGFR-MET interaction in MET targeted therapy can be translated, 
for example in the development of FRET EGFR-MET assays as a therapy partner test 
or to inform novel combinations of EGFR and MET therapies.  Much is yet to be 
learned about the more complex interactions between these receptors, for example 
stoichiometry, directionality, specialised roles of particular mutants and the precise 
molecular nature of the interaction.  Finally, considering EGFR and MET as a simplified 
paradigm of a wider system of derailed signaling in lung cancer, we can study the 
relevance of receptor interdependence.  Through such an approach we might hope to 
understand how to tackle the wider complexities of the challenge of finding more 
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